#### МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ

#### УЧРЕЖДЕНИЕ ОБРАЗОВАНИЯ «ГОМЕЛЬСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ»

Кафедра общей и клинической фармакологии

# КРАТКО О ЛЕКАРСТВЕННЫХ СРЕДСТВАХ

Учебно-методическое пособие для студентов 3 и 6 курсов факультета иностранных студентов учреждений высшего медицинского образования

> В двух частях Часть 2

# **DRUGS IN SHORT**

Practical workbook for 3 and 6 year students Faculty for International Students of medical higher educational institutions

> In two parts Part 2

Гомель ГомГМУ 2020

#### УДК 615.2 (072)=111 ББК 52.81я73=432.1 К 78

#### Авторы:

Е. И. Михайлова, В. А. Саварина, Г. М. Бронская, О. Л. Палковский, Л. И. Новогран, А. В. Сенникова, Ж. В. Шуляк, Б. С. Ярошевич, Т.П. Яшина

#### Рецензенты:

доктор медицинских наук, доцент, заведующий хирургическим отделением гепатологического центра Гомельской областной специализированной клинической больницы **В. М. Майоров;** кандидат медицинских наук, заведующий оториноларингологическим отделением Гомельской областной клинической больницы **А. В. Черныш** 

Кратко о лекарственных средствах: учеб.-метод. пособие для студентов 3 и 6 курсов факультета иностранных К 78 студентов учреждений высшего медицинского образования: в 2 ч. = Drugs in short: practical workbook for 3 and 6 year students Faculty for International Students of medical higher educational institutions: in 2 parts / Е. И. Михайлова [и др.]. — Ч. 2. — Гомель: ГомГМУ, 2020. — 76 с. ISBN 978-985-588-126-2

Учебно-методическое пособие содержит сведения о классификациях, синонимах, механизмах действия, фармакодинамике, показаниях к применению, побочных эффектах, противопоказаниях и условиях рационального применения лекарственных средств из групп периферических и центральных нейротропов, а также средств, влияющих на функции органов дыхания и пищеварения.

Предназначено для студентов 3 и 6 курсов факультета иностранных студентов учреждений высшего медицинского образования.

Утверждено и рекомендовано к изданию научно-методическим советом учреждения образования «Гомельский государственный медицинский университет» 18 декабря 2018 года, протокол № 7.

УДК 615.2 (072)=111 ББК 52.81я73=432.1

© Учреждение образования «Гомельский государственный медицинский университет», 2020

ISBN 978-985-588-126-2 (ч. 2) ISBN 978-985-588-124-8

## CONTENTS

List of abbraviations	1
List of abbreviations	4
Introduction	6
1. Cardiotonics. Antiarrhythmic drugs	7
2. Antianginal agents. Lipid-lowering drugs	10
3. Antihypertensive agents. Antihypotensive agents	14
4. Drugs affecting tone of uterus	17
5. Drugs affecting blood	19
6. Agents regulating tissue metabolism. Polypeptide hormons and antigormonal agents. Steroid hormons	
7. Antioxidants. Vitamins.enzymes and anti-enzymes	
8. Antiinflammatory and antigoat drugs. Anti-allergic drugs. Immunomodulators	
9. Chemotherapeutic agents. Concept of chemotherapy. Antibiotics (ß-lactam antibiotics, macrolides, tetracyclins)	
10. Antibiotics (ending). Synthetic antimicrobial agents	53
11. Antimicobacterial, anti-spirochete, antiviral, antifungal drugs	
12. Antiprotozoic and antiparasitic drugs. Antiseptics and disinfectants	64
13. Antineoplastic agents	69
14. Principles of treatment of acute drugs intoxications	73
Reccomended reading	76

## LIST OF ABBREVIATIONS

ACE	— angiotensin-converting enzyme
AIDS	— acquired immunodeficiency syndrome
AH	— arterial hypertension
ATP	— adenosine triphosphate
BP	— blood pressure
CHF	— chronic heart failure
CNS	— central nervous system
COX	— cyclooxygenase
СРК	— creatine phosphokinase
FAD	— flavin adenindinucleotide
FMN	— flavin mononucleotide
GIT	— gastrointestinal tract
HIV	— human immunodeficiency virus
H. pylori	— Helicobacter pylori
IM	— intramuscularly
IOP	— intraocular pressure
IV	— intravenous
MI	— myocardial infarction
m/o	— microorganisms
MRSA	— methicillin-resistant staphylococcus aureus
MRSE	— methicillin-resistant epidermal staphylococcus

NA	— noradrenaline
Na <sub>2</sub> -EDTA	— disodium salt of ethylenediaminetetraacetic acid
NAD	— nicotinamide adenine dinucleotide
NADP	— nicotinamide adenine dinucleotide phosphate
NIRTs	— nucleoside reverse transcriptase inhibitors
NNIRTs	— non-nucleoside reverse transcriptase inhibitors
NSAIDs	— non-steroidal anti-inflammatory drugs
PABA	— para-aminobenzoic acid
Per os	— orally
PRSA	— penicillin-resistant staphylococcus aureus
RAAS	— renin-angiotensin-aldosterone system
RSV	— respiratory syncytial virus
STIs	— sexually transmitted infections
THF	— tetrahydrofolic acid
TPR	— total peripheral resistance
VMC	— vasomotor center
	<i>Sellos</i> .

## **INTRODUCTION**

This guide will help you to study drugs affecting the cardiovascular system, kidney function, the blood system, regulating tissue metabolism, chemotherapeutic agents, and also reflects the principles of treatment of acute drug poisoning.

The study guide contains information on 14 topics according to the program. Pharmacological characteristics include modern classifications, the nomenclature of drugs, mechanisms and spectra of action, indications, side effects and contraindications. So it's a rather big amount of information but it is self-explanatory: these tables will help you to study pharmacological logic. If you know mechanism of action you will know drugs pharmacodynamics. If you know pharmacodynamics you will identify indications for use. If you know side effects you will understand contraindications.

This study guide is written in a simple form and contains obvious information you should know after a year of pharmacology.

- erlositi

# **1. CARDIOTONICS. ANTIARRHYTHMIC DRUGS**

#### **Cardiotonic agents**

Cardiotonics (inotropics) are drugs that affect the strength of cardiac contraction

Classification	Cardiac glycosides	No	n-glycoside agents	
Drugs	<u>Drugs of digitalis:</u> 1. Digoxin (Lanicore, Dilacor) 2. Digitoxine (Cardiotoxin) 3. Lanatoside (Celanide, Isolanide) 4. Methylldigoxine (Bemecor, Digi-cor)	Drugs of strophant:         5. Strofantin         6. Strofantin G         Drugs of lily of the valley:         7. Corglycon         Drugs of Adonis:         8. Adonisid	9. Dobutamine (Dobutrex) 10. Dopamine	<ol> <li>Amrinon (Vincoram, Inocor)</li> <li>Milrinon (Primacor, Corothrop)</li> </ol>
Mechanism of action	Block of SH-group of Na+/K <sup>+</sup> -ATPase $\rightarrow$ violati $\uparrow$ Na <sup>+</sup> $\rightarrow \downarrow$ difference between intra- andextracell Na <sup>+</sup> /Ca <sup>2+</sup> metabolism $\rightarrow \downarrow$ elimination of Ca <sup>2+</sup> from Ions of Ca <sup>2+</sup> interact with the troponin complex a proteins of the myocardium $\rightarrow$ there is an interact myocardial contraction.	on of Na <sup>+</sup> and K <sup>+</sup> flowinside the cell $\downarrow$ K <sup>+</sup> and lular concentration of Na <sup>+</sup> $\rightarrow$ $\downarrow$ transmembrane om the celland $\uparrow$ its intracellular concentration; nd eliminateits inhibitory effect on contractile tion of actin with myosin $\rightarrow$ rapid and severe	<ol> <li>See "Adrenergic drugs"</li> <li>(9)</li> <li>Stimulation of peripheral dopamine receptors, β1-, α- adrenergic receptors (10)</li> </ol>	Inhibition of phosphodiesterase (III) $\rightarrow \uparrow$ cAMP $\rightarrow \uparrow$ intake of Ca2+ into myocardial cells and stimulation of the function of contractileproteins
Pharmacological effects	<ul> <li><u>Cardiac:</u></li> <li>1. Positive inotropic effect (strengthening and showledge of the heart);</li> <li>2. Positive bathmotropic effect (↑ excitability of 3. Negative chronotropic effect (bradycardia → e 4. Negative dromotropic effect (↓ conduction of the 4. Negative dromotropic effect (↓ conduction of the 4. Negative dromotropic effect (↓ conduction of the 5. ↑ diuresis (inhibition of Na+/K<sup>+</sup>-ATPase in the and ↓ reabsorption of Na+),</li> <li>6. ↑ glomerular filtration (improvement of renal minute volume of the heart),</li> <li>7. ↓ edema (↑glomerular filtration and diuresis);</li> <li>8. Vasodilating effect and ↓ activity of RAAS (due system),</li> <li>9. ↑ smooth muscle tone (inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPAS)</li> </ul>	ortening of the systole, ↑ minute and stroke the myocardium); elongation of the diastole); the myocardium). e cells of the epithelium of the renal tubules circulation by increasing the impact and e to the depression of the sympathoadrenal IPase of smooth muscle cells).	<ol> <li>Positive inotropic effect</li> <li>Positive chronotropic effect</li> <li>↑ blood flow in internal organs (10)</li> </ol>	<ol> <li>Positive inotropic effect</li> <li>Vasodilating effect</li> </ol>
Indications	<ol> <li>Acute heart failure (3.5–7)</li> <li>Chronic heart failure (1–4,8)</li> <li>Supraventricular tachyarrhythmias (1,2,7)</li> </ol>		<ol> <li>Acute heart failure</li> <li>Chronic heart failure (CHF)</li> <li>According to some data, the u chronic heart failure leadstoan</li> </ol>	), exacerbation se of PDE inhibitors in increase in the death rate of

		patients.				
Side effects	<ol> <li>Extrasystole, bradycardia, AV blockade</li> <li>Nausea, vomiting, diarrhea</li> <li>Visual impairment (↓ acuity, impaired perception of the spectrum, ↓ visualfields)</li> </ol>	<ol> <li>Tachyarrhythmias, headache</li> <li>Exacerbation of existing myocardial ischemia</li> </ol>	<ol> <li>Tachyarrhythmia, ↓ BP</li> <li>Thrombocytopenia, hepatotoxicity</li> <li>Nausea, vomiting</li> </ol>			
Contraindications	<ol> <li>Digital intoxication</li> <li>Severe bradycardia, WPW syndrome and sick sinus syndrome</li> <li>Acute myocarditis, endocarditis, unstable angina</li> <li>Hypertrophic and restrictive cardiomyopathy</li> <li>Paroxysmal ventricular tachycardia</li> </ol>	<ol> <li>Cardiac tamponade, pericarditis, severe aortic stenosis</li> <li>Ventricular arrhythmias</li> </ol>	<ol> <li>Obstructive cardiomyopathy</li> <li>Acute hypovolemia</li> </ol>			
NB!	Physico-chemical structure of cardiac glycosides: polar glycosides (strophanthin, corglycon), relatively polar (digoxin, celanide), nonpolar (digitoxin). Polar drugs are administered parenterally, act briefly, have a predominant systolic effect; non-polar act for a long time, are administered orally, have a predominant diastolic effect.         Disadvantages of cardiac glycosides: narrow therapeutic window → possibility of intoxication; no effect in hyperthyroidism, mitral stenosis, chronic pulmonary heart.         In decompensation of CHF and acute heart failure, levosimendan can be used. This substance increase sencitivity of contractile proteins to calcium ions. Currently, levosimendan has not yet become wide spread in the clinic					

# Glycoside intoxication

Clinics:	Treatment:
1. CVS: arrhrythmias (AV blockade, ventricular extrasystoles, etc.)	1. The withdrawal of the drug;
2. GIT: anorexia, nausea, vomiting and diarrhea	2. Antidotes for cardiac glycosides: digitalis-antidote (antibodies to cardiac glycosides),
3. Central nervous system: dizziness, headache, hallucinations, etc.	unitiol (donor of SH-groups that binds cardiac glycosides) and EDTA (binds calcium
4. Visual function: xantopsy (visual impairment, in which all objects appear yellow-	ions);
colored), photophobia, loss of visual fields, mydriasis.	3. Preparations of K <sup>+</sup> : KCl (1–1.5 g in 100 ml of 5 % glucose + 4 units of insulin, up to
	8 g of potassium chloride per day) into the vein, or tablets "Asparcam", "Panangin";
	4. Antiarrhythmics: lidocaine, phenytoin (difenin), β-adrenoblockers, in AV blockade —
	muscarinic antagonists (atropine).
201	

#### ANTIARRHYTHMICS

Cleasification	Class I (Na <sup>+</sup> -channel blockers)			Class II	Class III	Class IV
Classification	IA	IB	IC	(ß-blockers)	(K <sup>+</sup> -channel blocker)	(Ca <sup>2+</sup> -channel blockers)
Drugs	<ol> <li>Quinidine</li> <li>Procainamide</li> <li>Dysopyramide</li> </ol>	<ol> <li>4. Lidocaine</li> <li>5. Phenytoin</li> </ol>	<ul><li>6. Propaphenone</li><li>7. Ethacizinev</li></ul>	<ol> <li>8. Propranolol</li> <li>9. Atenolol</li> <li>10. Metoprolol</li> </ol>	<ol> <li>Amiodarone</li> <li>Bretiliumtosylate</li> </ol>	13. Verapamil
Mechanism of action	↓ Permeability of membranes for Na <sup>+</sup> andCa <sup>2+</sup> ions→↓ Depolarization rate;↓ automaticity and conductivity;↑ repolarization.	Blockage of Na <sup>+</sup> entry in the phase 4 and $\uparrow$ permeability of membranes for K <sup>+</sup> ions in the phase 3 $\rightarrow \downarrow$ automaticity; $\downarrow$ duration of repolarization. <i>Do not</i> <i>affect the conductivity</i> <i>and heart beat strength</i>	Na <sup>+</sup> -channel blockage $\rightarrow \downarrow$ depolarization and automatism. Do not affect repolarization.	S S	<ol> <li>↓ permeability of the cardiomyocyte membrane for potassium ions, delay repolarization (11)</li> <li>NA synaptic release blockage and ↓ of the effect of the neurotransmitter on adrenoceptors (12)</li> </ol>	The slow transmembrane current of Ca 2+ ions is blocked in the cell $\rightarrow$ phase 0 inhibition in the cells with "slow response" $\rightarrow \downarrow$ automaticity of SA- and AV- nodes and ectopic foci.
Pharmacological effects	1. Antiarrhythmic       2. Anticonvulsant (5)       3. Local anesthetizing (4)				<ol> <li>↓ permeability of the cardiomyocyte membrane for potassium ions, delay repolarization (11)</li> <li>NA synaptic release blockage and ↓ of the effect of the neurotransmitter on adrenoceptors (12)</li> </ol>	The slow transmembrane current of Ca 2+ ions is blocked in the cell $\rightarrow$ phase 0 inhibition in the cells with "slow response" $\rightarrow \downarrow$ automaticity of SA- and AV- nodes and ectopic foci.
Indications for use	<ol> <li>Atrial fibrillation (1, 2)</li> <li>Ventricular tachycardia</li> <li>Supraventricular paroxysmal tachycardia (1-3, 7)</li> <li>Atrial fibrillation / flutter (2, 6)</li> </ol>		See the topic «Adrenergic drugs»	<ol> <li>Supraventricular and ventricular tachyarrhythmia, including life threatening</li> <li>Refractory arrhythmias</li> </ol>	<ol> <li>Supraventricular tachyarrhythmia and extrasystoles</li> <li>Angina pectoris</li> <li>Arterial hypertension</li> </ol>	
Side effects	<ol> <li>Negative inotropic effect</li> <li>Nausea, vomiting</li> <li>Cholinolytic effect</li> <li>a-blocking effect (1)</li> </ol>	<ol> <li>Headache, dizziness</li> <li>Tremor</li> <li>Gingival enlargement</li> <li>(5)</li> </ol>	<ol> <li>Negative inotropic effect</li> <li>Proarrhythmo genicaction</li> <li>Headache</li> </ol>		<ol> <li>Intestinal pneumonia;</li> <li>Hypo-/hyperthyroidism (11)</li> <li>Hypotension</li> <li>Ataxia, tremor (11)</li> <li>Deposition of lipofuscin in the cornea (11)</li> </ol>	<ol> <li>Nausea, vomiting</li> <li>Hyperemia of the face</li> <li>Bradycardia, AV blockade</li> <li>Peripheral edema</li> <li>Constipation</li> </ol>

# Antiarrhythmic agents are drugs used to treat heart rhythm disturbances (arrhythmias).

Classification	Class I (Na <sup>+</sup> -channel blockers)			Class II	Class III	Class IV		
	IA	IB	IC	(ß-blockers)	(K <sup>+</sup> -channel blocker)	(Ca <sup>2+</sup> -channel blockers)		
Contraindications	<ol> <li>Intra cardiac blockades</li> <li>Decompensation of heart failure</li> </ol>	<ol> <li>Sick sinus syndrome</li> <li>Liver diseases</li> </ol>	<ol> <li>Sick sinus syndrome</li> <li>Severe heart failure</li> </ol>		<ol> <li>Sick sinus syndrome (11)</li> <li>Violation of thyroid function (11)</li> <li>Arterial hypotension (12)</li> </ol>	<ol> <li>Nausea, vomiting</li> <li>Hyperemia of the face</li> <li>Bradycardia, AV blockade</li> <li>Peripheral edema</li> <li>Constipation</li> </ol>		
NB!	<ul> <li>Treatment of bradyarrhythmia: <i>muscarinic antagonists</i> (eliminate the influence of the vagus nerve); β1-agonists (dobutamine, dopamine).</li> <li>Additional drugs for the treatment of arrhythmias: <i>cardiac glycosides</i> for supraventricular arrhythmias, <i>potassium</i> preparations (panangin, asparcam) in arrhythmias to prevent hypokalemia; <i>dihydropyridine calcium channel blockers</i> (nifedipine, amlodipine, etc.) in brady-dependent arrhythmias (↑ heart rate); inhibitors of angiotensin-converting enzyme (captopril, enalapril, etc.) for ventricular arrhythmias. Lidocaine is a drug of choice for ventricular tachiarrythmias in myocardial infarction.</li> </ul>							

# 2. ANTIANGINAL AGENTS. LIPID-LOWERING DRUGS

Antianginal drugs are substances used for angina pectoris — pain in the heart due to ischemia (usually because of coronary atherosclerosis).

Classification	Nitrates and *sydnonimine derivatives	ß-adrenoblockers	Calcium channel blockers
	1. Nitroglycerine	<u>Non-selective β-blockers:</u>	Dihydropyridine:
	Short-acting (tablets Nitrolingual, Nitrostat; spray Nitromist)	5. Propranolol	9. Nifedipine
	Long-acting (buccal form Nitrogard; patch Minitran)	<u>Selective <i>B1-blockers:</i></u>	10. Amlodipine
Druge	2. Isosorbide dinitrate (Isordil)	6. Atenolol, Metoprolol, Bisoprolol	<u>Phenylalkylamine:</u>
Drugs	3. Isosorbide-5-mononitrate (Imdur, Ismo)	$\beta 1$ , $\alpha 1$ -blockers with vasodilating activity:	11. Verapamil
	*4. Molsidomine	7. Carvedilol, Labetalol	<u>Benzothiazepine:</u>
		With ISA (intrinsic sympathomimetic activity)	12. Diltiazem
		8. Acebutalol, Talinolol	
	SH-groups $\rightarrow$ are metabolized into S-nitrosothiols with NO release $\rightarrow$	Blockage of $\beta$ -adrenergic receptors $\rightarrow \downarrow$	Blockade of slow calcium
	activate guanylate cyclase, intracellular cGMP is accumulated $\rightarrow \downarrow$ flow	$cAMP \rightarrow \downarrow Ca^{2+}entry and \downarrow intracellular$	channels $\downarrow$ entry of Ca <sup>2+</sup> ions
Machaniam of	into the cells and accelerates the release of Ca <sup>2+</sup> , relaxes the smooth	concentration of $Ca^{2+} \rightarrow \downarrow$ force of the heart	into the cell $\rightarrow \downarrow$ conversion
Action	muscles of the veins and arterioles (including the coronary vessels) (1-3).	contractions.	of phosphate energy into
	*Is converted to NO, does not form S-nitrosothiols (4).		mechanical work $\rightarrow$ muscle
	Blockage of $\beta$ -adrenergic receptors $\rightarrow \downarrow cAMP \rightarrow \downarrow Ca^{2+}$ entry and $\downarrow$		fiber does not develop
	intracellular concentration of $Ca^{2+} \rightarrow \downarrow$ force of the heart contractions.		sufficient mechanical stress.

Pharmacological effects	<ol> <li>Antianginal (↓pre- and afterload)</li> <li>Antiplatelet</li> </ol>	<ol> <li>Antianginal</li> <li>Hypotensive</li> <li>Antiarrhythmic</li> </ol>	<ol> <li>Antianginal</li> <li>Hypotensive</li> <li>Antiarrhythmic (11,12)</li> </ol>
Indications	<ol> <li>Angina pectoris (all kinds)</li> <li>Acute myocardial infarction (IV 1, 2)</li> <li>Chronic heart failure (2–4)</li> <li>Pulmonary edema (1)</li> </ol>	<ol> <li>Angina pectoris</li> <li>Arterial hypertension</li> <li>CHF</li> <li>Tachyarrhythmia</li> <li>Migraines</li> </ol>	<ol> <li>Angina pectoris, vasospastic angina</li> <li>Arterial hypertension</li> <li>Supraventricular tachyarrhythmias (11, 12)</li> </ol>
Side effects	<ol> <li>Headache, tinnitus, reflex tachycardia</li> <li>Hypotension, orthostatic collapse</li> <li>Nausea, vomiting</li> <li>Tolerance (1-3)</li> <li>↑ intraocular and intracranial pressure</li> </ol>	<ol> <li>Bronchospasm</li> <li>Hypotonia</li> <li>Bradycardia, AV blockade</li> </ol>	<ol> <li>Headache, dizziness, skin hyperemia, tachycardia, legs edema (9, 10)</li> <li>Bradycardia, AV blockage (11)</li> <li>Tachy-, bradycardia (12)</li> </ol>
Contraindications	<ol> <li>Allergy</li> <li>Arterial hypotension</li> <li>↑ intraocular pressure</li> <li>Closed-angle glaucoma</li> </ol>	1. Bronchial asthma2. Bradycardia, AV blockade3. Arterial hypotension, severe CHF4. Pregnancy	<ol> <li>Severe hypotension</li> <li>Acute MI, progressive HF</li> <li>Sick sinus syndrome</li> </ol>
NB!	Angina attack treatment: nitroglycerine sublingually.	New drugs: ivabradine (funny channel blocker, ↓HR, doesn't affect BP conductivity)	Metabolictherapy:trimetazidine(preductal),nicorandil,meldonium(mildronate).

## LIPID-LOWERING DRUGS

Lipid-lowering drugs — agents decreasing level of plasma lipids.

je.

Classification	Statins	Bile acid sequestrants	Fibrates	Derivatives of nicotinic acid	Inhibitors of sterol intestinal absorption	Other
Drugs	1. Atorvastatin3. Pravastatin2. Lovastatin4. Simvastatin	<ol> <li>5. Cholestyramine</li> <li>6. Colestypol</li> </ol>	<ul><li>7. Fenofibrate</li><li>8. Gemfibrozil</li></ul>	10. Nicotinic acid (niacin)	11. Ezetimibe	12. Probucol

Classification	Statins	Bile acid sequestrants	Fibrates	Derivatives of nicotinic acid	Inhibitors of sterol intestinal absorption	Other	
Mechanism of action	1.↓synthesis of cholesterol in the liver due to competitive inhibition of the enzyme HMG- CoA reductase $\rightarrow \uparrow$ number of receptors for LDL $\rightarrow \uparrow$ capture of cholesterol from the plasma 2.The LDL particles also contain triglycerides (TG) $\rightarrow \downarrow$ TG	↑catabolism and excretion of bile acids and cholesterol	<ol> <li>Violate lipid metabolism → stimulated lipoprotein lipase and ↑ catabolism of VLDL</li> <li>Inhibit acetyl-CoA carboxylase, inhibition of lipolysis → ↓ synthesis of TG</li> <li>↑ intake of cholesterol and TG by HDL</li> </ol>	<ol> <li>Directly inhibits hepatic VLDL → ↓ synthesis of TG</li> <li>↓ plasma cholesterol level</li> </ol>	Selectively inhibits the absorption of phytosterol and cholesterol in the small intestine	Inhibits the synthesis of lipids, ↓ absorption of cholesterol and atherogenic properties of lipoproteins	
Pharmacological effects	1. $\downarrow$ total cholesterol plasma level3. $\uparrow$ HDLP level (1-4, 7-9, 12)2. $\downarrow$ triglycerides plasma level (1-4, 7-10)4. Antiplatelet (1-4)						
Indications	<ol> <li>Atherosclerosis,</li> <li>Hyperlipoproteinemia IIa; IIb (1-</li> </ol>	-4, 7–12); III and IV (1-	-4, 7–9, 10), 3.Hypercho 4.Hypertrig	lesterolemia (1–6, 10, 1 lyceridemia (1–4, 7–10)	1)		
Side effects	<ol> <li>Dyspepsia</li> <li>Liver function impairment</li> <li>Myalgia, myosite</li> </ol>	<ol> <li>Constipation, bloating</li> <li>Malabsorbtion</li> </ol>	<ul> <li>1.Nausea, vomiting, diarrhea</li> <li>2. ↑ bile cholesterol level → ↑</li> <li>cholelythiasis risk</li> <li>3. ↑ ALT, AST</li> </ul>	<ol> <li>Skin hyperemia</li> <li>Hepatotoxicity</li> <li>Hyperuricemia</li> </ol>	1. Liver function impairment	1.Diarrhea, bloating, nausea 2.QT widening	
Contraindications	<ol> <li>↑ ALT, AST</li> <li>↑ creatinkynase</li> <li>3.Pregnancy, lactation, age before 18</li> </ol>	1. Severe hypertriglyceridemia	<ol> <li>Hepatitis</li> <li>Cholelithiasis</li> </ol>	<ol> <li>Gastroduodenal ulcers</li> <li>Liver function impairment</li> <li>Gout</li> </ol>	1. Hepatic diseases 2. Hyper sensibility	1.QT widening, ventricular tachyarrhythmia 2.Pregnancy, lactation	
NB!	<ol> <li>The basic treatment of hyperlipid</li> <li>Bile acid sequestrants should be</li> <li>Statins are taken in the evening synthesized in the night.</li> </ol>	demia is the DIET, not taken during meal. 5 before going to bed b	the drugs! 4. Omega- antiplatelet, because cholesterol is lowering th	3 polyunsaturated fatty , anti-inflammatory effe erapy.	acids have lipid-low cts. Can be used as a	rering (↓ TG, VLDL), a supplement for lipid-	

**Myocardial infarction management** (MI is ischemic necrosis of heart muscle because of prolonged lack of oxygen supply — ischemia)

Aim	Group	Drugs
1. Pain management	1.1 <i>Opioid analgesics</i> 1.2 Neuroleptanalgesia	Morphine, Promedol, Fentanyl Fentanyl + droperidol
	1.3 Inhalation anesthesia	Nitrous oxide (80 vol % N <sub>2</sub> O and 20 vol % O <sub>2</sub> )

2.Restoration of coronary blood flow(trombolysis) and thrombi formation prevention	<ul><li>2.1 Fibrinolytics</li><li>2.2 Anticoagulants</li><li>2.3 Antiplatelets</li></ul>	Alteplase, Tenteplase (no antigenicity); Streptokinase Heparin, Enoxaparin, Fondaparinux Acetylsalicylic acid (250–500 mg to be chewed), Clopidogrel 300 mg
3. Necrosis zone restriction	3.1 Nitrates (6/6)	Nitroglycerin, isosorbide dinitrate
4. Acute cardiac uploading	<ul><li>4.1 β-blockers</li><li>4.2 ACE inhibitors</li></ul>	Metoprolol, Bisoprolol, Carvedilol, Atenolol Captopril, Enalapril, Lisinopril, Perindopril
5. Atherosclerotic plaque stabilization	5.1 Statins	Atorvastatin, Rosuvastatin
	Contraction of the second seco	
	13	

# **3. ANTIHYPERTENSIVE AGENTS. ANTIHYPOTENSIVE AGENTS**

Antihypertensives are medicines used for the treatment of hypertension. I<sup>st</sup> line drugs are used in the first complaints of the patient.

Classification	Drugs affecting the RAAS			β-blockers	Calcium channel blockers (calcium antagonists, CCB)
	Angiotensin converting enzyme inhibitors (ACE inhibitors)	Angiotensin II receptor antagonists (sartans)	See the topic	See the topic	See the topic
Drugs	Sulfhydryl-containing agents:1. Captopril (Capoten)Dicarboxylate-containing agents:2. Enalapril (Enap)3. Lisinopril (Diroton)4. Ramipril (Tritace)Phosphonate-containing agents:5. Fosinopril (Monopril)Hydroxame-containing agents:6. Idrapril	Losartan (Cozaar) Valsartan (Diovan) Irbesartan (Aprovel) Candesartan (Atacand) Eprosartan (Teveten) 12. Telmisartan (Micardis)	"Diuretics. Drugs affecting the tone and contraction activity of the myometrium»	«Adrenergic drugs»	«Antianginal and hypolipidemic agents»
Mechanism of action	<ol> <li>Inhibition of ACE → violation of the conversion of angiotensin I to angiotensin II → vasodilation, ↓ retension of Na and H<sub>2</sub>O, ↓ stimulating effect on the sympathetic innervation → ↓ BP.</li> <li>Inhibition of ACE → ↓ inactivation of bradykinin→ vasodilation.</li> </ol>	1. Antagonists of the angiotensin receptors → eliminate all the effects of angiotensin II (vasopressor action, ↑ production of aldosterone, stimulation of adrenergic innervation)			
Pharmacologic al effects	1. Hypotensive 2. Protection of organs (cardio, anglo - and penhroprotective action)				
Indications	2. Protection of organs (cardio, angle - and nephroprotective action)         1. Arterial hypertension         2. Diabetic nephropathy         3. CHF				
Side effects	<ol> <li>Dry cough, bronchospasm</li> <li>Hyperkalemia</li> <li>Deterioration of renal function in chronic renal failure. Hypotension</li> </ol>	<i>Rarely:</i> 1. Hypotension 2. Dyspepsia 3. Hyperkalemia			
Contraindicati ons	<ol> <li>Pregnancy and lactation</li> <li>Stenosis of the renal arteries</li> <li>Severe and chronic renal failure or hyperkalemia</li> </ol>	<ol> <li>Pregnancy and lactation</li> <li>Hyperkalemia</li> </ol>			
NB!	Classification of ACE inhibitors by duration of action: short The majority of ACE inhibitors (except captopril and lisinop	acting (captopril), intermediate-acting (enalar ril) are prodrugs.	oril), long-acting (r	amipril, lisinopr	il).

## ANTIHYPERTENSIVES (CONTINUED)

II<sup>nd</sup> line drugs are used when the I<sup>st</sup> line drugs are non-effective.

Classification	Central-acting drugs	Ganglionic blockers	α-adrenoblockers	Sympatholytics	Potassium channels openers
Drugs	<ol> <li>Clonidine hydrochloride (Clopheline)</li> <li>Moxonidine</li> <li>Methyldopha (Dopegit, Aldomet)</li> </ol>	Quaternary ammoniumcompounds:4. Hygronium5. Azamethonium bromide6. HexamethoniumAmines:7. Pempidine	Selective a1-adrenergic blockers: 8. Prazosin (Minipress) 9. Doxazosin (Cardura) 10. Terazosin (Kornam)	<ol> <li>Reserpine</li> <li>(Serpasil)</li> <li>Octavin</li> </ol>	13. Minoxidil 14. Diazoxide
Mechanism of action	1. Effect on $\alpha 2$ -adrenoreceptors (1,3) and imidazoline II receptors (1,2) of solitary tract nuclei $\rightarrow$ oppression of VMC and $\uparrow$ tonus of the vagus nerve $\rightarrow \downarrow$ cardiac workput, $\downarrow$ release of renin and $\downarrow$ TPR $\rightarrow \downarrow$ AD (1–3) 2. Stimulation of peripheral pre-synaptic $\alpha 2$ - adrenergic receptors $\rightarrow \downarrow$ of norepinephrine release in synaptic cleft (1)	See the topic «Cholinergic drugs. Nicotinic receptor agonicts. Nicotinic receptor antagonists (ganglionic blockers, neuromuscular blockers)» Not for long-time	0	Violate noradrenalin storing in the vesicles → ↓amount of the mediator released in response to nerve impulses	Open potassium channels in the smooth muscle vessels $\rightarrow$ vasodilation and $\downarrow$ BP.
Indications	<ol> <li>Hypotensive</li> <li>Sedative (1,3)</li> <li>↓ IOP</li> </ol>	administration	See the topic «Adrenergic drugs»	<ol> <li>Hypotensive</li> <li>↓IOP (12)</li> <li>Sedative,</li> <li>antipsyhotic (11)</li> </ol>	1. Hypotensive
Side effects	<ol> <li>Arterial hypotension</li> <li>The withdrawal syndrome (1.3)</li> <li>Drymouth (1,3)</li> <li>Drowsiness</li> </ol>			1. Resistant AH	<ol> <li>Resistant AH</li> <li>Hypertensivecrisis</li> </ol>
Contraindications	<ol> <li>Arterial hypotension</li> <li>Depression</li> <li>Sick sinus syndrome, AV-blockade</li> </ol>	*		<ol> <li>Peripheral edema</li> <li>Pain in the chest</li> <li>Bradycardia</li> <li>Dyspepsia</li> </ol>	1. Peripheraledema 2.Tachycardia, arrhythmia
NB!	Other drugs with antihypertensive action: nitrates, di	bazol, magnesium sulfate.			

Antihypotensive drugs — drugs increasing BP.

Group	Drug
1. α-adrenomimetics	Phenylephrine (Mezaton), Midodrine
2. β <sub>1</sub> -adrenomimetics	Dobutamine
3. Dopaminomimetics	Dopamine
4. Analeptics	Nikethamide (Coramine), Caffeine
5. Non-selective $\alpha$ - and $\beta$ -adrenomimetics	Epinephrine, Ethylphrine
6. Plant stimulants	Extracts and tinctures of ginseng and eleutherococcus

Extracts and tinctures o. \_ eleutherococcus Sodium ... edema, aortic dis edema, aortic dis Nitroglycerine aortic dissect<sup>\*</sup> Enalapril (\* stroke, sr Labeta<sup>\*</sup> strok F<sup>\*</sup>

**Hypertensive crisis** —an umbrella term for hypertensive urgency and hypertensive emergency. These two conditions occur when <u>blood</u> <u>pressure becomes very high</u>, possibly causing organ damage.

Hypertensive urgency (no impairment of organ	systems)			
Captopril	12,5–50 мг orally orsublingually			
Nifedipine	5–20 mg sublingually			
Metoprolol	25–50mg orally			
Propranolol	10–40 mg orally			
Clonidine (clonidine)	0,075–0,15 mg orally			
Moxonidine	0,4 mg orally			
Hypertensive emergency (acute life-threatening CNS, cardiovascular systems or the kidneys. M	g impairment of <u>organ systems</u> , especially the Ianagement depends on complications)			
Sodium nitroprusside (for pulmonary edema, aortic dissection)	0,25-10 mkg/kg/min IV slowly			
Nitroglycerine (for pulmonary edema, aortic dissection)	50–200 mkg/min IV slowly			
Enalapril (for pulmonary edema, ischemic stroke, subarachnoid hemorrhage)	1,25–5 mg IV quickly			
Labetalol (for aortic dissection, ischemic stroke, subarachnoid hemorrhage)	20-80 mgquickly, 1-2 mg/min quickly			
Furosemide (for pulmonary edema)	40–200 mg IV			
Magnesium sulfate (for convulsions, eclampsia – complication of pregnancy)	5–20 ml 20 % solution IV quickly			
Clonidine	IV 0,5–1,0 ml 0,01% solution or IM 0,5–2,0 ml 0,01 % solution			

## **4. DRUGS AFFECTING TONE OF UTERUS**

		Labor inducing drugs	0 0		Drugs fo	r hypotonic uterine ble	eding
Classification	(drugs increasing	the rhythmic contraction of	the myometrium)		(agents increasing	tonic contraction of th	e myometrium)
Classification	Hormonal drugs of the	Estrogenic preparations	Prostaglandins and the	eir	Ergot preparations	Ganglionic blockers	Herbal
	pituitary gland	and antiprogestagens *	synthetic analogues *				preparations
	1. Oxytocin	3. Estrone (Folliculin)	6. Dinoprost		9. Ergometrine	11. Pachycarpine	12. Grass of
	2. Demoxytocin	4. Estradiol dipropionate	7. Dinoprostone (Prost	tin E2)	maleate (Ergonovin)		shepherd's purse
Drugs		(Femoston)	8. Misoprostol * (Miro	olut)	10. Ergotamine		
		5. Mifepristone *					
		(Gynepriston)					
	1. Violation of the transmem	prane motion of ions in smoot	h musculature myometri	$ium \rightarrow$	1. Direct stimulation	n of the myometrium;	Partial agonist /
	uterine contraction $(1-5)$ .				antagonist of a-adre	energic, dopaminergic	and serotonergic
	2. Stimulation of cervical r	ipening Bue to the increased	activity of collagenas	se and	receptors (9, 10)		
Mechanism of	hyaluronidase $\rightarrow$ the opening	of the cervix during normal d	elivery (3–8).		2. Reduces the excit	tability of the ganglia	of the vegetative
action					nervous system and inhibits conduction of nerve impulses (11).		ve impulses (11).
				57 Contains vitamin K, choline and acetylcholine, tyramine,			
				coagulability (12)			
	1 Increase the tone and enhance rhythmic contractions of the myometrium (1_8, 11)						
Pharmacological	2. Causes prolonged tonic con	tractions of the uterus, vasoco	onstrictor effect. influenc	ce on the	e central nervous systen	n (9.10).	
effects	3. Increase the sensitivity of the uterus to oxytocin and prostaglandins (3–5).						
	4. Strengthen the walls of the	vessels of the uterus (12).					
	1. Weak contractions, premat	ure labor (1–8).	3. 7	Termina	tion of pregnancy for m	edical reasons (5-8).	
Indication	2. Hypotonic uterine bleedin	g, involution of the uterus af	ter childbirth and 4. C	Climax,	infertility, amenorrhea	(3, 4).	
	abortion (1, 2, 9–11).		5. I	Dysfunc	actional uterine bleeding and bleeding against fibroids (12).		
	1. Allergic reactions, dyspept	ic disorders (1–12).	4. A	Atony of	f the intestine and bladd	er (11).	
Side effects	2. Bradycardia, bronchospasm, water retention (1, 2). 5. Increase			Increase	e in blood clotting, le	owering blood pressure	e for a long-time
Side effects	3. Depression, weight gain, endometrial hyperplasia, tenderness of the application (12).						
	mammary glands, edema, liver damage (3–5).						
	1. Pregnancy.4. Inflammatory	pelvic disease.	•				
Contraindications	2. Hypersensitivity.5. Presend	ce of factors predisposing to ut	erine rupture.				
	3. Wrong fetal position 6. Sev	vere diseases of the heart, kidn	eys and liver.	•		<u> </u>	
NB!	Oxytocin to be used cautio	ously in combination with system of a structure of the section of a structure of the section of	ympathomimetics; when	n intrav	renous injection are p	erformed constant mon	itoring is needed.
	Ergometrine maleate strength	ens the action of other vasoco	nstrictors. It is not recom	nmende	a to take dinoprostone r	nore than for 2 days.	

# Tocomimetics are drugs increasing tone of uterus

## Tocolytics and drugs reducing the tone of the uterus

Classification	β2- adrenomimetics	Gestagenic agents
Drugs	<ol> <li>Fenoterol (Partusisten)</li> <li>Ritodrine</li> <li>Hexoprenaline (Ginipralin)</li> <li>Salbutamol</li> </ol>	<ul><li>5. Allylestrenol (Turinal)</li><li>6. Dydrogesterone (DUFASTON)</li><li>7. Progesterone (Utrogestan)</li></ul>
Mechanism of action	Excitation of $\beta$ 2-adrenoreceptors of myometrium $\rightarrow$ muscular relaxation	Interact with steroid membrane and cytosolic receptors $\rightarrow$ physiological and morphological changes in target organs
Pharmacological effects	<ol> <li>Tocolytic (1–7).</li> <li>Bronchodilating (1–4).</li> </ol>	
Indications	1. Prevention and treatment of threatening abortion and premature labor (1–7) 2. Violation of utero-placental circulation, endometriosis, infertility, dysmeno replacement therapy (5–7).	). rrhea, premenstrual syndrome, breast diseases, postmenopausal
Side effects	<ol> <li>Allergic reactions.</li> <li>Tachycardia, pain behind the sternum.</li> <li>Tremor, anxiety, headache, dizziness</li> <li>Dyspeptic disorders.</li> <li>Hyperglycemia, hyperkalemia.</li> <li>Muscle weakness, spasms.</li> </ol>	<ol> <li>Headache, drowsiness, decreased libido.</li> <li>Hirsutism, acne, weight gain.</li> <li>Depression.</li> <li>Edema</li> </ol>
Contraindications	<ol> <li>Hypersensitivity.</li> <li>Hypertrophic obstructive cardiomyopathy, tachyarrhythmias.</li> </ol>	<ol> <li>Hypersensitivity.</li> <li>Malignant neoplasms of genital organs and breast.</li> <li>Vaginal and uterine bleeding of unknown etiology.</li> <li>Diseases of the liver.</li> </ol>
NB!	When using $\beta$ 2 -adrenomimetics in obstetrics, it is recommended to monito and the heart rate in the fetus. During treatment with progesterone concentrat other potentially dangerous activities requiring rapidity of psychomotor re- currently in Western countries is considered unfounded.	r potassium levels in blood, blood pressure, heart rate in pregnant women, ion is dicreased (care must be taken when driving vehicles and engaging in eactions). The use of any progestogen to prevent a habitual miscarriage
<u> </u>		

# **5. DRUGS AFFECTING BLOOD**

## Agents increasing blood coagulation

Classification	Hemostatic agents		Inhibitors of fibrinolysis	
Classification	Topical	Resorptive	minibitors of indefinitiysis	
Drugs	<ol> <li>Thrombin</li> <li>Hemostatic sponge</li> </ol>	<ol> <li>3. Fibrinogen</li> <li>4. Vitamin K1 (phytomenadione), K3 (vicasol)</li> <li>5. Ethamylate (dicinone)</li> <li>6. Anti hemophilic Factor VIII, Factor VIIa, IX</li> </ol>	<ul> <li>7. Aminocaproic acid</li> <li>8. Tranexamic acid</li> <li>9. Aminomethyl benzoic acid (ambene)</li> <li>Inhibitors of proteolytic enzymes:</li> <li>10. Aprotinin (contrycal, gordox)</li> </ul>	
Mechanism of action	The natural components of the coagulation system — provide the formation of blood clot $(1-4, 6)$ , $\uparrow$ formation of thromboplastin (5).		Inhibition of activation of the plasminogen $\rightarrow$ plasmin formation inhibition. Brakekinin systems and the activity of fibrinolysis (7–9). Inhibit fibrinolysin (plasmin), heparin $\rightarrow$ inhibit fibrinolysis and $\uparrow$ activity of the coagulation system blood (10).	
Pharmacological effects	<ol> <li>Hemostatic</li> <li>Anti allergic effect, ↑ liver detoxification (7)</li> <li>Inhibition of proteolytic enzymes (trypsin, chymotrypsin, kallikrein, plasmin) (10)</li> </ol>			
Indications	<ol> <li>Bleeding: capillary (1, 2, 5) and parenchyma (1, 2, 5).</li> <li>Hypofibrinogenemia: postpartum hemorrhage. DIC-syndrome (3)</li> <li>Bleeding against liver diseases and vitamin K absorption disorders (4)</li> <li>Congenital/acquired coagulation factors deficiency (6)</li> </ol>		<ol> <li>Local (nasal bleeding, tonsillectomy, extraction of teeth, etc.) and generalized (in thoracic and abdominal surgery)</li> <li>Acute pancreatitis (contrycal), ↑ risk of bleeding (gordox)</li> <li>Bleeding during an overdose of fibrinolytic agents</li> </ol>	
Side effects	1. Allergic reactions, nausea, headache (5)		<ol> <li>Intra vascular thromboses</li> <li>Hypotension, arrhythmia</li> <li>Impairment of color vision (8)</li> <li>Allergic reactions (8, 10)</li> </ol>	
Contraindications	s 1. Increased blood clotting 2. Thrombo embolism		<ol> <li>DIC-Syndrome</li> <li>Bleeding from the kidneys and ureters</li> <li>Propensity for thrombosis and embolism</li> <li>Pregnancy</li> </ol>	
NB!	Not for IM or IV use $\rightarrow$ thrombosis Vegetable coagulant: Leaves of nettle	Not for IM or IV use → thrombosis e, yarrow, corn bark, arnica	<i>Aprotinin</i> is is used for extra corporeal circulation of blood during heart operations and liver transplantation.	

#### **Blood thinners**

## Anti platelets are drugs decreasing platelet aggregation

Anti plate	Anti platelets are drugs decreasing platelet aggregation					
Classification	Cyclooxygenase (COX) inhibitors	Phosphodiesterase inhibitors	ADP receptor blockers	Glycoprotein IIb / IIIa receptors blockers		
Drugs	1. Acetyl salicylic acid (aspirin) <i>in small doses</i>	2. Dipyridamole	<ol> <li>3. Ticlopidine</li> <li>4. Clopidogrel</li> </ol>	5. Abciximab 6. Tirofiban		
Mechanism of action	Their reversible blockade of COX of thrombocytes (an enzyme involved in the formation of thromboxane A2 and prostacyclin from arachidonic acid).	It blocks phosphodiesterase and adenosine uptake $\rightarrow \uparrow$ cAMP level $\downarrow$ intracellularcontentof Ca2 + $\rightarrow \downarrow$ platelet aggregation and has a vasodilating effect.	Block ADP receptors on the platelet membrane $\rightarrow$ interfere with the interaction of platelet receptors with fibrinogen.	Eliminate the activation of glycol protein receptors GP IIb / IIIa → disrupt platelet aggregation.		
Pharmacological effects	<ol> <li>Antiplatelet</li> <li>Improve myocardial and cerebral mi</li> <li>Coronary vasodilatation (2)</li> </ol>	crocirculation	$\langle O \rangle$			
Indications	<ol> <li>Angina pectoris</li> <li>Prevention of MI (in the presence of risk factors)</li> <li>Prevention of thrombosis and embolism after operations on the heart and vessel</li> </ol>	<ol> <li>Prophylaxis of ischemic trokein chronic cerebrovascularin sufficiency</li> <li>Prevention of thrombo embolic complications after operations on peripheral vessels</li> </ol>	<ol> <li>Prophylaxis of thrombosis in patients with is chemic heart disease (after MI)</li> <li>Atherosclerosis of cerebral and perioreric vessels</li> <li>Intolerance to acetylsalicylic acid</li> </ol>	<ol> <li>Acute coronary syndrome</li> <li>Atherectomy and angioplasty operations (in combination with aspirin and heparin).</li> </ol>		
Side effects	<ol> <li>Dyspepsia</li> <li>Risk of bleeding</li> <li>Allergic reactions</li> </ol>	<ol> <li>Coronary steal when IHD.</li> <li>Dyspepsia</li> <li>↓ AP, headache</li> </ol>	<ol> <li>Dyspeptic disorders</li> <li>Thrombocytopenic purpura</li> <li>Neutropenia, agranulocytosis (3)</li> </ol>	<ol> <li>Bleeding, thrombocytopenia</li> <li>Allergic reactions</li> </ol>		
Contraindications	<ol> <li>Exacerbation of erosion-ulcerative lesions of the gastrointestinal tract</li> <li>Pregnancy</li> <li>as an anti pyretic for viral infection in children</li> </ol>	1. Acute myocardial infarction, unstable angina	<ol> <li>Increased risk of bleeding</li> <li>The gastro duodenal ulcer</li> <li>Liver disease</li> </ol>	<ol> <li>Thrombocytopenia</li> <li>Hemorrhagic diathesis</li> <li>Aneurysm</li> </ol>		
NB!	The COX of the vascular wall restores its activity for several hours in contrast to the COX of platelets $\rightarrow$ anti trimboxane effect of prostacyclin. For $\downarrow$ irritating effect on the stomach $\rightarrow$ enteric-coated forms	Effective only in combination with aspirin or in direct anticoagulants	Antiplatelet effect $\rightarrow$ in 24–48 h. Peak action $\rightarrow$ in 3–10 days, and for acetylsalicylic acid in 1 h.	In the congenital absence of this re- receptor complex, blood loss develops-Glanzmann's thrombasthenia		

#### **Blood thinners (continued)**

Anticoagulants — drugs reducing blood coagulation and prolonging coagulation time.					
Classification	Direct anticoagulants		Indirect anticoagulants	Direct oral factor Xa inhibitors	
	Indirect thrombin inhibitors	Direct thrombin inhibitors			
Drugs	<ol> <li>Heparin Low molecular weight heparins (LMWHs):</li> <li>Nadroparin (Fraxiparine)</li> <li>Enoxaparin (Clexane)</li> <li>Dalteparin (Fragmin)</li> <li>Synthetic LMWH:</li> <li>Fondaparinux</li> </ol>	<ol> <li>6. Lepirudin,</li> <li>7. Bivalirudin</li> <li>8. Argatroban</li> </ol>	<ul> <li>9. Warfarin</li> <li>10. Fenindione,</li> <li>11. Acenocoumarol</li> <li>(syncumar)</li> <li>12. Ethyldicoumarol</li> <li>(Neodicum Marine)</li> </ul>	13. Rivaroxaban 14. Apixaban	
Mechanism of action	1. Heparin + Antithrombin III $\rightarrow$ blockage of thromb inactive center $\rightarrow$ inactivation of thrombin (factorIIa); inhibition of a number of activated coagulation factors (XIIa, XIa, IXa and especially Xa (prothrombinase)). 2. LMWH practically do not effect thrombin, mostly effect X coagulation factor (increase the effect of anti thrombin III on factor Xa).	Independently attach to the active center of thrombin and do not require binding to anti thrombin III.	Vitamin K antagonists: block the synthesis of vitamin K- dependent coagulation factors (II - prothrombin,VII,IX,X) in the liver.	Selectively inhibit pro thrombinase (factorXa) → the reisn convertion of prothrombin to thrombin.	
Pharmacological effects	1. Anticoagulant       4. Hypoglycemic, diuretic, anti-inflammatory, antiallergic, vasodilating (1)         2. Anti platelet       5. Cholagogue, relax the smooth musculature of the vessels, analgesic and sedative action (9–12)         3.   plasma lipid level (1.6–8)       5. Cholagogue, relax the smooth musculature of the vessels, analgesic and sedative action (9–12)				
Indications	Prevention and therapy of thromboembolic diseases and infarction, thrombosis and embolism of peripheral arteries	their complications (preventions and deep veins)	n of thrombosis during surgery	v, unstable angina, acute myocardial	
Side effects	<ol> <li>Bleeding of various localization, thrombosis- mourning</li> <li>Paradoxical thrombosis (antibodies to heparin)</li> <li>Allergic reactions</li> </ol>	1. Bleeding	<ol> <li>Bleeding</li> <li>Alopecia</li> <li>↑ level of liver enzymes</li> </ol>	<ol> <li>Bleeding</li> <li>↑ level of hepatic enzymes</li> <li>Nausea</li> </ol>	
Contraindications	<ol> <li>Hemophilia, thrombocytopenia, hemorrhagic diathesis, bleeding</li> <li>Malignant neoplasm and ulcerative lesions of the digestive tract</li> <li>Dysfunction of the liver and kidneys</li> </ol>				
NB!	Heparin is given to increase PPT (activated partial thromboplast in time) twice (30–35 sec) — this is optimal dose. Antidote for overdose – protamine sulfate.	For the treatment or prevention of thromboses associated with heparin- induced thrombocytopenia.	INR (international normalized ratio) should be controlled (INR < 2–3). Antidote is vitamin K (phytomenadione).	Do not require a regular study of blood clotting.	
			1		

Anticoagulants — drugs reducing blood coagulation and prolonging coagulation time.

Fibrinolytics- drugs	<b>ibrinolytics</b> – drugs disolving blood clots.		Anemia drugs <i>(erythropoiesis-stimulating agents)</i> Anemia is a medical condition in which the red blood cell count or hemoglobin is less than normal.			
Classification	I generation	II generation	Pathology	Drugs		
Drugs	<ol> <li>Streptokinase</li> <li>Urokinase</li> <li>Antistreplase</li> </ol>	<ol> <li>The tissue activator of plasminogen (alteplase)</li> <li>Recombinant plasminogen activator (reteplase)</li> <li>Tenecteplase</li> </ol>	Iron deficiency anemia (hypo chromic) <b>NB!</b> Ferrous iron (Fe <sup>2+</sup> ) c combination with vitamin C is absorbed better. An exception is preparations of iron (III)- hydroxyl deploy maltose complex (IPC, Maltofer)	Iron supplements: 1.Ferrousfumarate (Ferrocite) 2.Ferrousgluconate (Fergon, Ferralet) 3.Ferroussulfate (Ferrousal, Ferosul) 4.Maltofer Cobalt supplements: 5. Ionic cobalt Human recombinantery thropoietin: 6. Epoetin alfa — IV, s/c		
Mechanism of action	Equally activate both plasminogen on the surface of the thrombus and plasminogenin the plasma $\rightarrow$ plasmin (fibrinolysin)	Activate predominantly plasminogen on the surface of the thrombus	Megaloblasticanemia	Cyanocobalamin (B <sub>12</sub> ), folicacid (B <sub>c</sub> )		
Pharmacological effects	<b>1. Fibrinolytic</b> (dissolve the filaments of fibrin, destroy fresh thrombi in the arteries, veins and cavities)		<ul> <li><i>Rules for the prescribing of iron supplements:</i></li> <li>1. Treatment begins with oral administration of drugs;</li> <li>2. Iron preparations are taken in 1 hour before meals or 2 hours after meals;</li> </ul>			
Indications	<ol> <li>Thrombosis of veins and arteries</li> <li>Acute myocardial infarction (1–2</li> <li>Pulmonary thrombo embolism</li> </ol>	2 days)	<ul> <li>3. Monitor the effectiveness of therapy (a week later an increase in the number of reticulocytes, a month later — hemoglobin);</li> <li>4. If oral use has no effect the drugs should be given intravenously;</li> <li>5. Treatment begins with parenteral administration of drugs (afirst a tolerance test</li> </ul>			
Side effects	<ol> <li>Bleeding</li> <li>Allergic reactions (1–3)</li> </ol>		<ul> <li>impaired absorption (diseases of the stomach and intestines) and with the aim of achieving rapid effects in severe anemia;</li> <li>6. Prevent the simultaneous intake of iron preparations by mouth and by injection;</li> <li>7. The duration of the treatment is at least 2 months.</li> </ul>			
Contraindications	<ol> <li>Acute bleeding</li> <li>Recent (up to 10 days) surgery and trauma</li> <li>Violations of the blood coagulation system</li> <li>Recent hemorrhagic stroke</li> <li>Dissecting aortic aneurysm</li> </ol>		<ul> <li>8. To avoid darkening of the teeth, you should thoroughly rinse your mouth after taking iron- Containing drugs.</li> <li><i>Side effects:</i> Metallic taste in the mouth, nausea, vomiting, decreased appetite, constipation, black stool.</li> </ul>		<ul> <li>8. To avoid darkening of the teeth, you should thoroughly rinse your mout taking iron-</li> <li>Containing drugs.</li> <li><i>Side effects:</i> Metallic taste in the mouth, nausea, vomiting, decreased apper constipation, black stool.</li> </ul>	uld thoroughly rinse your mouth after usea, vomiting, decreased appetite,
NB!	<ol> <li>Apart from streptokinase, administered together with hepa usually for 24 to 48 hours.</li> <li>Trombolysis shouldn't be done syndrome but without ST-segment</li> </ol>	all thrombolytic drugs are rin (unfractionatedorLMWHs), in patients with acute coronary elevation.	<i>Iron poisoning:</i> Necrotizing gastroenteritis diarrhea, shock, metabolic acidosis, coma a <i>Help with poisoning</i> : gastriclavage, <i>antido</i> (correction of acidosis, anti-shock measures)	, vomiting, abdominal pain, bloody nd death. <i>te is deferoxamine,</i> symptomatic treatment s, gastrointestinal bleeding management.		

Classification	Leukopoiesis stimulants	Erythropoiesis inhibitors	Inhibitors of leucopoiesis
Drugs	<ol> <li>Methyluracil</li> <li>Pentoxyl</li> <li>Leukogen</li> <li>Human colony-stimulating factors:</li> <li>Filgrastim (Neupogen)</li> <li>Lenograstim (granitocyte)</li> <li>Molgraimost (leukomax)</li> </ol>	7. Phosphorus-32-radio labeled solution of sodium phosphate	<ol> <li>8. Methotrexate</li> <li>9. Mercaptopurine</li> <li>10. Busulfan (myelosan)</li> <li>11. Cyclophosphamide</li> </ol>
Mechanism of action	<ol> <li>↑ synthesis of nucleic acids, proteins, cell division, leucopoiesis, tissue regeneration (1, 2)</li> <li>2. ↑ leucopoiesis in severe disturbances (3)</li> <li>3. Bond to the receptors of myeloid cells and</li> <li>↑ Proliferation and differentiation of cells-</li> <li>Precursors of neutrophils (4,5) and monocytes / macrophage (6)</li> </ol>	↓ Red bone marrow	<ol> <li>Violation of the formation of purine and thymidine → ↓ DNA synthesis (8).</li> <li>Disrupts the bio synthesis of purine nucleotides (9).</li> <li>Inhibits myeloid tissue and granulocytopoiesis (10).</li> <li>Active metabolites are formed in the liver (phosphamide and acrolein) → antitumor effect (11).</li> </ol>
Pharmacological effects	<ol> <li>1. ↑ Leucopoiesis, accelerate regeneration processes (1-3)</li> <li>2. Regulate the production of neutrophils and their entry from the bone marrow into the blood (4,5)</li> <li>3. regulates the production of granulocytes and monocytes / macrophages (6)</li> </ol>	↓ erythrocyte formation	↓ leukocyte formation
Indications	<ol> <li>Leukopenia</li> <li>Patients with burns, long-lasting wounds (1, 2)</li> <li>Aplasticanemia (6)</li> <li>Bone marrow transplantation (4,6)</li> </ol>	1. Polycythemia (erythremia)	<ol> <li>Acuteleukemia (8,9,11)</li> <li>Lymphogranulomatosis (8)</li> <li>Chronic myelogenous leukemia (10)</li> </ol>
Side effects	<ol> <li>Allergic reactions (1-3)</li> <li>Skin vasculitides, musculo-articular pain, edema, pericardial and pleural effusion (6)</li> <li>Leukocytosis, thrombocytopenia (4,5)</li> </ol>	<ol> <li>Thrombocytopenia</li> <li>Anemia</li> </ol>	<ol> <li>Leukopenia, anemia</li> <li>Nausea, vomiting, ulcerative stomatitis</li> <li>Headache</li> </ol>
Contraindications	<ol> <li>Lymphogranulomatosis (1–3)</li> <li>Myeloid leukemia (1–6)</li> </ol>	<ol> <li>Anemia, leucopenia, thrombocytopenia,</li> <li>Heart failure,</li> <li>Dysfunction of the liver and kidneys</li> </ol>	<ol> <li>Hypersensitivity</li> <li>Leukopenia, thrombocytopenia</li> <li>Pregnancy (8, 10, 11)</li> <li>Diseases of the liver and kidneys</li> </ol>

## Drugs effecting erythropoiesis and leucopoiesis (continued): agents stimulating / depressing erythropoiesis and leucopoiesis.

## 6. AGENTS REGULATING TISSUE METABOLISM. POLYPEPTIDE HORMONS AND ANTIGORMONAL AGENTS. STEROID HORMONS

Classification	Hypothalamic h	ormones	Pituitary horme	ones
Drugs	Releasing hormones1. Thyrotropin-releasing hormone(protirelin)2. Gonadotropin-releasing hormoneGnRH (gonadorelin and syntheticanalogues: goserelin, leuprolide,nafarelin, buserelin, gistrelin)3. Growth hormone–releasing hormone(somatorelin)4. Corticoliberin	<ul> <li>Hormone secretion inhibitors</li> <li>5. Somatostatin (octreotide)</li> <li>6. Gonadotropin-releasing hormone antagonists (cetrorelix, ganirelix)</li> <li>7. Antigonadotropins (androgen danazol)</li> </ul>	<ul> <li>Anterior lobe</li> <li>8. Somatotropin</li> <li>9. Thyrotropin (thyrogen)</li> <li>10. Adrenocorticotropic hormone</li> <li>ACTH (cosyntropine)</li> <li>11. Follicle-stimulating hormone FSH (urofolllotropin)</li> <li>12. Luteinizing hormone LH (human chorionic gonadotropin: pregnil)</li> </ul>	Posterior lobe 13. Oxytocin Analogues of vasopressin: 14. Desmopressin 15. Terlipressin
Mechanism of action	Interacte with membrane receptors and chan	nge protein synthesis in the cells		
Pharmacological effects	<ol> <li>Release of TSH and prolactin (1)</li> <li>Release of LH and FSH (with constant admission - suppression) antitumor, antiandrogenic effect (2)</li> <li>Release of somatotropin (3)</li> <li>Release of ACTH (4)</li> </ol>	<ol> <li>Suppression of excretion of somatotropin, glucagon, insulin, serotonin, gastrin (5)</li> <li>Suppression of LH and FSH release (6)</li> <li>Suppression of GnRH, FSH and LH release, proliferation of lymphocytes (7)</li> </ol>	<ol> <li>Anabolic, growth stimulation (8)</li> <li>Release of thyroid hormones (9)</li> <li>Release of hormones of the adrenal cortex (10)</li> <li>Stimulates folliculogenesis in women and spermatogenesis in men (11)</li> <li>Stimulation of ovulation and estrogen secretion (12)</li> </ol>	<ol> <li>↑ tonus and contractile activity of the uterus, stimulation of lactation (13)</li> <li>Antidiuretic effect. ↑ Tone smooth muscle (14)</li> <li>Vasopressor, hemostatic (↑ activity of VIII factor of blood coagulation) (15)</li> </ol>
Indications	<ol> <li>Diagnosis of hypothyroidism, hypo- and agalactia in women (1)</li> <li>Hormone-dependent prostate cancer, endometriosis, uterine fibroids, preparation for superovulation in IVF (constant intake). Infertility (pulse reception) (2)</li> <li>Diagnosis of pituitary nanism in children (3)</li> <li>Diffiagnosis of Cushing's disease and</li> </ol>	<ol> <li>Acromegaly, endocrine tumors of the gastroentero-pancreatic system, bleeding from varicose veins of the esophagus in cirrhosis of the liver, refractory diarrhea in AIDS patients (5)</li> <li>In vitro fertilization, endometriosis, fibromatosis (6)</li> <li>Endometriosis with concomitant infertility, benign neoplasms of the</li> </ol>	<ol> <li>Violation of growth processes in children (8)</li> <li>In combination with the radioactive isotope of iodine - for visualization of metastases of thyroid gland cancer and its residues after thyroidectomy (9)</li> <li>Evaluation of the function of the adrenal glands cortex (10)</li> <li>Polycystic ovarian syndrome, infertility of ovarian genesis (11)</li> </ol>	<ol> <li>Stimulation of labor, hypotonic uterine bleeding, hypolactia (13)</li> <li>Diabetes insipidus, polyuria and polydipsia after pituitary operations, haemophilia A, von Willebrand's disease (14)</li> <li>Gastrointestinal and genito-urinary bleeding</li> </ol>

#### Hypothalamic and pituitary hormone

Classification	Hypothalamic	hormones	Pituitary horm	ones
	secretion of ACTH by ectopic foci of the tumor (4)	breast, PMS, gynecomastia; Hereditary angioedema (7)	5. In women: anovulatory infertility. In men: pituitary hypogonadism, cryptorchidism, delayed puberty (12)	(15)
Side effects	<ol> <li>Fluctuations of blood pressure (1)</li> <li>Headache, mood and libido changes, gastrointestinal disturbances (2)</li> <li>Pain at the injection site, headache (3)</li> <li>Redness of the face (4)</li> </ol>	<ol> <li>Nausea, vomiting, diarrhea (5)</li> <li>Ovarian hyperstimulation syndrome (6)</li> <li>Hirsutism, acne, menstrual irregularities, mood changes, hepatotoxicity (7)</li> </ol>	<ol> <li>Hypothyroidism, headache, nausea</li> <li>Nausea, headache, sensation of cold</li> <li>Nausea, headache, sensation of cold</li> <li>Infiltrates at the injection site; See glucocorticoids (10)</li> <li>Dyspeptic disorders, lung atelectasis, respiratory distress, non-cardiogenic pulmonary edema, ovarian hyperstimulation syndrome, thromboembolic complications (11)</li> <li>Headache, depression, edema, premature puberty, gynecomastia (12)</li> </ol>	<ol> <li>Nausea, vomiting, arrhythmia and bradycardia (including the fetus), ↑ AD, bronchospasm (13)</li> <li>Nausea, abdominal pain, tachycardia (14)</li> <li>Hypertension, bradycardia, difficulty breathing (15)</li> </ol>
Contraindications	<ol> <li>Organic CNS damage, epilepsy (1)</li> <li>Age under 14 years (2)</li> <li>Pregnancy, lactation (3)</li> <li>Heart failure (4)</li> </ol>	<ol> <li>Hypersensitivity (5)</li> <li>Pregnancy, lactation, postmenopause (6)</li> <li>Androgen-dependent tumors, breast cancer, thromboembolism, genital bleeding, pregnancy, lactation (7)</li> </ol>	<ol> <li>Malignant neoplasms, pregnancy (8)</li> <li>Pregnancy, lactation (9)</li> <li>See glucocorticosteroids (10)</li> <li>High level of FSH in primary ovarian failure, decompensated thyroid and adrenal pathology, pituitary tumors (11)</li> <li>Bronchial asthma, epilepsy, hormone- sensitive tumors of genital organs (12)</li> </ol>	<ol> <li>Narrow pelvis, premature birth, threating uterine rupture, uterus after multiple births, AH (13)</li> <li>Polydipsia, anuria, unstable angina (14)</li> <li>Anuria, epilepsy, pregnancy (15)</li> </ol>

**Thyroid and antithyroid drugs** Thyroid drugs - preparations of thyroid hormones (TG). Antithyroid drugs - drugs that supress biosynthesis of thyroid hormones.

	Thyroid drugs		
Classification	T4 drugs	T3 drugs	Antithyroid drugs
Drugs	L-thyroxine (eutiroks, levothyroxine) Iodothyrox (levothyroxine sodium + potassium iodide)	3. Lyotyronin	<ul><li>4. Thiamazole (Mercazolil, tyrosol)</li><li>5. Propylthiouracil</li></ul>
Mechanism of action	Receptor binding to the genome, a change in oxidative metabolism in the mitochondria		Thyroid peroxidase is blocked and iodination of thyronine in T4 in T3 is inhibited.
Pharmacological effect	In small doses - anabolic, in moderate - ↑ activity of the cardiovascular system and tissues oxygen demand, in big - oppression of thyrotropin-releasing hormone and thyroid-stimulating		↓ T3and T4 levels in the blood
Indications for use	1. Hypothyroidism       7. Hypothyroid obesity         2. Euthyroid goiter       3. Autoimmune thyroiditis         4. Substitution therapy after surgical treatment of thyroid cancer         5. Myxedema (3)         6. Cretynism (3)		<ol> <li>Thyrotoxicosis</li> <li>Preparation for resection of thyroid gland or treatment</li> <li>Postoperative relapse of thyrotoxicosis (4)</li> <li>Nodular goiter (4)</li> </ol>
Side effects	<ol> <li>Arrhythmia</li> <li>Tachycardia</li> <li>Angina pectoris</li> <li>↑ temperature</li> <li>Anxiety, insomnia</li> </ol>		<ol> <li>Arthralgia</li> <li>Allergic reactions</li> <li>Suppression of myelopoiesis</li> <li>Dysfunction of the liver</li> <li>Vasculitis</li> <li>Hypothyroidism</li> </ol>
Contraindications	<ol> <li>Uncompensated pituitary or adrenal insufficiency</li> <li>Thyrotoxicosis</li> <li>Acute myocardial infarction</li> <li>Myocarditis</li> <li>Pancarditis</li> <li>Cachexia (3)</li> </ol>		<ol> <li>Hypersensitivity</li> <li>Leukopenia, agranulocytosis</li> <li>Hypothyroidism</li> <li>Hepatic insufficiency</li> <li>Cirrhosis of the liver</li> <li>Active hepatitis</li> <li>Cholestasis (4)</li> <li>Pregnancy, lactation</li> </ol>

#### Parathyroid and antiparatyroid drugs

#### **Parathyroid drugs** — drugs that make up the deficit of parathyroid (PTG) hormones. **Antiparatyroid drugs** — drugs that exert a retarding effect on the biosynthesis of PTG hormones.

Classification	Parathyroid drugs	Antiparatyroid drugs
Drugs	<ol> <li>Calcitonin (myacalcin, fortical)</li> <li>Parathyroid hormone (natpara)</li> </ol>	3. Cinacalcet (sensipar, mimpara)
Mechanism of action	<ol> <li>Inhibits the activity of osteoclasts, promotes bone mineralization due to the transition of Ca<sup>2+</sup> from the blood to the bone (1)</li> <li>↑ absorption of Ca<sup>2+</sup> in the intestine, promotes the release of Ca<sup>2+</sup> from bones (2)</li> </ol>	Calcium-mimetic action - ↑ sensitivity of PTG receptorsto calcium
Pharmacological effect	<ol> <li>Hypocalcemic, inhibition of bone resorption, analgesic (1)</li> <li>Hypercalcemic, increased bone resorption, stimulation of the formation of vit. D3 (2)</li> </ol>	Hypocalcemic, ↓ level of parathyroid hormone
Indications for use	<ol> <li>Prevention of osteoporosis, Paget's disease of bone (osteitis deformans), hypercalcemia, algodystrophy (1)</li> <li>Tetania, spasmophilia, bronchial asthma, urticaria, vasomotor rhinitis, hay fever, other allergic conditions (2)</li> </ol>	<ol> <li>Secondary hyperparathyroidism in dialysis patients with chronic renal failure</li> <li>Hypercalcemia from pancreatic carcinoma</li> <li>Primary hyperparathyroidism in the absence of parathyroidectomy</li> </ol>
Side effects	<ol> <li>Nausea, vomiting, dizziness, flush of the face accompanied by a sense of heat (1)</li> <li>General weakness, lethargy, vomiting and diarrhea, bone resorption and hyperplasia of fibrous tissue (2)</li> </ol>	<ol> <li>Secondary hyperparathyroidism in dialysis patients with chronic renal failure</li> <li>Hypercalcemia from pancreatic carcinoma</li> <li>Primary hyperparathyroidism in the absence of parathyroidectomy</li> </ol>
Contraindications	<ol> <li>Hypersensitivity, hypocalcemia (1)</li> <li>Hypersensitivity, previous hypercalcemia, severe renal failure, bone metastases or bone tumors in anamnesis, pregnancy, lactation (2)</li> </ol>	<ol> <li>Hypocalcemia</li> <li>Anorexia</li> <li>Dizziness</li> <li>Nausea, vomiting</li> <li>Rash, myalgia</li> <li>Asthenia</li> </ol>

#### Insulins and synthetic hypoglycemic agents

Classification	Insulins	Oral hypoglycemic agents
Drugs	Rapid-actingLong-actingLispro (Humalog)- insulin glargine (Lantus, Basaltag)Aspart (Novolog)- insulin determir (Levemir)Glulisine (Apidra)- insulin deglutec (Tresiba)Short-actingPre-mixedRegular (R) or Novolin- Humulin 70/30Velosulin (for insulin pump)- Novolin 70/30Intermediate-acting- Novolog 70/30NPH (neutral protamineHagedorn)- Humulin 50/50	Sentesizers       Secretagogues         Biguanides       Sulphonilureas         Metformine       Ist generation (tolbutamide, tozalamide)         Buformine       IInd generation (gliclazide, glipizide, gliquidone)         Thiazolidinedione (glitazones)       Non-sulphonilurea secretagogues (meglitinides)         Rosiglitazone       - meglitinide         Pioglitazone       - repaglinide         Troglitazone       - repaglinide         Glucosurics(gliflozins)       Glucagon-like peptide analogues         Sergliflozine       - exanatide         Remogliflozin       - liraglutide
		Alpha-glucosides inhibitors       Dipeptidyl peptidase-4 inhibitors(gliptins)         Acarbose       - alogliptin         - sitagliptin       - sitagliptin
Mechanism of action	Binding to insulin receptors, inclusion in the cytoplasmic membrane of intracellular vesicles with glucose transfer proteins, transport of glucose to the cell.	Sentesizers: ↑ uptake of glucose by the periphery. Secretagogues, gliptin, glucagon-like peptide analogues: ↑ insulin output from the pancreas. Glucosurics: block the re-uptake of glucose in the renal tubules, promoting loss of glucose in the urine. Alpha-glucosides inhibitors: slow the digestion of starch in the small
Pharmacological effect	<ol> <li>Hypoglycemic</li> <li>Anabolic (enhancing the synthesis of proteins and fats)</li> <li>Anticatabolic (\$\protein hydrolysis and lipolysis)</li> </ol>	1. Hypoglycemic
Indications for use	<ol> <li>Type 1 diabetes mellitus</li> <li>Type 2 diabetes mellitus (resistance to oral hypoglycemic agents, intercurrent diseases, pregnancy)</li> </ol>	<ol> <li>Type 2 diabetes mellitus</li> <li>Obesity (14–18)</li> </ol>
Side effects	<ol> <li>Hypoglycemia 2. Visual impairment</li> <li>Lipodystrophy in the injection site.</li> </ol>	<ol> <li>Hypoglycemia 2. Nausea, vomiting</li> <li>Diarrhea</li> </ol>
Contraindications	1. Hypoglycemia, 2. Hypersensitivity	<ol> <li>Type 1 diabetes mellitus</li> <li>Diabetic ketoacidosis 3. Dysfunction of the liver and kidneys</li> </ol>
NB!	<ul> <li>Rules for insulin administration:</li> <li>Short-acting insulin: 30 minutes before meals.</li> <li>intermediate-acting insulin: 45-60 minutes before meals. (Both types - to simulate stimulated secretion of insulin)</li> <li>Long-acting insulin: once a day to simulate the basal secretion of insulin.</li> </ul>	

Hypoglycemic agents are drugs used to normalize blood glucose levels in diabetes mellitus.

Classification	Adrenal cortex hormones	Adrenal medulla hormones
Drugs	Mineralocorticoids Fludrocortisone (florinef) Glucocorticoids (see below) Sex hormones (see below)	<ul><li>2. Adrenaline</li><li>3. Noradrenaline</li></ul>
Mechanism of	$\uparrow$ reabsorption of Na + and water in the distal part of the renal tubules	1. Stimulation of $\alpha$ and $\beta$ -adrenergic receptors
action	$\uparrow$ secretion of K + and H +.	2. Stimulation of $\alpha 1$ and $\alpha 2$ -adrenoreceptors, weakly — $\beta 1$ -adrenergic receptors
Pharmacological effect	<ol> <li>Water and sodium retention in the body</li> <li>↑ Blood pressure</li> <li>↓ synthesis of ACTH</li> </ol>	<ol> <li>Spasm of peripheral vessels</li> <li>↑ blood pressure</li> <li>Tachycardia (1)</li> <li>Bronchodilation (1)</li> <li>↓ intraocular pressure (1)</li> <li>Bradycardia (2)</li> </ol>
Indications for use	<ol> <li>Primary and secondary adrenal insufficiency</li> <li>Adrenogenital syndrome</li> <li>Hypovolemia</li> <li>Arterial hypotension</li> </ol>	<ol> <li>Immediate type allergic reaction, bronchospasm, asystole, arterial hypotension, hypoglycemia, glaucoma, bleeding from the surface vessels. Prolongation of the action of anesthetics in combined application (2)</li> <li>Acute ↓ blood pressure (3)</li> </ol>
Side effects	<ol> <li>Arterial hypertension</li> <li>Peripheral edema</li> <li>Hypokalemia</li> </ol>	<ol> <li>Angina pectoris, arrhythmia, psychomotor agitation, nausea, vomiting, hypokalemia (2)</li> <li>Bradycardia, myocardial ischemia (3)</li> </ol>
Contraindications	1. Systemic mycoses	<ol> <li>Hypertrophic obstructive cardiomyopathy, pheochromocytoma, arterial hypertension, tachyarrhythmia, IHD, ventricular fibrillation, pregnancy (2)</li> <li>Thrombosis of mesenteric and peripheral vessels (as causes their constriction), pronounced hypoxia and hypercapnia (3)</li> </ol>
	Rellog	

## Adrenal gland hormones

#### Glucocorticoids

## Glucocorticoids are steroid hormones synthesized by the adrenal cortex, and their synthetic analogs.

Drugs       1. Cortisone       3. Prednisolone       6. Beclomethasone         Mechanism of action       They interact with nuclear receptors that regulate the transcription of genes, and change the synthesis of proteins and enzymes.         Mechanism of action       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of proteins and enzymes.         Pharmacological effect       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of proteins and leukotrienes. Immunosuppressive: ↓ activity of leukocyte: and tissue macrophages, ↓ lymphocytes count. Antiexulative, antiproliferative effects. Anti-shock effect         Pharmacological effect       Anti-inflammatory: inhibition of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Suching's syndrome         2. Type 2 diabetes mellitus       7. Phycroagulation       9. Growth retardation in children	Classification	Natural	Synthetic	
Drugs       2. Hydrocortisone       4. Methylprednisolone       7. Fluticazone         Mechanism of action       They interact with nuclear receptors that regulate the transcription of genes, and change the synthesis of proteins and enzymes.         Pharmacological effect       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of prostaglandins and leukotrienes. Immunosuppressive: ↓ activity of leukocyte: and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Pharmacological effect       Anti-inflammatory: inhibition of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Cushing's syndrome         2. Type 2 diabetes mellitus       9. Growth retardation in children		1. Cortisone	3. Prednisolone 6. Beclomethasone	
Mechanism of action       5. Triamcinolone       8. Budesonide         Mechanism of action       They interact with nuclear receptors that regulate the transcription of genes, and change the synthesis of proteins and enzymes.         Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of prostaglandins and leukotrienes. Immunosuppressive: ↓ activity of leukocyte: and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Suppression of fibroblasts and collagen synthesis.       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         I. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       8. Hypercoagulation         9. Growth retardation in children       9. Growth retardation in children	Drugs	2. Hydrocortisone	4. Methylprednisolone 7. Fluticazone	
Mechanism of action       They interact with nuclear receptors that regulate the transcription of genes, and change the synthesis of proteins and enzymes.         Pharmacological effect       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of prostaglandins and leukotrienes. Immunosuppressive: ↓ activity of leukocytes and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Suppression of fibroblasts and collagen synthesis.       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency 3. Prevention of tranplant rejection 4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema) 5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         Indications for use       1. Steroid ulcers 5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         Indications for use       1. Steroid ulcers 5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         Indications for use       1. Steroid ulcers 7. Cushing's syndrome 8. Hypercoagulation 9. Growth retardation in children	_		5. Triamcinolone 8. Budesonide	
action       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of prostaglandins and leukotrienes. Immunosuppressive: ↓ activity of leukocytes and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Pharmacological effect       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       6. Allergic diseases         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, crebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       9. Growth retardation in children	Mechanism of	They interact with nuclear receptors that regulate the transcription of genes, and chang	the synthesis of proteins and enzymes.	
Pharmacological       Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of prostaglandins and leukotrienes. Immunosuppressive: ↓ activity of leukocyte: and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Suppression of fibroblasts and collagen synthesis.       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, 9. Malignant tumors anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Cushing's syndrome         8. Hypercoagulation       9. Growth retardation in children	action			
Pharmacological       and tissue macrophages, ↓ lymphocytes count. Antiexudative, antiproliferative effects. Anti-shock effect         Suppression of fibroblasts and collagen synthesis.       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen.         Catabolic: in the connective, bone, lymphoid tissue.       ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Cushing's syndrome         8. Hypercoagulation       9. Growth retardation in children		Anti-inflammatory: inhibition of phospholipase A2, inhibition of the synthesis of pros	taglandins and leukotrienes. Immunosuppressive: $\downarrow$ activity of leukocytes	
Pharmacological effect       Suppression of fibroblasts and collagen synthesis. Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		and tissue macrophages, $\downarrow$ lymphocytes count. Antiexudative, antiproliferative effects.	Anti-shock effect	
effect       Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen. Catabolic: in the connective, bone, lymphoid tissue. ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       9. Malignant tumors         10. Gout       5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children	Pharmacological	Suppression of fibroblasts and collagen synthesis.		
Catabolic: in the connective, bone, lymphoid tissue.         ↑ secretion of ACTH, FSH, TTG.↑ brain excitability.↑ production of hydrochloric acid and pepsin.         Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children	effect	Anabolic: stimulation of gluconeogenesis, lipogenesis. Deposition of glycogen.		
Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         2. Acute adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		Catabolic: in the connective, bone, lymphoid tissue.		
Indications for use       1. Chronic adrenal insufficiency       6. Allergic diseases         1. Chronic adrenal insufficiency       7. Bronchial asthma         3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       9. Malignant tumors         anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		$\uparrow$ secretion of ACTH, FSH, TTG. $\uparrow$ brain excitability. $\uparrow$ production of hydrochloric acid	and pepsin.	
Indications for use       2. Acute adrenal insufficiency       7. Bronchial asthma         Indications for use       3. Prevention of tranplant rejection       8. Severe inflammatory processes         4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       9. Malignant tumors         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Cushing's syndrome         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		1. Chronic adrenal insufficiency       6. Allergic diseases		
Indications for use       3. Prevention of tranplant rejection       8. Severe inflammatory processes         use       4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       9. Malignant tumors         anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)       7. Cushing's syndrome         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		2. Acute adrenal insufficiency 7. Bronchial asthma		
use       4. Emergencies (asthmatic status, collapse, anaphylactic shock, cerebral edema)       9. Malignant tumors         anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children	Indications for	3. Prevention of tranplant rejection 8. Severe inflammatory processes		
anaphylactic shock, cerebral edema)       10. Gout         5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children	use	4. Emergencies (asthmatic status, collapse, 9. Malignant tumors		
S. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)         1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		anaphylactic shock, cerebral edema) 10. Gout	<b>1 1 1 1 1 1</b>	
1. Steroid ulcers       7. Cushing's syndrome         2. Type 2 diabetes mellitus       8. Hypercoagulation         3. Hypertension       9. Growth retardation in children		5. Autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, vasculites, polymyosites, dermatopolymyosites)		
2. Type 2 diabetes mellitus 3. Hypertension 9. Growth retardation in children		1. Steroid ulcers 7. Cushing's syndr	rome	
Side effects 9. Growth retardation in children		2. Type 2 diabetes mellitus 8. Hypercoagulat	10n	
	Side effects	3. Hypertension 9. Growth retarda	ation in children	
4. Immunosuppression and attachment of secondary infection 10. Hypokalemia		4. Immunosuppression and attachment of secondary infection 10. Hypokalemia		
5. Poor healing of wounds, striae ( July history of constants) ( July his		5. Poor healing of wounds, striae 11. Arrhythmias,	seizures	
6. Inhibition of adrenal function 12. Hallucinations, psychosis		6. Inhibition of adrenal function 12. Hallucination	s, psychosis	
1. Viral, fungal, bacterial diseases 5. Myasthenia gravis Absolute: intolerance.		1. Viral, fungal, bacterial diseases 5. Myasthenia gravis	Absolute: intolerance.	
2. Acid-dependent diseases of the digestive 6. Glaucoma Relative: tuberculosis, viral infections, acute myocardial infarction	Contracting Providence	2. Acid-dependent diseases of the digestive 6. Glaucoma	Relative: tuberculosis, viral infections, acute myocardial infarction	
Contraindications tract /. Immune deficiency (scar rupture is possible), psychosis, epilepsy, peptic ulcer, diabetes mallitus	Contraindications	Tract 7. Immune deficiency 2. Disketes mellitus	(scar rupture is possible), psychosis, epilepsy, peptic ulcer, diabetes	
5. Diabetes mentus     8. Infomoophine conditions       4. Thyrotoxicosis, hypothyroidism		5. Diabetes mentus     8. Infomoophine conditions       4. Thyrotoxicosis, hypothyroidism	mennus.	
$= \frac{1}{2}$		Faujualant dagaa of CCa: 5 mg of produisalana = 25 mg of cortigona = 20 mg of hudroa	articono = 1 ma of mothulnradnicalono = 1 ma of triamoinalono = 0.75 ma	
Equivalent doses of GCs. 5 mg of predinsoione – 25 mg of corusone – 20 mg of nydrocorusone – 4 mg of methylpredinsoione – 4 mg of uraniciholone – $0.75$ mg of devanethasone		Equivalent doses of GCs. 5 mg of predinsolone – 25 mg of cordsone – 20 mg of hydroco of devamethasone = $0.75$ mg of betamethasone	-4  mg of the model of the matrix of t	
Glucocorticoid treatment regimens to prevent adrenal supression:		Glucocorticoid treatment regiments to prevent adrenal supression:		
<b>NB!</b> Alternate day therapy — treatment once in every 28 hours. Prednisolone or methylprednisolone in the morning:	NRI	Alternate day therapy treatment once in every 28 hours. Prednisolone or methylni	eduisalane in the marning:	
- Intermittent therapy — short-term therapy (3-4 days) with 4-day breaks between courses:	110.	- Intermittent therapy — cleatment once in every 20 hours. I realisoione of methyppi	urses.	
-Pulse therapy — short-term high-dose (250 mg-1 g of methylprespisolone) urgent therapy. The drug of choice is methylpredpisolone because it better enters		- Pulse therapy — short-term high-dose (250 mg-1 g of methylprespisolone) urgent th	erany. The drug of choice is methylprednisolone because it better enters	
inflamed tissues and less often causes side effects)		inflamed tissues and less often causes side effects)	erupy. The drug of choice is methylpreditionone bedduse it better effers	

Classification	Estrogens	Anti-estrogens	Gestagens	Antigestagens
Drugs	<ol> <li>Estriol</li> <li>Estradiol</li> <li>Ethinylestradiol (see <i>Hormonal contraception</i>)</li> </ol>	<ol> <li>Tamoxifen</li> <li>Toremifene</li> <li>Fulvestrant</li> </ol>	<ol> <li>7. Dienogest</li> <li>8. Dydrogesterone</li> <li>9. Progesterone</li> <li>10. Norethisterone</li> <li>11. see Hormonal contraception</li> </ol>	12. Mifepristone
Mechanism of action	Binding to estrogen receptors (in the uterus, vagina, mammary gland, liver, hypothalamus, ovaries), changes in the gene transcription and protein synthesis	Competitive binding to estrogen receptors in the target organs	Binding to progesterone receptors in the endometrium	Competitive blockage of progesterone receptors
Pharmacological effect	<ol> <li>Growth and differentiation of the vaginal epithelium</li> <li>Stimulation of the development of secondary sexual characteristics</li> <li>Proliferation of the endometrium</li> <li>↓ lactation</li> <li>↓ bone resorption</li> <li>Antimineralocorticoid, antiandrogenic effects (3)</li> </ol>	<ol> <li>↑ secretion of gonadotropins (prolactin, FSH, LH), stimulation of ovulation (small doses)</li> <li>2. ↓ secretion of gonadotropins and ovulation (large doses)</li> </ol>	↓ uterine excitability during pregnancy Endometrium progress to a secretory phase (cessation of proliferation, transition of the uterine mucosa from the proliferative phase to the secretory one)	<ol> <li>↑ contractile activity of myometrium</li> <li>2. Desquamation of the decidua of the uterus, fertilized egg is expelled</li> </ol>
Indications for use	<ol> <li>Atrophy of the vaginal mucosa due to estrogen deficiency (1)</li> <li>Amenorrhea, menopause, postmenopausal osteoporosis;</li> <li>Substitution therapy after ovarian excision (2)</li> <li>Contraception, acne, severe form of PMS (3)</li> </ol>	Estrogen-dependent tumors: 1. Breast Cancer 2. Breast cancer in men after castration (4–5) 3. Kidney cancer (4–5) 4. Melanoma (4–5) 5. Ovarian cancer (4–5) 6. Prostate cancer (4–5)	<ol> <li>Endometriosis (7, 8)</li> <li>Threatening miscarriage (8)</li> <li>Dysmenorrhea (8) dysfunctional uterine bleeding (8)</li> <li>Progesterone deficiency (9), infertility (9)</li> <li>PMS (10)</li> <li>Mastodinia (9, 10)</li> </ol>	<ol> <li>Early medical abortion (up to 42 days amenorrhea)</li> <li>Induction of labor 3. Emergency postcoital contraception (up to 72 hours)</li> <li>Leiomyoma of the uterus</li> </ol>
Side effects	<ol> <li>Libido changes</li> <li>Soreness of the mammary glands</li> <li>Uterine and vaginal bleeding</li> <li>Fluid retention</li> </ol>	<ol> <li>Thrombosis</li> <li>Fluid retention</li> <li>Dysmenorrhea</li> <li>↑ risk of proliferative changes in the endometrium</li> <li>Dyspepsia</li> </ol>	<ol> <li>Acne</li> <li>Fluid retention</li> <li>↑ body weight</li> <li>Dysmenorrhea</li> </ol>	<ol> <li>Bleeding</li> <li>Pain in the lower abdomen</li> <li>Inflammation of the uterus and appendages</li> <li>Dysmenorrhea, amenorrhea</li> <li>Violation of hemostasis</li> </ol>
Contraindications	<ol> <li>Thrombosis</li> <li>Estrogen-dependent tumors</li> <li>Pregnancy, lactation</li> </ol>	<ol> <li>Pregnancy, lactation</li> <li>Tumor or pituitary insufficiency</li> </ol>	<ol> <li>Depression, insomnia</li> <li>Thrombosis</li> <li>Hormone-dependent tumors</li> <li>Uterine bleeding</li> </ol>	<ol> <li>Adrenal insufficiency</li> <li>Long-term GCs intake</li> <li>Renal and / or hepatic impairment</li> <li>The scar on the uterus</li> <li>Inflammatory diseases of female genital organs</li> </ol>

## Female sex hormones and their antagonists

#### Hormonal contraception

Classification	Gestagens	Combined_oral_contraceptive_pills (estrogen+gestagen)
Drugs	Progestogen-only pills «Exluton» (lynestrone) 2. «Cerazette», «Lactinette» (desogestrel) Injection «Depo-provera» (Medroxyprogesterone) Birth-controle implants «Implanon» (etonogestrel) Hormone-releasing intrauterine systems «Mirena» (levonorgestrel) Morning after pills (post-coital, emergency contraception) «Postinor», «I-pill», «Plan B» (levonorgestrel)	Monophasic         «Loestrin» (ethinyl estradiol + norethindrone acetate)         8. «Yasmin» (drospirenone / ethinyl estradiol)         Biphasic         «Aranelle» (norethindrone / ethinyl estradiol)         «Mircette» (desogestrel / ethinyl estradiol)         Triphasic         11. «Tri-Levlen» (levonorgestrel / ethinyl estradiol)         12. «Tri-Sprintec» (norgestimate / ethinyl estradiol)         13. «Triphasil» (levonorgestrel / ethinyl estradiol)         4-phasic         14. «Qlaira» (dienogest / estradiol valerate)
Mechanism of action	See the table "Female sex hormones and their antagonists"	
Pharmacological	1. Suppression of ovulation, $\uparrow$ mucus viscosity of the cervix, oppression of the transport function of the fallopian tubes (1–4, 6–13)	
effect	2. ↓ Implantation properties of the endometrium, thickening of the mucous cervical canal (5, 6)	
Indications for use	Contraception Polycystic ovary syndrome Anovulatory infertility (stimulation of superovulation upon cano Painful menstruation PMS	cellation)
Side effects	<ol> <li>Dysmenorrhea</li> <li>Lability of mood</li> <li>Change in body weight</li> <li>Pain of the mammary glands</li> <li>Change in libido</li> </ol>	<ol> <li>Change in libido</li> <li>Pain in the mammary glands</li> <li>Uterine and vaginal bleeding</li> <li>Fluid retention</li> <li>Acne</li> <li>↑ body weight</li> <li>Dysmenorrhea</li> </ol>
Contraindications	<ol> <li>Thromboembolism</li> <li>Progesterone and estrogen-dependent tumors</li> <li>Uterine and vaginal bleeding</li> </ol>	<ol> <li>Thromboembolism</li> <li>Progesterone and estrogen-dependent tumors</li> <li>Uterine and vaginal bleeding</li> </ol>
NB!		<ul> <li>Features of the composition of combined contraceptives:</li> <li>Monophasic - all tablets have the same content of estrogens and progestins.</li> <li>Biphasic - ↑ the progestogen content of the drug in the second phase of the menstrual cycle.</li> <li>Triphasic - ↑ dose of progestogen in tablets occurs in 3 stages. These mimics the level of hormones in the physiological menstrual cycle.</li> </ul>

Hormonal contraceptives are synthetic analogues of female sex hormones preventing pregnancy.

#### Androgens and their antagonists

Androgens are preparations of male sex hormones.

Androgens a	Androgens are preparations of male sex normones.			
Classification	Androgens	Antiandrogens		
Drugs	<ol> <li>Testosterone (andriol, androgel, nebido)</li> <li>Mesterolon (proviron)</li> <li>Testosterone esters (sustanon)</li> </ol>	Androgen recertor antagonistsAndrogen synthesis inhibitors         7. Abiraterone (Zytiga)         SteroidalEstrogens         4. Cyproterone (Androcur, Diane) Gonadotropin releasing hormone         analogues         Non-steroidalAntigonadotropins Progestogens         5. Flutamide (Eulexin)(see below)         6. Bicalutamide (Casodex)		
Mechanism of action	Binding to androgen receptors of target cells	<ol> <li>Inhibition of the enzyme CYP17 converting pregnenolone and progesterone into testosterone precursors (7)</li> <li>Competitive binding to tissue receptors of androgens in target organs (4–6)</li> </ol>		
Pharmacological effect	<ol> <li>Anabolic: stimulation of protein synthesis, potassium retention and calcium fixation in bones.</li> <li>↑ reabsorption of sodium.</li> <li>Maintaining the male phenotype and androgen-dependent functions (spermatogenesis, sex glands)</li> </ol>	Antiandrogenic		
Indications for use	Hormone replacement therapy of hypogonadism (1, 2, 3) In men: psycho-vegetative disorders, ↓ performance, potency disorders, infertility, aplastic anemia. (2) In men: impotence of endocrine genesis, post-stroke syndrome, oligospermia, hypo-androgenic osteoporosis. In women: hormone-dependent tumors, menopause, functional bleeding in hyperestrogenism, uterine fibroids (3)	<ol> <li>Prostate cancer</li> <li>Hirsutism</li> <li>Androgenic alopecia in women, acne and / or seborrhea</li> </ol>		
Side effects	1. Hypercalcemia       5. Priapis         2. Thrombophlebitis       6. Acne         3. Vyrilization       7. Diarrhea         4. ↑ libido	<ol> <li>Hepatotoxicity, dyspepsia, fractures, arterial hypertension, hypokalemia, hypertriglyceridemia, heart failure, angina pectoris, arrhythmias</li> <li>Change in body weight, suppression of spermatogenesis, gynecomastia, depression</li> <li>Diarrhea, jaundice, hepatitis</li> </ol>		
Contraindications	<ol> <li>Prostate or breast cancer</li> <li>Liver tumors</li> <li>Hypercalcemia</li> </ol>	<ol> <li>Severe liver dysfunction</li> <li>Cachexia, severe depression, thromboembolism, decompensated diabetes mellitus, pregnancy</li> <li>Severe kidney and thyroid disease</li> </ol>		

#### Anabolic steroids

Preparations that simulate the action of testosterone and have a pronounced anabolic effect.

Classification	Androstane derivatives	Estrene derivatives
Drugs	<ol> <li>Methandrostenolone (dianabol, danabol, naposim)</li> <li>Turinabol</li> <li>Oxymetholone (anapolone, anadrol)</li> <li>Boldenon (equipoz, boldabol)</li> </ol>	<ul><li>5. Nandrolone (retabolil, deca-durabolin)</li><li>6. Trenbolone (tren, parabolane)</li></ul>
Mechanism of action	Binding to androgen receptors of target cells	
Pharmacological effect	<ol> <li>Anabolic: increase in muscle mass, ↑ red blood cells count, fixation of calcium in bone tissue, ↓ fat stores, ↑ appetite.</li> <li>Androgenic: masculinization, virilization, hair loss on the head and ↑ their growth on the body, ↑ libido.</li> </ol>	
Indications for use	<ol> <li>Cachexia, asthenia</li> <li>Osteoporosis</li> <li>Chronic liver and kidney disease</li> <li>Reconvalence period after severe injuries, surgeries, burns</li> <li>Severe infectious diseases accompanied by loss of protein</li> <li>Correction of catabolic effects of glucocorticoids</li> <li>Progressive muscular dystrophy.</li> </ol>	
Side effects	<ol> <li>↑ libido</li> <li>↑ Blood pressure</li> <li>Acne</li> <li>Edema</li> <li>Hypertrophy of the prostate, testicular atrophy</li> <li>Gynecomastia</li> <li>Masculinization</li> <li>Hepatotoxicity</li> <li>Hypertrophy of the myocardium and ischemia</li> <li>Irritability ("roid rage")</li> </ol>	
Contraindications	<ol> <li>Prostate Cancer</li> <li>Acute liver disease</li> <li>Decompensated diabetes mellitus</li> <li>Acute and chronic prostatitis</li> <li>Pregnancy, lactation</li> <li>The pubertal age.</li> </ol>	

# 7. ANTIOXIDANS. VITAMINS.ENZYMES AND ANTI-ENZYMES

Vitamins are exogenous organic substances of various chemical structures necessary for normal metabolism maintaining.

#### **Fat-soluble vitamins**

	Vitamin A, retinyl	Vitamin D, calciferols	Vitamin E, tocopherol	Vitamin K, naphthoquinones
Drugs	<ol> <li>Retinyl acetate, retinyl palmitate</li> <li>Beta-caroten</li> </ol>	<ol> <li>3. Ergocalciferol (D<sub>2</sub>)</li> <li>4. Cholecalciferol (D<sub>3</sub>)</li> <li>5. Calcitriol (D<sub>3</sub>)</li> </ol>	6. Tocoferol acetate	<ul> <li>7. Phytomemandione (K<sub>1</sub>)</li> <li>8. Menaquinone (K<sub>2</sub>)</li> <li>9. Menadione (K<sub>3</sub>, Vikasol)</li> </ul>
Mechanism of action	Bind to cytoplasmic receptors in the target tissues (muscles, heart, liver), penetrate into the nucleus and effect gens $\rightarrow$ synthesis of mucopolysaccarides, phospholipids and glycoproteins	↑ Calcium and phosphate absorption in the intestines and tissue transport	↓ free radical reactions; proteins and heme synthesis, tissue breathing, cells proliferation; some enzymes cofactor; ↓ unsaturated fatty acids oxidation	↓ prothrombin and proconvertin synthesis; ↑ blood coagulability due to ↑ in synthetases of II, VII, IX, X coagulating factors; take part in CPK and ATP synthesis
Pharmacological effects	1. Regulation of: night vision; epithelial tissue growth and differentiation; calcium and phosphate metabolism	Regulation of calcium and phosphate metabolism	<ol> <li>Regulation of: Reproductive system Muscles metabolism;</li> <li>Antioxidant and regenerative action.</li> </ol>	Anti hemorrhagic action
Indications for use	Hypo- and avitaminosis Xerophthalmia Intertrigo, burns, skin diseases Rickets (in combination with vitamin D)	Hypocalcaemia, hypophosphatemia Rickets, osteodistrophy, tetany seizures Hypocalcaemia prevention in patients undergoing artificial kidney apparatus hemodialysis	Anemia Dermatitis, hair loss Miscarriage risk Cardiac disease, bursitis, liver steatosis. 5. Improving of physical and sexual activity	Warfarin-induced bleeding (7) Hemorrhagic disease of newborn (prevention and treatment)
Side effects	Drowsiness, slackness, headache Nausea, vomiting, irritability, lower extremities bone pain Nephro- and hepatotoxicity In children: skin rush, hyperthermia, sweating, increased cerebrospinal fluid pressure with bulging fontanelles and hydrocephaly development	appetite, nausea, headache Weakness, irritability, insomnia Hyperthermia, nephrotoxicity, soft tissues calcification	<ol> <li>Muscle weakness, trembling</li> <li>Reduction of reproductive function</li> <li>Disorders of the gastrointestinal tract</li> </ol>	↓ in blood cougulability (bleeding)
Contraindications	1. Pregnancy (teratogenicity).	Hypercalcemia, hyperphosphatemia Pregnancy (suppresses parathyroid function of fetus)	<ol> <li>Hypersensitivity</li> <li>Cardiosclerosis, myocardial infarction</li> </ol>	1. Hypersensitivity2. Cholestatic jaundice3. The tendency tothromboembolism andthrombosis, increased bloodcoagulability

	Vitamin B1, thiamine	Vitamin B2, riboflavin	Vitamin B3, PP, nicotinic acid	Vitamin B5, pantothenic acid
Drugs	<ol> <li>Thiamine hydrochloride</li> <li>Thiamine pyrophosphate (co-carboxylase)</li> </ol>	3. Riboflavin	<ul><li>4. Nicotinic acid</li><li>5. Nicotinamide</li><li>6. Xanthinal nicotinate</li></ul>	<ul><li>7. Calcium pantothenate</li><li>8. Dexpanthenol</li></ul>
Mechanism of action	It is decarboxylase co-enzyme (oxidative decarboxylation of α-keto acids, pyruvate) and transketolase (pentose phosphate pathway of glucose breakdown)	As a part of the FMN and FAD participates in the transport of electrons in the respiratory chain, deamination of amino acids, oxidative phosphorylation	As parts of NAD and NADP are involved in glycolysis and gluconeogenesis, oxidation of substrates in the respiratory chain	In the structure of acetyl-CoA is involved in the processes of acetylation and oxidation, carbohydrate and lipid metabolism, the synthesis of acetylcholine, triglycerides and steroids
Pharmacological effects	Neuroprotective, cardiotrophic, hypoglycemic action, elimination of metabolic acidosis	Stimulates the development of the fetus, the division of the epithelium of the mucous membranes and eye tissues	Vasodilator, cardiotrophic, hepatoprotective, detoxicating, anticholesterolemic, hypoglycemic, ↑ microcirculation	↑ Tissue metabolism, contractile activity of the myocardium
Indications	<ol> <li>Vitamin deficiency</li> <li>Neuritis, radiculitis, neuralgia, paralysis</li> <li>Diabetes mellitus</li> <li>Dermatoses, itching, pyoderma, eczema, psoriasis</li> <li>Atony of the intestine</li> <li>Myocardial dystrophy, endarteritis</li> <li>Abstinence syndrome with alcoholism, drug addiction</li> </ol>	<ol> <li>Insufficiency of the vitamin</li> <li>Diseases of the eyes (hemostalopia, conjunctivitis, iritis, keratitis, corneal ulcers, cataracts)</li> <li>Non-healing wounds and ulcers</li> <li>Radiation sickness</li> <li>Asthenia</li> <li>Sprue, viral hepatitis</li> </ol>	<ol> <li>Pellagra</li> <li>Vascular spasm (obliterating endoarteritis, Raynaud's disease, migraine, etc.)</li> <li>Diseases of the gastrointestinal tract (hepatitis, cirrhosis, etc.)</li> <li>Neuritis of the facial nerve</li> <li>Hyperlipidemia (in high doses)</li> <li>Infectious diseases</li> </ol>	<ol> <li>Prevention of vitamin deficiency</li> <li>Polyneuritis, neuralgia, paresthesia</li> <li>Stress, depression</li> <li>Trophic ulcers, eczema, burns</li> <li>Malabsorption, atony of the intestine</li> <li>Abstinence syndrome with alcoholism, drug addiction</li> </ol>
Side effects	<ol> <li>A slight decrease in blood pressure</li> <li>Anaphylaxis (with intravenous administration), nausea, urticaria</li> <li>Painful injections due to low pH of the solution</li> </ol>	<ol> <li>Yellow-orange coloration of urine</li> <li>in subconjunctival administration - headache, dizziness, lacrimation</li> </ol>	<ol> <li>Flushing of the face and neck (increase in histamine release)</li> <li>Itching, dry skin</li> <li>Headache, dizziness, pain in the heart, hypotension</li> <li>Pain in the injection site.</li> </ol>	<ol> <li>Nausea, vomiting, heartburn</li> <li>Pain in the injection site</li> </ol>
Contraindications	Hypersensitivity	<ol> <li>Hypersensitivity</li> <li>Nephrolithiasis</li> </ol>	<ol> <li>Hypersensitivity</li> <li>Gastro duodenal ulcers</li> <li>Severe liver function disorders</li> <li>Gout, hyperuricemia</li> <li>Severe forms of hypertension (IV)</li> </ol>	1. Hypersensitivity

#### Water-soluble vitamins
Drugs	Vitamin B6, pyridoxine	Vitamin B9, Folic acid	Vitamin B12, cyanocobalamin	Vitamin C, Ascorbic acid	Vitamin R, Bioflavonoids
Diugs	<ol> <li>Pyridoxine hydrochloride</li> <li>Magnesium-B6</li> </ol>	3. Folic acid	<ol> <li>4. Cyanocobalamin</li> <li>5. Oxycobalamin</li> </ol>	6. Ascorbic acid	7. Rutozid 8. Ascorutin (6 + 7)
Mechanism of action	In the process of metabolism, they are converted into pyridoxalphosphate, which participates in many processes of nitrogen metabolism (trans-amination, deamination of amino acids, metabolism of tryptophan, serotonin, etc.)	In the process of metabolism, it is converted into tetrahydrofolic acid, which is necessary for meglobalasts forming and transformation into normoblasts. Participates in the exchange of purines and pyrimidines, amino acids, nucleic acids	Participates in the reducing of folic acid in tetra- hydrophilic, in the transfer of methyl fragments, which is necessary for the formation of methionine, choline, creatine, nucleic acids, maturation of erythrocytes	Regulates the transport of water in many biochemical reactions, improves the use of glucose in the Krebs cycle, and participates in the formation of THF, steroid hormones, collagen. Activates proteolytic enzymes, promotes phagocytosis	Reactivates the sulfhydryl groups of proteins and glutathione, vitamin C and tocopherol. Suppresses the activity of hyaluronidase.
Pharmacological effects	Neuroprotective, cardiotonic, hepatoprotective, antihypoxic, anti- cholesterolemic, stimulation of erythro- and leucopoiesis	Hematopoietic, anti-anemic, metabolic, regenerative	Hematopoietic, anti-anemic, metabolic, regenerative, influence on conduction of nerve impulse, immunostimulating, hepatoprotective, hypocholesterolemic	Metabolic, regulation of oxidation-reduction processes, antioxidant, regenerative, immunotropic, anti-inflammatory, antiallergic	Angioprotective (reduces permeability of capillaries, swelling, inflammation, strengthens the vessel wall, inhibits aggregation), antioxidant
Indications	<ol> <li>Vitamin deficiency</li> <li>Isoniazid intake</li> <li>Hypochromic anemia, leukopenia</li> <li>Parezy, paralysis, neuritis, neuralgia</li> <li>Hepatitis, cholecystitis</li> <li>Skin diseases</li> </ol>	<ol> <li>Megaloblastic anemia</li> <li>Hypo-and avitaminosis (sprue, pregnancy, etc.)</li> <li>Drug and radiation anemia</li> </ol>	<ol> <li>Hypo-and avitaminosis         <ul> <li>(sprue, pregnancy, etc.)</li> <li>Chronic anemia</li> <li>(megaloblastic anemia, aplastic, etc.)</li> <li>Diseases of the nervous system (neuralgia, polyneuritis, diabetic neuropathy, etc.)</li> <li>Skin diseases (psoriasis, photodermatitis, etc.)</li> <li>Chronic hepatitis, liver cirrhosis</li> </ul> </li> </ol>	<ol> <li>Hypovitaminosis</li> <li>Infectious diseases</li> <li>Alcohol and nicotinic intoxication</li> <li>Bleeding</li> <li>Metabolic and respiratory acidosis</li> </ol>	<ol> <li>Varicose veins</li> <li>Chronic venous insufficiency</li> <li>Lymphostasis</li> <li>Diabetic retinopathy</li> <li>Radiation therapy</li> </ol>
Side effects	<ol> <li>Allergic reactions</li> <li>Redness of the skin, heat</li> </ol>	1. Allergic reactions (bronchospasm, erythema,	<ol> <li>Allergic reactions</li> <li>Nervous stimulation</li> </ol>	1. Irritation of the mucosa of the gastrointestinal tract	<ol> <li>Dyspeptic disorders</li> <li>Headache, pain</li> </ol>

#### Water-soluble vitamins (continued)

	sensation	fever, skin rashes)	3. Headache, head-spin	(nausea, vomiting, diarrhea)	3. Rashes on the skin
	3. Paresthesia, drowsiness	2. Dyspepsia	4. Pain in the heart,	2. Hyperglycemia, a	
	4. Burning and pain at the	3. In high doses - increased	arrhythmia (decrease in the	decrease in the synthesis of	
	injection site	excitability of the central	level of K <sup>+</sup> )	insulin	
	5. Increased gastric acidity	nervous system (up to		3. Urolithiasis	
		seizures)		4. Increased blood clotting	
				5. Headache, tachycardia	
				6. Ulcerogenicity	
	1. Hypersensitivity	1. Hypersensitivity	1. Hypersensitivity	1. Hypersensitivity	1. Hypersensitivity
			2. Hyper coagulation	2. Thrombophlebitis, a	2. Pregnancy (I trimester)
Contraindications			(including acute thrombosis)	tendency to thrombosis	
			3. Erythremia, erythrocytosis	3. Diabetes mellitus (in high	
				doses and long-term use)	
	Take into account physico-che	emical incompatibility of vitam	ins when prescribing a combina	ition. Vitamins B <sub>1</sub> , B <sub>6</sub> , B <sub>12</sub> , PP	and C cannot be mixed in the
	same syringe, as they are destroyed or oxidized. Vitamin overdose: vitamin A — adsorbents, vitamin C, hepatoprotectors, diuretics, glucocorticoids; vitamin				
NRI	D — glucocorticoids, vitamins A and E, sodium sulfate, Na2-EDTA, insulin + glucose, symptomatic therapy; vitamin E — plasma substitution solutions,				
IND;	antihypertensive, hepatoprotec	tors. The most severe complicat	ion of vitamin therapy is anaphy	lactic shock (B <sub>1</sub> , B <sub>6</sub> , B <sub>12</sub> , PP, and	1 C).
	Preference is given in most cas	ses to multivitamin preparations	. In practice, multivitamins are u	used for combined use in order to	o provide a more powerful and
	versatile action.				

Enzyme and antienzyme agents Read study guide for the topic «Drugs affecting digestive system».

.rudy <sub>b</sub>

# 8. ANTIINFLAMMATORY AND ANTIGOAT DRUGS. ANTI-ALLERGIC DRUGS. IMMUNOMODULATORS

**NSAIDs** are drugs with anti-inflammatory, antipyretic and analgesic effects.

Classification	Non-selective COX inhibitors	Preferential COX-2 inhibitors	Selective COX-2 inhibitors	Antipyretic analgesics		
Drugs	<ol> <li>Acetylsalicylic acid (Aspyrin)</li> <li>Diclofenac sodium (Voltaren, Orthofen)</li> <li>Ibuprofen (Ibufen, Nurofen)</li> <li>Ketoprofen (Ketonal, Ultrafaыteen, Fastum gel)</li> <li>Indomethacin (Metindol)</li> <li>Phenylbutazone (Butadione)</li> </ol>	<ol> <li>7. Meloksikam (Movalis)</li> <li>8. Nimesulid (Sulide, Coxtal, Sintalgin, Octaprin, Nimesil)</li> <li>9. Eudolacus (Elderin)</li> </ol>	10. Celecoxib (Celebrex) 11. Rofecoxib (Rofika, Denebol)	<ol> <li>Mephenamic acid (Pomstal)</li> <li>Paracetamol</li> <li>Ketorolac</li> <li>Metamizole (Analgin)</li> </ol>		
Mechanism of action	<ul> <li>1. Inhibition of COX-1 and COX-2 (1-6) or COX 2 (7-10) → suppression of prostaglandin synthesis (PG) from arachidonic acid; inhibition of thromboxane A2 synthesis</li> <li>2. Affect the synthesis of PG associated with the mobilization of Ca in smooth muscle (anti-Ca mechanism of anti-inflammatory effect)</li> <li>3. Block the interaction of bradykinin with tissue receptors → Restoration of impaired microcirculation, ↓ extradilatation of capillaries, ↓ exudation of plasma, its proteins, proinflammatory factors and blood cells (bradykinin mechanism of anti-inflammatory effect)</li> <li>(1-3, 5)</li> <li>4. Inhibit the release of histamine, serotonin and biogenic amines (antihistamine and antiserotonin component of anti-inflammatory effect)</li> <li>5. Bind to with G-protein in the cell membrane → affect the transmission of membrane signals, ↓ transport of anions, affect biological processes (membrane stabilizing component of anti-inflammatory effect)</li> <li>6. Inhibition of inflammation → ↓ pain, because inflammation in the peripheral tissues stimulates pain receptors</li> <li>7. ↓ synthesis of prostaglandins (PG E1) stimulating thermoregulation center in the hypothalamus, peripheral vasodilatation → ↓ body temperature</li> <li>8. ↓ capillary permeability → impair immunocompetent cells contact with antigen and antibodies contact with a substrate; macrophages lysosomal membranes stabilization</li> <li>9. ↓ chemotaxis of monocytes, eosinophils, lymphocytes, leukocytes</li> </ul>					
Pharmacological effects	<ol> <li>Anti-inflammatory effect (1-11)</li> <li>Analgesic effect</li> <li>Antipyretic effect</li> <li>Antiplatelet effect (1)</li> <li>Immunosuppressive effect (3, 5, 6)</li> <li>Desensitizing effect</li> </ol>					

Indications	<ol> <li>Rheumatic diseases (rheumatoid arthritis, gouty and psoriatic arthritis, ankylosing spondylitis, etc.) (1-11);</li> <li>Non-rheumatic diseases of the musculoskeletal system (osteoarthritis, myositis, tendovaginitis, trauma, etc.);</li> <li>Moderate pain syndrome of various etiologies (headache and toothache, postoperative pain, algodismenorea) (12-14);</li> <li>Neurological diseases (neuralgia, radiculitis, etc.) (12-14);</li> <li>† body temperature &gt;38,5 °C (1,3,13,15);</li> <li>Prevention of "white" (arterial) thrombi formation (1).</li> </ol>
Side effects	<ol> <li><i>NSAID-induced gastropathy</i> (inhibition of the synthesis of PG and prostocycline → ↓ pH; ↓ mucosa reparation- 1–6)</li> <li><i>Nephrotoxicity</i> (vasoconstriction and deterioration of renal blood flow due to PG-E2 and prostacyclin synthesis inhibition in the kidneys → ischemic changes in the kidneys, ↓ glomerular filtration and volume of diuresis → water retention, edema, hypernatremia, hyperkalemia, ↑ serum creatinine level, ↑ blood pressure - most expressed in 1,5,6; direct influence on the renal parenchyma → interstitial nephritis - most expressed in 1,5,6,15)</li> <li><i>Coagulopathy</i> (antiplatelet and moderate anticoagulant effect due to inhibition of prothrombin formation in the liver → bleeding - 1)</li> <li><i>Hematotoxicity</i> (hypochromic microcytic anemia, hemolytic anemia, thrombocytopenia - 1, 5; leukopenia, agranulocytosis and thrombocytopenia due to hematopoiesis suppression in the bone marrow — 15)</li> <li><i>Hepatotoxicity</i> (immunoallergic hepatitis at the beginning of the drug taking — more often 6; in long intake and high doses - toxic hepatitis more often at 2, 6)</li> <li><i>Allergic reactions</i></li> <li><i>Reve syndrome</i> (rapidly progressive, vitally threatening acute encephalopathy combined with liver damage and caused by the intake of NSAIDs against the background of a viral infectious disease - more often 1)</li> <li>Dizziness, headache</li> <li>Retinopathy, keratopathy (5); optic neuritis (3)</li> <li>Bronchospasm (more often in people with bronchial asthma - most pronounced in 1)</li> <li>Erosive-ulcerative lesions of the digestive tract</li> <li>Sevice dysfunction of the digestive tract</li> </ol>
Contraindications	<ol> <li>Severe dystillation of the liver and kidneys</li> <li>Cytopenia</li> <li>Individual intolerance</li> <li>Pregnancy</li> </ol>
NB!	NSAIDs should be taken after meals and washed down with milk or alkaline water. NSAIDs should be administered with caution to patients with bronchial asthma, as well as individuals who previously identified unwanted reactions when taking any other NSAIDs. Patients with hypertension or heart failure should choose those NSAIDs, which have the least effect on the renal blood flow. Older people should take minimum effective doses and undergo short courses of NSAIDs.
in and the second s	

Classification	Uricosuric agents	Uricodepressive drugs	Uric acid-specific enzymes (PEGyulated uricase)
Drugs	<ol> <li>Sulfinpyrazone (Anturan)</li> <li>Probenecid (Probalan)</li> <li>Benzbromarone (Normurat, Hypuric)</li> </ol>	<ul><li>4. Allopurinol (Milurite)</li><li>5. Febuxostat (Adenuric)</li></ul>	6. Pegloticase (Krystexxa)
Mechanism of action	1. ↓ reabsorption of uric acid in the proximal renal tubules $\rightarrow \uparrow$ its excretion in the urine (1–3)	1. Inhibits xanthine oxidase $\rightarrow$ prevents the uric acid formation from hypoxanthine and xanthine	Metabolizes uric acid to soluble allantoin to be eliminated
Pharmacological effects	1. Antigout effect		
Indications	<ol> <li>Chronic gout</li> <li>Hyperuricemia</li> </ol>	<ol> <li>Chronic gout</li> <li>Urolithiasis</li> <li>Prevention of hyperuricemia in radiation therapy and chemotherapy (4)</li> </ol>	<ol> <li>Drug-resistant gout</li> <li>High disease activity with high blood level of uric acid</li> <li>Intolerance to other antigoat drugs</li> </ol>
Side effects	<ol> <li>Kidney stones</li> <li>Dyspepsia</li> <li>Gastroduodenal ulcer (1)</li> </ol>	<ol> <li>Acute gout attack</li> <li>Dyspepsia</li> <li>Eosinophilia</li> </ol>	<ol> <li>Anaphylaxis</li> <li>Infusion reactions</li> </ol>
Contraindications	<ol> <li>Hyperuricosuria</li> <li>Liver and renal disfunctions</li> <li>Urolithiasis</li> <li>Pregnancy and lactation</li> <li>Gastroduodenal ulcer (1)</li> </ol>	1. Severe liver and renal disfunctions	1. Glucose-6-phosphate dehydrogenase deficiency (risk of hemolysis and methemoglobinemia)
NB!	Acidic medium of the urine facilitates uric acid crystallization and stones formation; therefor urine alkalization is needed (12–18 g of potassium citrate orally daily). The patient is to perform urine pH dipstick tests by himself regularly.	Urate-lowering therapies should not be initiated during an acute attack. But in patients already receiving these agents the urate-lowering medication should be continued without interruption. Exeption – long-duration attack (several weeks), in this case we discontinuate uricodepressants.	High allergic intravenous drug; premedication by antihistamines and glucocorticoids is needed. Expensive (about 2 000\$)

## Antigout agents — medicines used to prevent gout by uric acid level dicrease.

#### Treatment of acute gout attack

1. Complete rest 2. Elevated position of affected limbs 3. In acute inflammation — cold (soak limbs in cold water). After pain relief – warming. 4. Increased fluid consumption (alkaline mineral water) NSAIDs Diclofenac 100-150 mg daily orally or IM; or ibuprofen 1200-2400 mg daily orally; or meloxicam 15 mg daily orally or IM; or nimesulide 200-400 mg daily orally; a celecoxib 400 mg daily orally Colchicine prevents microtubule assembly and thereby disrupts inflammasome activation, microtubule-based When **NSAIDs** Colchicine are ineffective inflammatory cell chemotaxis, generation of leukotrienes and cytokines, and phagocytosis. Doesn't affect uric or contraindicated acid metabolism. 1 tablet 2-3 times daily Prednisolone 15–30 mg daily (methylprednisolone 12–24 mg/ kg daily) orally in the first day, followed by a NSAIDs Glucocorticoids When and colchicine are ineffective decrease in the dose of 5 mg/day (4 mg/day) every subsequent day till withhold the drugs, or Betamethasone 1-2 ml (5-10 mg) or triamcinolone 40-80 mg or methylprednisolone 40-80 mg or contraindicated (intraarticularly not often than 2–3 times/year into one joint or periarticularly). In the hospital: you can start with IV injections of methylprednisolone 250–500 mg daily 1β-interleukin inhibitors Canakinumab 150 mg suncutaneously. In apsent effect repeated infusion isn'r given. When all the previous drugs are ineffective / Interval between administrations not less than 12 weeks. contraindicated Tuberculosis to be excluded before use. Expensive (about 6 000\$)! Proton pump inhibitors Omeprazole 20–40 mg daily or rabeprazole 20–40 mg daily, or lansoprazole 30–60 mg daily When there is gastrointestinal complications risk H2 histamine receptor blockers Ranitidine 0.15–0.3 / day orally or famotidine 0.02–0.04 g / day orally

Classification	I generation	II generation	III generation			
	1. Diphenhydramine	7. Loratadin (Claritin)	13. Cetirizine (Zirtek)			
	2. Clemastin (Tavegil)	8. Dimethindene (Fenistil)	14. Fexofenadine (Telfast)			
Drugs	3. Chloropyramine (Suprastin)	9. Ebastin (Kestin)	15. Desloratadine (Erius)			
Diugs	4. Mebrogroline (Diazolin)	10. Azelastine (Allergodyl)				
	5. Quifenadine (Fenkarol)	11. Astemizole (Gismanal)				
	6. Prometazine (diprasine, Pipolphen)	12. Terfenadine (Bronal, Histadine)				
Mechanism of	Block H1-histamine receptors, as well as cholinergic	and serotonin receptors H1-histamine recepto	rs are blocked			
action	• · ·					
	1. Antihistamine	Unlike the Ist generation:	Unlike the II generation:			
	2. Sedative, hypnotic (1–3, 6)	Do not have a sedative and hypnotic effect	1. Are active metabolites of anti-histamine drugs			
DI I I I	3. Antiholinergic (1–4, 6)	(poorly penetrate through the blood-brain barrier	) of the previous generation.			
Pharmacological	4. Hypotensive (1,6)	Do not have anticholinergic and	2. DO NOT affect the QT interval			
enects	5. Resistance	$\alpha$ -adrenergic blocking properties				
	6. Antiemetic (1,6)	Do not cause resistance				
		Are long-acting (about 24 hours)				
	1. Urticaria, eczema, itchy skin, dermatitis					
	2. Allergic rhinitis and conjunctivitis					
Indications	3. Quincke's edema					
	4. Anaphylactic reactions with cutaneous manifestations					
	5. Marine and air sickness (1,6)					
	1. Drowsiness	1. Dyspeptic phenomena	1. Dyspeptic phenomena			
Sido offoata	2. Dry mouth	2. Dry mouth	2. Dizziness, headache			
Side effects	3. Hypotension (1.6)	3. Cardiotoxicity: prolongation of QT, rhyt	hm			
	4. Dyspeptic phenomena	disturbance (11, 12)				
	1. Closed-angle glaucoma (1–4, 6)	1. Pregnancy, breast-	feeding			
Controindiantions	2. Hypertrophy of the prostate (1–4, 6)					
Contraindications	3. Severe liver diseases, erosive-ulcerative lesions of	the gastroduodenal zone				
	4. Pregnancy, breast-feeding					
	1. Drugs with sedative and hypnotic effects can't be	prescribed to drivers and other persons whose job	requires a rapid mental and motor reaction.			
	2. Groups of drugs with antihistamine action: g	glucocorticosteroids, mast cell stabilizers, leuko	otriene receptor inhibitors, "universal" adrenomimetic			
NB!	(epinephrine).					

## Antihistamines — drugs that block H1-histamine receptors.

Acute managem	ent of anaphyla	xis
8		

I line management	1. Assess respiratory tract patency, the presence and adequacy of breathing, the level of consciousness, the state of skin.
	2. Adrenaline (epinephrine) 0,1 % 0,3–0,5 ml IM into the middle of the anterolateral lateral surface of the thigh or IV
	3. Cardiopulmonary resuscitation in cardiac or respiratory arrest. Ratio of breaths to compression — 2:30
II line menorement	4. When hypotension: lay the patient with raised lower limbs, ensure the supply of moistened oxygen (if available), the introduction of sodium chloride solution 0,9 % IV (to 20 ml/kg)
11 line management	5. When bronchospasm: sitting position of the patient, ensure the supply of moistened oxygen (if available), inhalation of $\beta$ 2-agonists — salbutamol 100 mkg via a metered aerosol inhaler (1–2 doses) or a nebulizer 2,5 mg/3 ml
	6. If there is no response within 5–10 minutes, reapply adrenaline 0,1 % 0,3–0,5 ml
	7. Corticosteroids (prednisolone 90–120 mg)
III line management	8. Introduction of antihistamines for the treatment of skin symptoms B/M clemastine 2 mg or chloropyramamine 20 mg or definehydramine 25–50 Mr i/, IV or orally
NB!	If only an angioedema or urticaria it's not anaphylaxis and management includes: 1. Antihistamines IM, IV, clemastine 2 mg orally, chloropyramamine 20 mg, definehydramine 25–50 mg 2. corticosteroids (prednisolone 25–30 mg)
	Retlogin

#### Immunosuppressive drugs are drugs inhibiting or preventing activity of the immune system.

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell.

Classification	For cancer	For organ transplantation	For autoimmune diseases	For infectious, allergic diseases and other diseases
Drugs	<ol> <li>Avastin (Bevacizumab)</li> <li>Herceptin (Trastuzumab)</li> <li>MabThera (Rituximab)</li> <li>Erbitux (Cetuximab)</li> </ol>	5. Simulekt (Baziliximab)	<ul><li>6. Actemra (Tocilizumab)</li><li>7. Humirah (Adalumumab)</li><li>8. Remicade (Infliximab)</li></ul>	9. Xolar (Omalizumab) 10. Lucentis (Ranibizumab)
Mechanism of action	<ol> <li>Selectively binds to the growth factor of the endothelial vessels and neutralizes it → violation of angiogenesis, ↓ vascularization and depression of growth of the tumor (1)</li> <li>Blocks human epidermal growth factor receptor type 2 (HER-2) on tumor cells → ↓ division of malignant cells (2)</li> <li>↓ level of circulating CD20 + B-lymphocytes (3)</li> <li>↓ Blocks epidermal growth factor receptor (EGFR) →</li> </ol>	1. Blocks the $\alpha$ -chain of the interleukin-2 receptor (CD25) $\rightarrow \downarrow$ T cell proliferation (5)	<ol> <li>Suppresses receptors of interleukin-6 (6)</li> <li>Inhibit tumor necrosis factor-α (TNF-α) (7,8)</li> </ol>	1. It binds to Ig E and prevents its interaction with Fc-R1 $\rightarrow \downarrow$ Ig E (9) 2. Prevents the interaction of endothelial growth factor of the vessels (VEGF-A) with receptors on the surface of endothelial cells $\rightarrow \downarrow$ neovascularization and vascular proliferation (10)
Pharmacological effects	1. Antitumor effect	1. Immunodepressive effect	<ol> <li>Immunodepressive effect</li> <li>Anti-inflammatory effect</li> </ol>	<ol> <li>Antiallergic effect (9)</li> <li>Antiproliferative effect (10)</li> </ol>
Indications	<ol> <li>Metastatic colorectal cancer (1.4)</li> <li>Breast and pulmonary cancer (1,2)</li> <li>Renal cell carcinoma (1)</li> <li>Stomach cancer (2)</li> <li>Squamous cell carcinoma of the head and neck (4)</li> <li>B-cell CD20-positive non-Hodgkin's lymphomas, chronic lymphocytic leukemia (3)</li> </ol>	1. Prevention of kidney transplant rejection	<ol> <li>Rheumatoid arthritis</li> <li>Ulcerative colitis and Crohn's disease (7,8)</li> <li>Plaque psoriasis in children (7)</li> </ol>	<ol> <li>Atopic bronchial asthma (9)</li> <li>Chronic idiopathic urticaria (9)</li> <li>Neovascular (wet) form of age- related macular degeneration (10)</li> </ol>
Side effects	<ol> <li>Perforation of gastrointestinal tract (1)</li> <li>Bleeding, thromboembolism (1)</li> <li>Neutropenia, leukopenia, thrombocytopenia (1-3)</li> <li>Hypertension</li> <li>Diarrhea, nausea, vomiting, abdominal pain</li> <li>Heart failure, tachyarrhythmia (1-3)</li> <li>Upper respiratory and urinary infections</li> <li>Allergic reactions</li> </ol>	<ol> <li>Diarrhea, nausea, vomiting, abdominal pain</li> <li>Hypertension, headache</li> <li>Hyperkalemia, hypercholesterolemia, hypophosphaemia4. Upper respiratory and urinary infections</li> <li>Allergy</li> </ol>	<ol> <li>Upper respiratory infections</li> <li>Hypertension, headache</li> <li>Leukopenia, neutropenia</li> <li>↑ hepatic enzyme activity</li> <li>Benign tumors (7)</li> <li>Allergic reactions</li> </ol>	<ol> <li>Upper respiratory and urinary infections (10)</li> <li>Anemia (10)</li> <li>Intraocular inflammation, visual disturbances (10)</li> <li>Headache</li> <li>Allergic reactions</li> </ol>
Contraindications	<ol> <li>Hypersensitivity</li> <li>Patients with dyspnea at rest (2)</li> </ol>	1. Hypersensitivity	<ol> <li>Hypersensitivity</li> <li>Sepsis, active tuberculosis</li> </ol>	<ol> <li>Hypersensitivity</li> <li>Eye infections (10)</li> </ol>
NB!	Other drugs with immunosuppressive action: cytostatics,	glucocorticoids, immunoglobuli	ns (antitimocyte immunoglobulin	)

Classification	Interferons	Interferon inductors	Interleukins	Colony-stimulating factors
Drugs	Natural:1. Human leukocvte interferon (α-feron)2. Velferon (α-feron)3. Toraferon (β-feron)Recombinant:4. Reaferon. Viferon (α2A-interferon)5. Intron-A. Laferon (α2B-interferon)6. Betaferon, Fron (β-feron)7. Gammaferon, Immukin (γ-feron)	8. Amiksin 9. Poludan 10. Arbidol 11. Ingavirin	1. ↑ amount of lymphocytes and their cytotoxicity, the activity of cell-killer killers, and the activity of tumor necrosis factor	<ol> <li>↑ expression of class II histocompatibility antigens on human monocvtes and ↑ production of antibodies: ↑ phagocvtosis of bacteria, activate cytotoxic effector cells</li> <li>Activates the maturation of myeloid and lymphoid cells</li> </ol>
Mechanism of action	<ol> <li>Influenza, ARVI (1)</li> <li>Hepatitis B and C (1–7)</li> <li>Severe bacterial infections (7)</li> <li>AIDS-associated Kaposi's sarcoma (1, 4, 5)</li> <li>Hairv cell leukemia (1, 2, 4)</li> <li>Chronic mvelogenous leukemia (1, 2, 5)</li> <li>Kidnev cancer (1, 2, 4, 5)</li> <li>Multiple sclerosis (1, 6, 4)</li> <li>Larynx papillomatosis (2, 4)</li> </ol>	1. Influenza, ARVI 2. Hepatitis A, B and C (8) 3. Keratitis, uveitis (9)	<ol> <li>Septic conditions accompanied by immunosuppression</li> <li>Renal cell carcinoma (12)</li> <li>Pulmonary tuberculosis (12, 13)</li> <li>Toxic leukopenia of 2–4 grade complicating chemo- and radiotherapy of malignant tumors (13)</li> </ol>	<ol> <li>Antitumor agents-induced neutropenia; HIV infection</li> <li>Neutropenia in patients with mvelodysplastic syndrome (15)</li> <li>Bone marrow transplantation</li> </ol>
Pharmacological effects	1. Immunomodulating3. Antiviral2. Antineoplastic4. Antibacterial	1. Immunomodulating 2. Antiviral	1. Immunomodulating	
Indications	<ol> <li>Influenza, ARVI (1)</li> <li>Hepatitis B and C (1–7)</li> <li>Severe bacterial infections (7)</li> <li>AIDS-associated Kaposi's sarcoma (1, 4, 5)</li> <li>Hairy cell leukemia (1, 2, 4)</li> <li>Chronic mvelogenous leukemia (1, 2, 5)</li> <li>Kidney cancer (1, 2, 4, 5)</li> <li>Multiple sclerosis (1, 6, 4)</li> <li>Larynx papillomatosis (2, 4)</li> </ol>	<ol> <li>Influenza, ARVI</li> <li>Hepatitis A, B and C (8)</li> <li>Keratitis, uveitis (9)</li> </ol>	<ol> <li>Septic conditions accompanied by immunosuppression</li> <li>Renal cell carcinoma (12)</li> <li>Pulmonary tuberculosis (12, 13)</li> <li>Toxic leukopenia of 2–4 grade complicating chemo- and radiotherapy of malignant tumors (13)</li> </ol>	<ol> <li>Antitumor agents-induced neutropenia; HIV infection</li> <li>Neutropenia in patients with myelodysplastic syndrome (15)</li> <li>Bone marrow transplantation</li> </ol>
Side effects	<ol> <li>Asthenovegetative syndrome</li> <li>Flu-like syndrome</li> <li>Nausea. diarrhea. anorexia</li> <li>Thrombocyto leukopenia (2–7)</li> <li>Hepatotoxicity 6. Nephrotoxicity (2–7)</li> <li>Convulsive syndrome (2–6)</li> <li>Depression (1–6)</li> <li>Cardiotoxicity (2–7)</li> </ol>	1. Dyspeptic phenomena 2. Short-term chills (8)	<ol> <li>Flu-like svndrome</li> <li>Dyspeptic phenomena</li> <li>Hematotoxicity (anemia, thrombocvtopenia, leukopenia), cardio-toxicity (mvocardial ischemia, atrial arrhythmias), arterial hvpertension (12)</li> <li>Neurotoxicity (drowsiness, delirium)</li> </ol>	<ol> <li>Anorexia. nausea. vomiting, diarrhea, abdominal pain</li> <li>Headache, dizziness</li> <li>Hypotension, arrhythmia, heart failure</li> <li>Bronchospasm</li> </ol>
Contraindications	<ol> <li>Hypersensitivity</li> <li>Expressed violations of the liver, kidney, heart functions, hematopoiesis system</li> <li>Epilepsy, mental illness</li> </ol>	1. Hypersensitivity 2. Childhood	<ol> <li>Hypersensitivity</li> <li>Autoimmune diseases</li> <li>Severe cardiovascular diseases</li> </ol>	<ol> <li>Hypersensitivity</li> <li>Myeloid leukemia</li> </ol>

## **Immunomodulators** — medicines correcting immunity disorders.

Classification	Thymus preparations	Synthetic drugs	Substances of bacterial origin	Vegetable drugs
Drugs	<ol> <li>Timalin (Timosin)</li> <li>Tactivin</li> <li>Timopentin</li> </ol>	<ul><li>4. Levamisol (Decaris)</li><li>5. Leakadine</li><li>6. Berlopentin</li></ul>	7. Prodigiosan9. Broncho Munal8. Ribomunil10. Imudon	11. Echinacea purpurea
Mechanism of action	1. Regulates the number of T- and B-lymphocytes, enhances the response of cellular immunity and phagocytosis, as well as the regeneration and hemopoiesis processes in case of their inhibition (1) 2. $\uparrow \alpha$ - and $\gamma$ -interferons, restores the activity of T-killers, normalizes immunity indices (2) 3. $\uparrow$ number of T-lymphocytes (3)	<ol> <li>Stimulates the function of T-lymphocytes, macrophages, strengthens cellular immunity mainly, and also disrupts the bioenergetic processes of helminthes (4)</li> <li>↓ level of T-suppressors, normalizes the ratio of T-helpers and T-suppressors, ↑ cytotoxicity of natural killers and monocytes, inhibits tumor growth (5)</li> <li>↑ the proliferation and differentiation of bone marrow stem cells without increase in pathological immune responses (6)</li> </ol>	<ol> <li>Activates T-lymphocytes and adrenal cortex function, ↑ formation of endogenous interferon (7)</li> <li>Stimulates the formation of specific antibodies to the antigens of klebsiella and streptococci, activates T and B lymphocytes, the formation of interleukin-1 and interferon- α (8.9)</li> <li>Stimulate local humoral immunity, ↑ the production of lgA in the mucus-stern of the upper respiratory tract and ↑ the content of lysozyme (10)</li> </ol>	<ol> <li>Activates         leukopoiesis and ↑         phagocytic activity of         macrophages → ↓         bacterial growth and         helps to kill         pathogenic bacteria.         </li> </ol>
Pharmacological effects	1. Immunomodulating	<ol> <li>Immunomodulating</li> <li>Antiparasitic (4)</li> <li>Antineoplastic (5)</li> </ol>	1. Immunomodulating	<ol> <li>Immunomodulating</li> <li>Antiviral</li> <li>Antibacterial</li> </ol>
Indications	<ol> <li>Acute and chronic bacterial and viral infections</li> <li>Malignancies (2,3)</li> <li>Chronic viral hepatitis (2,3)</li> </ol>	<ol> <li>Auxiliary postoperative cancer treatment (4)</li> <li>Nematodeases (4)</li> <li>Kaposi's sarcoma, skin lymphoma (5)</li> <li>Psoriasis (5)</li> <li>Immunodeficiency in HIV / AIDS (6)</li> </ol>	<ol> <li>Decreased immunity due to chronic inflammatory diseases, after operations (7)</li> <li>Chronic bronchitis, tracheitis, rhinitis (8, 9, 11)</li> <li>Gingivitis, periodontitis, stomatitis (10)</li> </ol>	1. Uncomplicated viral and bacterial diseases of the respiratory tract.
Side effects	1. Allergy	<ol> <li>Nausea, vomiting, diarrhea</li> <li>Risk of agranulocytosis (4)</li> <li>Thrombocytopenia (5)</li> <li>↑ blood pressure (5)</li> <li>Burning pain at the injection site (6)</li> </ol>	<ol> <li>Headache (7)</li> <li>2. ↑ body temperature (7)</li> <li>3. Allergic reactions</li> <li>4. Nausea, vomiting</li> </ol>	1. Allergy
Contraindications	1. Hypersensitivity 2. Atopic asthma (2)	<ol> <li>Hypersensitivity</li> <li>Agranulocytosis (4)</li> <li>Thrombocytopenia (5)</li> <li>The gastroduodenal ulcer (5)</li> </ol>	1. Central nervous system lesions (7)         2. Myocardial infarction (7)         3. Autoimmune diseases (8)	1. Hypersensitivity 2. Autoimmune diseases
NB!	Bacillus Calmette-Guérin (BCG) va	accine is also an bacterial immunomodulator (vacc	ine against tuberculosis)	

#### Immunomodulators (continued)

# 9. CHEMOTHERAPEUTIC AGENTS. CONCEPT OF CHEMOTHERAPY. ANTIBIOTICS (B-LACTAM ANTIBIOTICS, MACROLIDES, TETRACYCLINS)

*Chemotherapeutic agents* are medicinal substances suppressing the vital functions of pathogens of infectious diseases or tumor cells.

*Antibiotics* are medicinal substances of predominantly microbial origin, as well as their semisynthetic and synthetic analogues, which have the ability to suppress the viability of susceptible microorganisms.

Currently, 3 types of antibiotic treatment are used:

1. *Preventive treatment* - prescribing antibiotics for the prevention of infectious diseases (for example, for seasonal prevention of acute rheumatic fever or postoperative complications).

2. *Empirical or initial treatment* — administration of broad-spectrum antibiotics suppressing microorganisms associated with the given pathology without the results of bacterial culture and antibiotic susceptibility testing (eg, community-acquired pneumonia is most often caused by pneumococcus susceptible to aminopenicillins).

3. *Final treatment* — administration of narrow-spectrum antibiotics in accordance with the results of bacterial culture test (type of detected pathogens and its susceptibility to antibiotics).

#### Principles of rational chemotherapy.

*The choice of the drug should be carried out taking into account:* 

1) Diagnosis (therapy can be empirical and etiotropic);

2) The spectrum of drugs activity (it is preferable to administer narrow-spectrum antibiotics);

3) The state of the patient's organism taking into account his age, pregnancy and concomitant diseases;

4) Toxicity of drugs, their side effects;

5) Localization of the infection (the substance should reach the focus of infection);

6) Route of administration (In severe cases, drugs are administered parenterally);

7) The possibility of combining drugs in order to enhance the pharmacological effect and prevention of the development of resistance of microorganisms to antibiotics;

8) Drugs cost.

When prescribing treatment adequate dose of the drug, frequency of its administration and duration of the course of antibiotic therapy should be chosen.

		Semisynthetic				
Classification	Natural	β -lactamase-resistant	Aminopenicillins	Antipseudomonal	Penicillinase-resistant	
Drugs	<ul> <li>Short acting:</li> <li>1. Benzylpenicillin sodium and potassium salts</li> <li>2. Phenoxymethylpenicillin Long-acting:</li> <li>3. Benzylpenicillin novocaine salt</li> <li>4. Bicillin-1, bicillin-5</li> </ul>	5. Oxacillin 6. Cloxacillin	<ul><li>7. Ampicillin</li><li>8. Amoxicillin</li></ul>	Carboxypenicillins: 9. Carbenicillin 10. Ticarcillin Ureidopenicillins: 11. Piperacillin 12. Azlocillin	<ul> <li>13. Amoxicillin / clavulanic acid (Augmentin)</li> <li>14. Ampicillin / сульбактам (Unazine)</li> <li>15. Ticarcillin / clavulanic acid (Timentin)</li> <li>16. Piperacillin / Tazobactam</li> </ul>	
Mechanism of action	Suppress the synthesis of the b	+ Inhibition of $\beta$ -lactamases due to sulbactam, clavulanate $\rightarrow$ Are active against PRSA				
Spectrum of activity	<ol> <li>Gr (+) cocci: non- penicillinase producing staphylococci: streptococci, pneumococci</li> <li>Gr (-) cocci: meningococci</li> <li>Gr (+) sticks: Listeria, causative agents of diphtheria, anthrax</li> <li>Spirochetes, anaerobes</li> </ol>	See natural penicillins + 5. Penicillinase-producing staphylococci (PRSA)	<ol> <li>Gr (-) bacteria: E. coli, hemophilic rod, salmonella, shigella</li> <li>Gr (+) cocci: non- penicillinase producing staphylococci, Streptococci (enterococcus), pneumococci</li> <li>Gr (-) cocci: meningococci</li> <li>Gr (+) sticks: listeria, exciters of diphtheria, anthrax</li> <li>Spirochetes, anaerobes</li> </ol>	Similar to Ampicillin, but + 1. Pseudomonas aeruginosa 2. Ampicillin-resistant Gr (-) m/o: Enterobacter, Proteus, Morganella 3. Gr (-) non-sporeforming anaerobes	The broadest spectrum of activity among all penicillins	
Indications for use	<ol> <li>Erysipelas, scarlet fever</li> <li>Syphilis</li> <li>Bacterial endocarditis</li> <li>Anaerobic infections</li> <li>Borreliosis, anthrax</li> </ol>	1. Staphylococcal infections (infections of the skin and soft tissues, bones and joints, hospital pneumonia, etc.)	<ol> <li>Urinary tract infection</li> <li>Upper respiratory infection (Acute otitis media, acute sinusitis)</li> <li>Lower respiratory infection (bronchitis, community- acquired pneumonia)</li> </ol>	1. Diseases caused by Pseudomonas aeruginosa (skin, abdominal organs, urinary and biliary tracts infections, etc.)	1. Diseases caused by Pseudomonas aeruginosa (skin, abdominal organs, urinary and biliary tracts infections, etc.)	
Side effects	Allergy, headache, nausea, vomiting, pseudomembranous colitis, pain in IM administration, phlebitis in IV administration					
Contraindications	Allergy, I semester of pregnancy (amoxicillin / clavulanic acid)					

#### Penicillins

Classification	I generation	II generation	III generation	IV generation	V generation
Drugs	<ul> <li>IV, IM</li> <li>1. Cefazolin (Kefzol)</li> <li>per os</li> <li>2. Cephalexin (Keflex)</li> <li>3. Cefadroxil (Duricef)</li> </ul>	<ul> <li><i>IV, IM</i></li> <li>4. Cefuroxime (Ceftin)</li> <li>5. Cefamandole (Mandol)</li> <li><i>per os</i></li> <li>6. Cefaclor (Ceclor)</li> <li>7. Cefuroxime (Zinacef)</li> </ul>	<ul> <li><i>IV, IM</i></li> <li>8. Cefotaxime (Claforan)</li> <li>9. Ceftriaxone (Rocephin)</li> <li>10. Cefoperazone (Cefobid)</li> <li>11. Ceftazidime (Fortu)</li> <li><i>per os</i></li> <li>12. Cefixime (Fixx)</li> <li>13. Ceftibuten (Cedax)</li> </ul>	<i>IV, IM</i> 14. Cefepime (Maxipime) 15. Cefpirome (Cefrom)	<i>IV, IM</i> 16. Ceftobiprole 17. Ceftaroline
Mechanism of action	Suppress the synthesis of the b	acterial cell wall (bactericidal ac	tion)		
Pharmacological effects	<ol> <li>Gr (+) cocci: streptococci, staphylococci</li> <li>Gr (-) cocci and bacilli insignificantly</li> </ol>	<ol> <li>Gr (-) bacteria: hemophilic rod, Klebsiella, proteus</li> <li>Gr (+) cocci: streptococci, staphylococci</li> </ol>	<ol> <li>Gy (-) bacteria (including polyre-resistant strains of enterobacteria)</li> <li>Anaerobes (8,9)</li> <li>Gr (+) cocci: strepto-, pneumococci (8.9)</li> <li>Pseudomona (10, 11)</li> </ol>	See III generation	<ol> <li>MRSA (methicillin- resistant Staphylococcus aureus)</li> <li>Penicillin-resistant streptococci and enterococci</li> </ol>
Indications	<ol> <li>Perioperative chemoprevention</li> <li>Strepto- and staphylococcal infections of the musculoskeletal system, skin, soft tissues</li> </ol>	+ 3. Urinary tract infection 4. Respiratory infections (community-acquired pneumonia, acute sinusitis and otitis media)	<ol> <li>Infections of the respiratory system (including, hospital pneumonia)</li> <li>Urinary tract infection</li> <li>Abdominal, pelvic infections</li> </ol>	+ 4. Infections caused by hospital strains of Enterobacteria, staphylococci, Pneumococcus and Pseudomonas aeruginosa	1. Infections of the skin and soft tissues
Side effects	Allergic reactions; hematological reactions: in rare cases - leukopenia, eosinophilia; disulfiram-like reaction with alcohol intake (5,10); headache; nausea, vomiting; Superinfections caused by enterococci, MRSA; pain and thrombophlebitis in the site of injection				
Contraindications	Allergy	$\sim$			
NB!	<ul> <li>1. Cephalosporins are resistant to bacterial beta-lactamases, BUT combination of cefoperazone + sulbactam (Beta-lactamase inhibitor) expands the spectrum of action up to resistant enterobacteria and akinetobacter; suppresses nesporogenous anaerobes → therapy of abdominal and pelvic infections.</li> <li>2. Each subsequent generation is superior to the previous when comparing the spectrum of activity among the Gp (-) bacteria, but loses activity against Gr (+). AN EXCEPTION! IV generation (high activity against Gr +)</li> </ul>				
	$\mathbf{Q}$				

## Cephalosporins

Classification	Carbapenems	Monobactams
Drugs	<ol> <li>Imipenem-cilastatin (Tienam)</li> <li>Meropenem (Meronem)</li> <li>Doripenem (Doriprex)</li> <li>Ertapenem (Invanz)</li> </ol>	3. Aztreonam
Mechanism of action	Suppress the synthesis of the bacterial cell wall (bactericidal action)	
Spectrum of activity	<ul> <li>Record wide:</li> <li>1. Gr (+) cocci: streptococci, staphylococci, pneumococci</li> <li>2. Gr (-) cocci: neiesseria, gonococcus and meningococcus</li> <li>3. Gr (-) bacteria: Listeria, Hemophilus rod, Proteus, Shigella, Salmonella, Escherichia coli, Klebsiella, Citrobacterium, Campylobacter, Pseudomonas aeruginosa, Serratia</li> <li>4. Anaerobes: clostridia, fusobacteria, bacteroides</li> </ul>	1. Gr (-) flora: gonococcus, meningococcus, Escherichia coli, Salmonella, Shigella, Klebsiella, Proteus, Citrobacterium, Pseudomonas aeruginosa.
Indications	Last resort antibiotic 1. Infections of the lower respiratory and urinary tracts, abdominal organs, skin, soft tissues 2. Meningitis 3. Sepsis * Including caused multidrug-resistant bacteria	<ul> <li>Last resort antibiotic (infections caused by resistant to other β-lactam antibiotics and aminoglycosides strains of Gr (-) bacteria or in case of intolerance to aminoglycosides)</li> <li>1. Sepsis</li> <li>2. Urinary tract infection (cystitis, pyelonephritis)</li> <li>3. Hospital pneumonia, cystic fibrosis</li> <li>4. Infections of the skin, musculoskeletal system</li> </ul>
Side effects	<ol> <li>Nausea, vomiting, diarrhea, abdominal pain</li> <li>Thrombophlebitis at the injection site</li> <li>Allergy</li> <li>Pseudomembranous colitis (rarely)</li> </ol>	<ol> <li>Pain and swelling at the injection site (B/M), thrombophlebitis (B/B)</li> <li>Nausea, vomiting, diarrhea, abdominal pain, pseudomembranous colitis 3. Hepatitis, jaundice</li> </ol>
Contraindications	1. Hypersensitivity to carbapenems	1. Hypersensitivity in anamnesis
NB!	<ol> <li>Carbapenems are resistant to most β-lactimases of m/o (but MRSA is resistant to carbapenems).</li> <li>Cilastatin inhibits the enzyme dehydropeptidase I which destroys the imipenem in the renal tubules.</li> </ol>	It is destroyed by β-lactamases of many microbes.
	QC.	

#### Carbapenems and monobactams

	Tetracycl	ines	Macrolides		
Classification	Natural	Semisynthetic	Natural	Semisynthetic	
Drugs	1. Tetracycline	2.Metacyclin (rondomycin) 3.Doxycycline (vibramycin)	<ul> <li>14- membered:</li> <li>4. Erythromycin</li> <li>5. Oleandomycin</li> <li>16- membered:</li> <li>6. Josamycin</li> <li>7.Midekamycin (macropen)</li> </ul>	<ul> <li>14-membered:</li> <li>8.Roxithromycin (rulid)</li> <li>9.Clarithromycin (clamed)</li> <li>15- membered:</li> <li>10.Azithromycin (Sumamed)</li> <li>16- membered:</li> <li>11.Midequamycin acetate</li> </ul>	
Mechanism of action	Suppress the synthesis of the protein of the ribosomes (bacteriostatic). In high doses	he microbial cells at the level of the bactericida action (macrolides).			
Spectrum of activity	<ol> <li>Gr (-) bacteria: plague, cholera, brucel coli, salmonella, shigella, Klebsiella</li> <li>Gr (-) cocci: moraxella</li> <li>Gr (+) bacteria: anthrax, listeria</li> <li>Others: spirochaetes, rickettsia, ch (tropical malaria and amoebiasis)</li> </ol>	losis, tularemia, hemophilic rod, E. Iamydia, mycoplasmas, protozoa	<ol> <li>Gr (+) cocci: strepto-, pneumo-, staphylococcus, enterococcus (including β-lactamase-producing)</li> <li>Intracellular pathogens (mycoplasmas, chlamydia, legionella)</li> <li>Gr (+) sticks: listeria, pathogens of diphtheria</li> <li>Gr (-) bacteria: causative agent of whooping cough, hemophilic rod,</li> <li>Gr (-) cocci: gonococcus (10); Others: spirochetes</li> </ol>		
Indications	<ol> <li>Especially dangerous infections (plagu</li> <li>Borreliosis (Lyme disease), rickettsiosi</li> <li>Community-acquired pneumonia</li> <li>STIs (non-gonococcal urethritis, chlam</li> <li>Acne</li> </ol>	e, tularemia, anthrax) is ydial infection, syphilis)	<ol> <li>Infections of the upper and lower zillofaringitis, acute sinusitis, acute pneumonia, exacerbation of chronic brond 2. Chlamydiosis, ureaplasmosis, syphilis</li> <li>3. Eradication of H. pylori (9)</li> </ol>	respiratory tract (streptococcal tone- otitis media, community-acquired chitis, whooping cough, diphtheria)	
Side effects	<ol> <li>Gastrointestinal disorders</li> <li>Dysbacteriosis, superinfection</li> <li>Violation of bone and dental tissue form</li> <li>Photosensibilization</li> <li>Hepatotoxicity</li> <li>Allerg</li> </ol>	mation	<ol> <li>Gastrointestinal disorders         Rarely:         Reversible hear impairment         Thrombophlebitis at the injection site         Superinfections         Allergy     </li> </ol>		
Contraindication s	<ol> <li>Age before 8</li> <li>Pregnancy, lactation</li> <li>Severe liver pathology</li> </ol>		<ol> <li>Hypersensitivity in anamnesis</li> <li>Pregnancy (1-9)</li> <li>Lactation (6-9)</li> </ol>		
NB!	The majority of Gr (+) cocci: strept anaerobes (clostridia, actinomycetes) are	o-, pneumo-, staphylococcus and resistant to tetracycline	Azithromycin: prolonged T1 / 2 → is given once a day (0,5 g daily during 3 days or 0,5 g in the first day, 2nd -5th day -0,25 g daily). The bactericidal concentration in the focus of infectious inflammation is being maintained for 5- 7 days after the last dose		

#### Tetracyclins and macrolides

# **10. ANTIBIOTICS (ENDING). SYNTHETIC ANTIMICROBIAL AGENTS**

## Amphenicols and aminoglycosides

Classification	Amfenicols	Aminoglycosides
Drugs	1. Chloramphenicol (Levomycetin)	I generation2. NeomycinII generation5. Tobramycin (tobrex)III generation1. Streptomycin3. Kanamycin4. Gentamicin6. Nethylmycin7. Amikacin
Mechanism of action	It binds to the 50S-subunit of the bacterial ribosome $\rightarrow$ inhibits aminoacids integration into the polypeptide chain $\rightarrow$ inhibition of protein synthesis (mainly bacteriostatic action)	Attach to the 30S-subunit of the ribosome $\rightarrow$ disruption of their binding to transfer RNA $\rightarrow$ disturbance of protein synthesis of the microbial cell $\rightarrow$ cell death (bactericidal action)
Spectrum of action	<ol> <li>Gr (+) cocci: streptococci</li> <li>Gr (-) cocci: Neisseria</li> <li>Gr (-) sticks: escherichia, salmonella, Haemophilus influenzae</li> <li>Intracellular parasites: rickettsia, chlamydia, mycoplasma</li> </ol>	Susceptible:Moderate susceptible:1. Gr (-) intestinal bacteria: Salmonella,1. Gr (+) cocci: penicillins (including resistant to penicillin and some MRSA strains), streptococci (including enterococci);2. Mycobacterium tuberculosis (1,3,7); 3. Pseudomonas aeruginosa (4-7).2. Gr (-) cocci: meningococci, gonococci. Resistant: anaerobes and pneumococcus (are useless when community-acquired pneumonia)
Indications	Topically: 1. Eye infections 2. Purulent inflammatory skin diseases Systemically — the 2nd line drug: Bacterial meningitis, brain abscess Intra-abdominal infections and infections of the pelvic organs Typhoid fever, plague, gas gangrene, rickettsiosis	1. Pseudomonas aeruginosa (4–7)2. Sepsis3. Infective endocarditis4. Fever in patients with neutropenia5. Nosocomial pneumonia6. Intra-abdominal infections, pelvic organs infections7. Specific therapy: plague (1), tularemia (1.4), brucellosis (1), tuberculosis (1,3,7)8. Antibiotic prophylaxis: decontamination of the intestine before routine operations on the large intestine (inside) (2)
Side effects	Hematotoxicity (dose-dependent reticulocytopenia, thrombocytopenia and anemia); "Gray syndrome of newborns" (vomiting, bloating, respiratory disorders, cyanosis, later vasomotor collapse, hypothermia, acidosis); gastrointestinal disorders (nausea, vomiting, diarrhea, superinfections)	Nephrotoxicity (significant increase or decrease in the amount of urine, a decrease in glomerular filtration, increased serum creatinine levels), ototoxicity (irreversible hearing loss!), vestibulotoxicity (dizziness, impaired coordination of movements, gait alteration), neuromuscular blockade (weakness of diaphragmatic and other respiratory muscles, respiratory paralysis), headache, drowsiness, paresthesia, seizures, allergic reactions (rare), local reactions (phlebitis, thrombophlebitis)
Contraindications	Allergic reactions in the anamnesis, pregnancy and lactation period, newborns, blood diseases	Allergic reactions in the anamnesis, pregnancy (only for vital indications!), lactation period (2)
NB!	It is extremely rare even with topical application may occur idiosyncrasy — aplastic anemia (100 % lethality!). It is necessary to monitor 2 times a week the level of platelets and reticulocytes. «Gray syndrome of newborns" occurs at doses> 50 mg / kg due to a low rate of metabolism in the liver.	<ol> <li>The risk of side effects increases with prolonged administration (more than 7–10 days), hypokalemia, dehydration, the use of large doses. If neuromuscular blockade occurs, calcium chloride should be introduced.</li> <li>Dosing is done only on kg of body weight. The entire daily dose should be administered once a day (except for the treatment of newborns, endocarditis and meningitis).</li> <li>Monitoring of kidney function (creatinine clearance).</li> </ol>

Classification	Lincosamides	Polymyxin
Drugs	NaturalSemisynthetic 1. Lincomycin2. Clindamycin (Dalacin)	1. Polymyxin B         2. Polymyxin M         3. Polymyxin E (colistat)
Mechanism of action	Suppress the synthesis of the microbial cells protein in the ribosomes (bacteriostatic action, in large doses - bactericidal action)	Violate the integrity of the cytoplasmic membrane of the microbial cell (bactericidal action)
Spectrum of action	<ol> <li>Gr (+) cocci: staphylococci (except MRSA), streptococci, pneumococci</li> <li>Anaerobes (but Cl. Difficile is resistant)</li> <li>Protozoa: toxoplasma, pneumocysts, tropical malaria (2)</li> </ol>	<ol> <li>Gr (-) bacteria: E. coli, Salmonella, Shigella, Klebsiella, Enterobacteria, Pseudomonas aeruginosa.</li> <li>Anaerobes: Fusobacteria and bacteroides are moderately sensitive</li> </ol>
Indications	<ul> <li>Drugs of last resort:</li> <li>1. Streptococcal and staphylococcal infections</li> <li>2. Infections caused by non-spore forming anaerobes: infections of the lower respiratory tract, skin and soft tissues, bones and joints, intra-abdominal infections and pelvic infections</li> <li>Locally: acne, bacterial vaginosis (2)</li> </ul>	<ol> <li>A drug of last resort for resistant pseudomonas infection; severe gram-negative infections caused by multidrug-resistant hospital strains (1.3);</li> <li>Bacterial infections of the eyes, ear (locally) (1)</li> <li>Local treatment of Pseudomonas aeruginosa (2)</li> </ol>
Side effects	Allergic reactions, gastrointestinal disorders, pseudomembranous colitis, neutropenia, thrombocytopenia	Severe nephrotoxicity (increased serum creatinine and urea levels, development of acute tubular necrosis with pronounced proteinuria and hematuria), neurotoxicity (paresthesia, peripheral poly-neuropathies, impaired consciousness, hearing impairment, neuromuscular blockade with the threat of development of the respiratory muscles paralysis), hematotoxicity (thrombocytopenia), hypokalemia, hypocalcemia
Contraindications	Allergic reactions in the anamnesis, pregnancy and lactation, gastrointestinal disease in prior period (ulcerative colitis, antibiotic-associated enteritis or colitis)	Allergic reactions in the anamnesis, renal failure, myasthenia gravis, botulism, the use of neuromuscular blockers
NB!	Cross-resistance with macrolides is possible. Clindamycin is better than lincomycin since it has a wider indication for use and a high stable bioavailability when taken orally. In severe infections and sepsis should be combined with fluoroquinolones or aminoglycosides	Simultaneous administration of polymyxin with aminoglycosides increases its nephrotoxicity, and with neuromuscular blockers — neural-muscular transmission disturbance.
	2°	

## Lincosamides and polymixines

## Glycopeptides, oxazolidinons and fuzidic acid

Classification		Glycopeptides	Oxazolidinones Antibiotics of different groups		
Drugs	I generation 1. Vancomycin 2. Teicoplanin	II generation (lipoglycopeptides) 3. Telavancin 4. Dalbavancin	1. Linezolid (zivox)	1. Fusidic acid (fusidate)	
Mechanism of action	Attache to peptidoglyc bacterial cell wall synthe	ans of bacterial cells $\rightarrow$ inhibition of esis (bactericidal action).	Suppress bacterial protein synthesis (bacteriostatic action)		
Spectrum of activity	<ol> <li>Gr (+) cocci: staphy streptococci, pneumococ</li> <li>Anaerobes: clostric corynebacteria</li> </ol>	cci, enterococci, dia (including Cl. Difficile), listeria,	Gr (+) cocci: including PRSA, MRSA, vancomycin-resistant enterococci	<ol> <li>Gr (+) cocci: staphylococci (S. aureus, including MRSA; S. Epidermidis, including MRSE)</li> <li>Anaerobes: Clostridia (including Cl. Difficile)</li> </ol>	
Indications	<ul> <li>Systemic administration</li> <li>Generalized infection</li> <li>Prevention of postope</li> <li>Oral administration:</li> <li>Pseudomembranous c</li> <li>Staphylococcal enteri</li> </ul>	: s caused by sensitive strains of bacteria erative complications politis (Cl. Difficile) tis	Staphylococcal and pneumococcal infections resistant to other drugs: I. Lower respiratory tract infections 2. Infections of the skin and soft tissues 3. Enterococcal infections caused by vancomycin-resistant strainsofEnterococcus faecalis and faecium	<ul> <li>A drug of last resort:</li> <li>Staphylococcal infections (with allergy or resistance to β-lactam antibiotics)</li> <li>Pseudomembranous colitis</li> </ul>	
Side effects	Allergic reactions, pl impairment), nephrotoxi neck syndrome (chest ar	nlebitis, ototoxicity (tinnitus, hearing icity, neutropenia, thrombocytopenia, red nd neck hyperemia, nausea, hypotension)	Allergic reactions, gastrointestinal disorders, hepatotoxicity, reversible anemia, thrombocytopenia	Gastrointestinal disorders, in rare cases – violations of the liver function, jaundice	
Contraindications	Allergic reactions in the	anamnesis, pregnancy and lactation			
NB!	Vancomycin isn't ad administered IV slowly syndrome develops due cells). Teykoplanin unl MRSA and enterococci, day), IM administration characterized by broade (administration once a d	ministered IM (tissue necrosis!); is (in push administration the "red neck" e to the release of histamine from mast ike vancomycin is more active against better tolerated, lasts longer (1 time per and IV push are allowed. II generation is er activity and longer duration of action ay (3) or once a week. (4)	Has a high bioavailability (bioavailability is 100 % even in oral administration)	It is non-toxic, but the resistance of microorganisms develops quickly.	

Classification	For resorptive use (well absorbed in the digestive tract)		For topical administration	Combined drugs	
	Short-acting	Long-acting	Ultra long-acting	Ĩ	
Drugs	<ol> <li>Streptocide</li> <li>Sulfacaramide</li> <li>Sulfadimezine</li> </ol>	<ol> <li>Sulfapyridazine</li> <li>Sulfadimethoxi</li> </ol>	6. Sulfalene	<ul> <li>7. Sulfacil sodium (albucid)</li> <li>8. Silver sulfadiazine (dermazin)</li> <li>9. Phthalazole</li> </ul>	<ul> <li>10.Sulfamethoxazole / trimethoprim (co-trimoxazole, biseptol)</li> <li>11.Sulfadoxine / pyrimethamine (fanzi-dar)</li> <li>12.Sulfapyridine / 5-ASA</li> </ul>
Mechanism of action	Being structural analogues of PABA (necessary for bacterial growth) competitively inhibit the enzyme dihydrofolate synthetase involved in the folic acid synthesis			+ The silver ion, when combined with DNA, accumulates on the surface of bacteria nucleus and inhibits their growth and division (8)	+ Trimethoprim and pyrimethamine block the enzyme dihydrofolate reductase
Spectrum of action	Highly susceptible pathogens: cocci (pneumococci, gonococci, meningococci, streptococci), intestinal bacteria (Escherichia coli, salmonella, vibrio cholerae), large viruses (trachoma, inguinal lymphogranulomatosis), chlamydia, causative agents of gas gangrene, diphtheria, etc. Moderately susceptible pathogens: staphylococci, enterococci, klebsiella, mycobacteria, actinomycetes, causative agents of leprosy, tularemia, leishmaniasis1.Gr(+) cocci: staphylococci (including MRSA and PRS streptococci), 2.Gr(-) cocci: meningococci, morocelles 3. Gr (-) rods: E. coli, salmonella, Klebsiella,Haemoph influenzae				<ol> <li>Gr(+) cocci: staphylococci (including MRSA and PRSA), streptococci (except for β-hemolytic streptococcus A)</li> <li>Gr(-) cocci: meningococci, morocelles</li> <li>Gr (-) rods: E. coli, salmonella, Klebsiella,Haemophilus influenzae</li> <li>Nocardia, pneumocysts, toxoplas</li> </ol>
Indications	<ol> <li>Acute coccal infections (pneumonia, tonsillitis, bronchitis, sinusitis, otitis, cholecystitis, meningitis, etc.) (4–6,10)</li> <li>Acute infections of the urinary and genital tract (cystitis, prostatitis, etc.) (2.10)</li> <li>Eye infections (conjunctivitis, blepharitis, etc.) (7)</li> <li>Burns and infected skin wounds (8)</li> <li>Acute intestinal infections (dysentery, enteritis, colitis, etc.) (9), ulcerative colitis and Crohn's disease (12)</li> <li>Treatment of trachoma malaria chlamudia toxonlasmosis actinomycosis leprosy. etc.</li> </ol>				
Side effects	Allergic reactions (dermatitis, Stevens-Johnson syndrome, etc.); violation of hematopoiesis (leukopenia, agranulocytosis, sulmmemoglobinemia, anemia); urinary disruption (crystalluria, hematuria, urinary retention); hepatotoxicity (hepatitis, in children jaundice due to insufficiency of glucuronyltransferase); neurotoxicity (dizziness, headache, depressive conditions); immunosuppression (10).				
Contraindications	Allergic reactions to sulfanilamides, furosemide, thiazide diuretics, carbonic anhydrase inhibitors, sulfonylurea preparations; do not use in children under 2 months, except for children of HIV-infected mothers; pregnancy; severe renal insufficiency; severe liver dysfunction; megaloblastic anemia associated with a deficiency of folic acid.				
NB!	In the acidic medium of urine sulphanilamides crystallize in the renal tubules, increased alkaline fluids are recommended. Alkaline medium promotes sulfonamides ionization and improves the drugs uptake by a microbial cell. Photosensitivity is provoked. Sulfanilamides increase effects of neuromuscular blockers and can cause respiratory muscles paralysis. In pregnant women, sulfonamides can affect the binding of bilirubin to protein and cause fetus hyperbilirubinemia. Drugs have a teratogenic effect, can cause hemolysis, jaundice of newborns, methemoglobinemia, congenital disorders of the nervous and cardiovascular systems. Within long-term treatment with sulfonamides, mandatory hematological monitoring is necessary.				

#### Sulphanilamide

#### Quinolones and fluoroquinolones

			Fluoroquinolones			
Classification	Non fluoringtod quinglongs	I generation	II generation	III generation		
Classification	Non-muor mateu quinoiones	("Gram-negative" mono-	("Respiratory" difluoro-	("Respiratory-anti-anaerobic"		
		fluoroquinolones)	quinolones)	trifluoroquinolones)		
	1.Nalidixic acid (nevigramon)	4. Norfloxacin	8. Levofloxacin	10. Moxifloxacin		
Drugs	2. Oxolinic acid	5. Ofloxacin	9. Sparfloxacin	11. Gemifloxacin		
Drugs	3.Pipemidic acid (palin)	6. Pefloxacin		12. Gatifloxacin		
		7. Ciprofloxacin				
Mechanism of	DNA gyrase is inhibited. Affect the RNA of	f bacteria and the synthesis of bacterial proteins, the stability of membranes and other life processes of bacterial				
action	cells (bactericidal action)					
	Gr (-) bacteria: Escherichia coli, Shigella,	Gr (-) bacteria, S. aureus;	Gr (-) bacteria, S. aureus + high	The same + anaerobes, atypical pathogens		
Spectrum of	Proteus	Low activity against	activity against Streptococcus			
action		Streptococcus pneumoniae,	pneumoniae, Mycoplasma			
uction		Mycoplasma, Chlamydophila	pneumoniae, Chlamydophila			
		<u> </u>	pneumoniae			
	1. Urinary tract infections: acute cystitis,	1. Upper respiratory tract infections: sinusitis, especially caused by multiresistant strains, malignant external				
	antiretroviral therapy for chronic forms of	otitis media. Infections of the l	ower respiratory tract: exacerbation	of chronic bronchitis, community-acquired		
	infection. Do not use for acute	and nosocomial pneumonia, leg	gionellosis.			
	pyelonephritis.	2. Intestinal infections: shigelic	osis, typhoid fever, generalized salm	onellosis, iersiniosis, cholera.		
	2. Intestinal infections: shigellosis,	3. Anthrax.				
Indications	bacterial enterocolitis (1).	4. Intra-abdominal infections a	nd infections of the pelvic organs.			
		5. Urinary tract infections: (cystitis, pyelonephritis). Prostatitis. Gonorrhea.				
		6. Infections of the skin, soft tissues, bones and joints.				
		7. Eye infections.				
		8. Sepsis.				
	Dissective disorders (hearthurn rain in th	9. Tuberculosis in combination	therapy for drug-resistant tuberculo	sis (3,0).		
Sida affaata	drowsings incompio headeaba digging	le epigastric region, anorexia,	nausea, vomiting, diarrnea); centr	al nervous system disturbance (ololoxicity,		
Side effects	notosensitization	ss, visual impairment, paresu	iesia, tremor, convuisions), anerg	gie reactions (rash, nening, angioedema),		
	Allerrie reaction: deficiency of charge 6 sharphote dehudrogeneses: programmy					
Contraindications	+ Severe dysfunction of the liver and	+ Childhood: lactation	icy.			
Contraindications	kidneys: severe cerebral atherosclerosis	r Childhood, lactation.				
	Absorption of fluoroquinolones in the gastr	ointestinal tract (unlike non-fluo	rinated quinolones) is not disturbed	by food but it deteriorates sharply with the		
	use of divalent calcium iron magnesium a	luminum zinc cations The com	bination of fluoroquinolones with the	heophylline metronidazole and NSAIDs can		
NB!	cause a convulsive reaction. Fluoroquinolon	es can increase the photosensitiv	ity of tissues. In the course of treatr	nent with fluoroquinolones and during 3 days		
	after its termination, contact with UV-irradia	ation is excluded.	· · · · · · · · · · · · · · · · · · ·			

Classification	Nitrofurans	Nitroimidazoles	Oxyquinolines
Drugs	1. Nitrofurantoin (furadonin)4. Furazolidone2. Furazidine (furamag)5. Nitrofural (furacilin)3. Nifuroxazide5. Nitrofural (furacilin)	<ul><li>6. Metronidazole (Trichopolum)</li><li>7. Tinidazole</li><li>8. Ornidazole</li></ul>	9. Nitroxoline
Mechanism of action	Being oxygen acceptors, they break the process of cellular respiration of bacteria, inhibit the biosynthesis of nucleic acids (depending on the concentration have a bacteriostatic or bactericidal effect)	Active reduced forms of drugs disrupt DNA replication and protein synthesis in a microbial cell; inhibit tissue respiration (bactericidal action)	Violate protein synthesis, form chelates, enhancing oxidative processes in the cytoplasm (bactericidal action)
Spectrum of activity	<ol> <li>Gr (+) cocci: streptococci, enterococci, staphylococci).</li> <li>Gr (-) bacteria: intestinal group.</li> <li>Protozoa: Giardia, Trichomonas (4).</li> </ol>	<ol> <li>Anaerobic bacteria</li> <li>Helicobacter</li> <li>The simplest (Trichomonas, Giardia, Amoeba, Balance-Tidia)</li> <li>Gardnerella</li> </ol>	<ol> <li>Gr (+) and Gr (-) bacteria (staphylococci, enterobacteria, etc.)</li> <li>The simplest (amoeba, lamblia, balantidia)</li> <li>Pathogenic fungi (candida)</li> </ol>
Indications	<ol> <li>Infections of the lower sections of the urinary tract: acute cystitis, suppressive therapy of chronic infections (1, 2)</li> <li>Preventive maintenance of infectious complications at urological operations, a cystoscopy, a catheterization of a bladder (1,2)</li> <li>Intestinal infections: acute infectious diarrhea, enterocolitis (3)</li> <li>Giardiasis, trichomoniasis (4)</li> <li>Local washing of wounds and cavities (2,5)</li> </ol>	<ul> <li>Systemically:</li> <li>1. Anacrobic infections of different locations</li> <li>2. Pseudomembranous colitis</li> <li>3. Perioperative prophylaxis for intra-abdominal and gynecological interventions</li> <li>4. Protozoal infections</li> <li>5. Eradication of H. pylori in peptic ulcer disease <i>Topically:</i> vaginitis, bacterial vaginosis, rosacea, seborrheic dermatitis, perioral dermatitis.</li> </ul>	Acute uncomplicated cystitis - treatment, prevention (as a drug of the II line)
Side effects	Allergic reactions (rash, eosinophilia, fever, arthralgia, myalgia, drug induced lupus erythematosus, rarely anaphylactic shock); disorders of the gastrointestinal function (nausea, vomiting, diarrhea), liver (transient increase in transaminase activity, cholestasis, hepatitis), lungs (pneumonitis, bronchospasm, cough, pain in the chest), nervous system (dizziness, headache, general weakness, drowsiness, peripheral polyneuropathies); hematological reactions (leukopenia, megaloblastic or hemolytic anemia).	Digestive disorders (bad taste in the mouth, abdominal pain, nausea, vomiting, diarrhea), CNS (headache, dizziness, impaired coordination of movements, impaired consciousness, seizures, in rare cases - epileptic seizures); allergic reactions (rash, itching); hematological reactions (leukopenia, neutropenia); topical reactions (phlebitis and thrombophlebitis after intravenous administration); cutaneous manifestations (photodermatitis).	Peripheral neuro- and myopathy, optic nerve damage, allergic reactions, abdominal pain and nausea.
Contraindications	Allergic reactions; renal failure (1,2); severe liver disease (4); deficiency of glucose-6-phosphate dehydrogenase; pregnancy - III trimester (1); newborn period.	Allergic reactions; organic diseases of the central nervous system with severe clinical manifestations; pregnancy (I trimester); lactation.	Diseases of the peripheral nervous system, liver; kidney failure; pregnancy, lactation; newborns.
NB!	Have disulfiram-like effect $\rightarrow$ can't be taken with alcohol. When taking nitrofurans tyrosine-contained products (cheese, cream, bananas) should be excluded from the diet due to the risk of increased blood pressure	The half-life of metronidazole is shorter than one of tinidazole and ornidazole, so it is prescribed 3 times a day, other drugs 1-2 times a day. They have a disulfiram-like effect $(6, 7)$ . May cause dark discoloration of urine $(6, 7)$ .	During treatment with nitroxoline, saffron-yellow color of the tongue, urine and feces is possible.

## Nitrofuranes, oxychinolines and nitroimidasezoles

# 11. ANTIMICOBACTERIAL, ANTI-SPIROCHETE, ANTIVIRAL, ANTIFUNGAL DRUGS

Antimycobacterial drugs are chemotherapeutic agents used to treat Mycobacteria infections (tuberculosis and leprosy).

Classification		First-line o	line drug		Second-line drugs	
	Derivatives of isonicotinic acid hydrazide	Derivatives of paraaminosalicylic acid	Antibiotics	Drugs of different chemical groups	Derivatives of isonicotinic acid thiamide	Antibiotics
Drugs	1.Isoniazid (H) 2.Phtivazide (Vanisid) 3.Fluenylidide	4. Sodium paraaminosalicylate (PAS) 5.Benzoyl-PAS- calcium (Bepask)	6.Sremptomycin sulfate (S) 7.Rifampicin(R)	8.Pyrazinamide (Z) 9.Ethambutol (E)	10. Ethionamide (Eto)	<ol> <li>Cycloserine</li> <li>Ofloxacin</li> <li>Levofloxacin</li> <li>Amicacin</li> <li>Kanamycin</li> <li>Capreomycin</li> </ol>
Mechanism of action	. Disturbance of mycobacterium cell membrane structure 2. Inhibits the synthesis of mycolic acid in the cell wall (1) 3. Inhibits metabolic and oxidative processes, the synthesis of nucleic acids (2) * Bactericidal action in reproduction (1) Bacteriostatic action ivity (1–3)	1.Selectively compete with para- aminobenzoic acid (PABA) and inhibit the synthesis of folate in mycobacteria *Bacteriostatic action	<ul> <li>1.Supresses protein synthesis in the cell</li> <li>(6)</li> <li>*Bacteriostatic action</li> <li>2. Inhibits DNA- dependent RNA- polymerase (7)</li> <li>*Bactericidal action</li> </ul>	<ol> <li>Inhibition of mycobacteriaL RNA synthesis</li> <li>* Bacteriostatic action</li> </ol>	1. Blocks the synthesis of mycolic acid in mycobacteria * Bacteriostatic action	1.Disturbance of protein synthesis of the cell wall (11, 16) 2.See "Antibiotics(end). Synthetic antimicrobial agents" (12–15)
Spectrum of activity	<ol> <li>Mycobacterium tuberculosis</li> <li>Chlamydia trachomatis (3)</li> </ol>		See the topic "Antibiotics (end). Synthetic antimicrobial agents"	<ol> <li>Mycobacterium tuberculosis</li> <li>Mycobacterium leprae (10, 11)</li> <li>E.coli, Proteus, cocci, causative agent of tularemia, etc. (11)</li> </ol>		
Indications	<ol> <li>Tuberculosis of various forms a</li> <li>Urogenital chlamydiosis (3)</li> <li>Poor PASK tolerance (5)</li> </ol>	and localizations		1. Tuberculosis of various forms and localizations	1. Pulmonary tuberculosis resistant to the 1st line drugs 2. Leprosy (10)	

Classification		First-line o	drug		Second-l	ine drugs
Sideeffects	<ol> <li>Dyspepsia (1,2)</li> <li>Neurotoxicity (1,2)</li> <li>Hepatotoxicity (1,2)</li> <li>Hypovitaminosis B6 (1,2)</li> </ol>	<ol> <li>Dyspepsia</li> <li>Hypothyroidism</li> <li>Crystalluria, agranu-locytosis (4)</li> <li>Allergic reactions</li> </ol>		<ol> <li>Dyspepsia</li> <li>Hyperuricemia (8)</li> <li>Polyneuropathy (9)</li> <li>↓ vision, scotomas formation (9)</li> </ol>	<ol> <li>Dyspepsia</li> <li>Headache, paresthesia</li> <li>Allergic reactions</li> </ol>	<ol> <li>Neuropsychiatric disorders (11)</li> <li>Dyspepsia</li> <li>Oto-, nephro-, hepatotoxicity (16)</li> </ol>
Contraindication s	<ol> <li>Epilepsy and a tendency to seizures (1, 2)</li> <li>Prior poliomyelitis (1, 2)</li> <li>Violations of the functions of the liver and kidneys (1,2)</li> <li>Hypersensitivity</li> </ol>	<ol> <li>Dysfunction of the liver and kidneys</li> <li>Gastroduodenal ulcers</li> <li>Myxedema</li> <li>Cardiac insufficiency</li> </ol>	See"Antibiotics (end). Synthetic antimicrobial agents"	<ol> <li>Dysfunction of the liver and kidneys</li> <li>Epilepsy (8)</li> <li>Gout (8)</li> <li>Optic neuritis (9)</li> </ol>	<ol> <li>Dysfunction of the liver and kidneys</li> <li>Gastroduodenal ulcers</li> <li>Hypersensitivity</li> </ol>	<ol> <li>Psychoses, epilepsy (11)</li> <li>Hypersensitivity</li> <li>Impairment of kidney function</li> </ol>
NB!	<ul> <li>World Health Organization classification of drugs used to treat drug-susceptible and drug-resistant tuberculosis:</li> <li>First-line anti-TB drugs (Group 1) are currently recommended in a four-drug combination for the treatment of drug-susceptible TB. Second-line anti-TB drugs (Groups 2, 3 and 4) are reserved for drug-resistant TB. Third-line anti-TB drugs (Group 5) have unclear efficacy or undefined roles.</li> <li>First-line anti-TB drugs</li> <li><i>Group 1</i>. Oral: isoniazid (H/Inh), rifampicin/rifampin (R/Rif), pyrazinamide (Z/Pza), ethambutol (E/Emb), rifapentine (P/Rpt) or rifabutin (Rfb).</li> <li>Second-line anti-TB drugs</li> <li><i>Group 2</i>. Injectable aminoglycosides: streptomycin (S/Stm), kanamycin (Km), amikacin (Amk). Injectable polypeptides: capreomycin (Cm), viomycin (Vim).</li> <li><i>Group 3</i>. Oral and injectable fluoroquinolones: ciprofloxacin (Cfx), levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), gatifloxacin (Gfx).</li> <li><i>Group 4</i>. Oral: <i>para</i>-aminosalicylic acid (Pas), cycloserine (Dcs), terizidone (Trd), ethionamide (Eto), prothionamide (Pto), thioacetazone (Thz), linezolid (Lzd).</li> <li>Third-line anti-TB drugs</li> <li><i>Chaferimine (Cfc)</i>. <i>Linezolid (Led)</i>.</li> </ul>					
Rettost						

Anti-spirocheteagents — drugs for infectious diseases caused by spirochetes (syphilis, relapsing fever) and leptospira (leptospirosis).

Classification	Antibiotics	Bismuth drugs		
Drugs	<ul> <li>Basic:</li> <li>1. Benzathine benzylpenicillin (Extensillin, Bicillin-1); Bicillin-3, Bicillin-5</li> <li>2. Benzylpenicillin sodium salt, novocaine salt Alternative:</li> <li>3. Ceftriaxone</li> <li>4. Doxycycline</li> <li>5. Erythromycin</li> </ul>	6. Biyohinol 7. Bismoverol		
Mechanism of action		Block SH-groups of enzymatic systems of spirochaetes		
Pharmacological effects		<ol> <li>Anti-spirochectis</li> <li>Anti-inflammatory</li> <li>Resolving effect</li> </ol>		
Indications	See the topic "Antibiotics (end). Synthetic antimicrobial agents"	<ol> <li>Different forms of syphilis (in combination with antibiotics)</li> <li>Nonsyphilitic lesion of the central nervous system (arachnoencephalitis, meningomyelitis)</li> </ol>		
Side effects		<ol> <li>Gingivitis, stomatitis, the appearance of a black line along the gums (bismuth line)</li> <li>Hepato- and nephrotoxicity</li> </ol>		
Contraindications		<ol> <li>Lesions of the oral mucosa</li> <li>Kidney disease</li> <li>Acute and chronic liver diseases with lesion of her parenchyma</li> <li>Hemorrhagic diathesis</li> </ol>		
NB!	<ul> <li>1) Primary syphilis of genital organs and other localizations therapy (outpatient care)</li> <li>Basic method: Benzathine benzylpenicillin — IM, the 1<sup>st</sup> injection —4,8 mln IU IM (2,4 mln IU for every glut), the 2<sup>nd</sup> — 2,4 mln IU with 1 week interval.</li> <li>Alternative methods: Novocain salt of benzylpenicillin — IM 600 thousand IU 2 pasa/cyr (with 12 hours interval) — 14 days <u>or</u> Bicillin -3 — IM 2,4 mln EД,</li> <li><u>or</u> Bicillin-5 1,5 mln IU 3 times a week 6 injections, <u>or</u> Ceftriaxone - IM 1,0 g once daily 14 days, <u>or</u> Doxycycline 0,1 g orally twice daily 20 days, <u>or</u> Erythromycin 0,5 g 4 times a day 20 days</li> <li>Children treatment is only inpatient.</li> <li>2) Therapy of leptospirosis: Benzylpenicillin up to 18 000 000 IU daily 7 days <u>or</u> Ampicillin up to 6 g daily IM or IV 7 days, <u>or</u> Doxycycline 200 mg daily or and the second seco</li></ul>			

#### Antisyphilitic drugs

#### Antiviral drugs

	Antiviral drugs	are medicines	for the	treatment	and	prevention	of	various	viral	diseases	•
--	-----------------	---------------	---------	-----------	-----	------------	----	---------	-------	----------	---

Classification	Anti-influenza agents	Antiherpetic, anticytomegalovirus agents	Antiretroviral agents	Agents for viral hepatitis
Drugs	1. Amantadine (Midantan)       6. Acyclovir (Zovirax)         2. Remantadine (Rimantadine)       7. Valaciclovir (Valtrex)         3. Oseltamivir (Tamiflu)       8. Ganciclovir (Cymeven)         4. Zanamivir (Relenza)       9. Idosukradin         5. Arbidol       10. Foscarnet		NIRTs:         11. Zidovudine (Retrovir)         12. Lamivudine (Zeffix)         NNIRTs         13. Nevirapine (Viramune)         Protease inhibitors (PIs)         14. Saquinavir (Invirase)         15. Indinavir (Crixivan)	<ul> <li>16. Ribavirin Interferons:</li> <li>17. Reaferon (Interferon- a2)</li> <li>18. Intron-A (Interferon-a2b) Interferon inductors:</li> <li>19. Cycloferon</li> <li>20. Tylorone</li> </ul>
Mechanism of action	<ol> <li>Inhibit M2 proton channels of the influenza A virus (1, 2) and neuro-minidase of influenza A and B viruses → block viral replication (3, 4).</li> <li>Prevents the fusion of viral lipid envelope with cell membranes, induces the synthesis of interferon (5).</li> </ol>	<ol> <li>Are phosphorylated in the infected cell with the formation of triphosphate derivatives → inhibit the synthesis of viral DNA-polymerase (6-8)</li> <li>Violates the synthesis of nucleic acids (DNA), selectively depresses the replication of the herpes simplex virus (9)</li> <li>Inhibits DNA polymerase and reverse transcriptase of HIV (10)</li> </ol>	<ol> <li>Inhibits the reverse transcriptase of viral DNA and selectively inhibits viral DNA replication (11,12)</li> <li>Bind directly to reverse transcriptase of HIV → destruction of enzymatic catalytic center (13)</li> <li>Inhibits proteases involved in the assembly of the viral virion at the exit from the affected cell (14, 15)</li> </ol>	<ol> <li>Inhibits synthesis of viral RNA and DNA (16)</li> <li>Inhibit the synthesis of viral matrix RNA, suppress the synthesis of proteins of the viral envelope (17, 18)</li> <li>Suppress the effect of tumor growth factors; destroy bacterial cells (17, 18)</li> <li>Stimulate the synthesis of endogenous interferon in the body (19, 20)</li> </ol>
Pharmacological effects	1. Antiviral, 2. Interferon-induci	ng (5,19,20), 3. Immunomodulating (5,17–20)	), 4. Antineoplastic (17,18), 5. Anti-infl	ammatory (19)
Indications	<ol> <li>Influenza A treatment (1–5,16</li> <li>Influenza B treatment (3–5,16</li> <li>Herpes simplex virus type 1 and</li> <li>Cytomegalovirus infection (6</li> <li>Acyclovir-resistant viral infection)</li> </ol>	5) and prevention (5) 6) 6) 6) and type 2 skin and mucosa infection (6–9), -8,10), shingles (6,7) 6,10) and a statements (10)	1. Treatment of infection caused by HIV-1 and HIV-2 (11, 12, 14, 15); HIV-1 (13)	<ol> <li>Chronical hepatitis C (16–20)</li> <li>Viral infections caused by RSV- virus (16)</li> <li>Acute viral hepatitis B (16–20)</li> <li>Kaposi's sarcoma (17,18)</li> </ol>
Side effects	1. Nausea, vomiting (1–3) 2. Headache, dizziness (1–3) <i>Relenza (Zanamivir) – very</i> <i>rarely</i>	<ol> <li>Nausea, vomiting (6–8,10)</li> <li>Headache (6–8)</li> <li>Anemia, granulocytopenia (8,10)</li> <li>Inflammation or edema of the eyelids (9)</li> <li>Nephro-, neurotoxicity (10)</li> </ol>	<ol> <li>Leukopenia, anemia (11, 12) granulocytopenia (11, 12, 13)</li> <li>Dyspeptic phenomena (11–15), a taste perversion (15)</li> <li>Peripheral neuropathies, myalgia (11–14)</li> </ol>	<ol> <li>↓ blood pressure (16,18)</li> <li>2. Thyroid disfunction (16)</li> <li>3. Leukemia and thrombocytopenia (16–18)</li> <li>4. Flu-like condition</li> <li>5. Allergic reactions</li> </ol>
Contraindications	<ol> <li>Diseases of the liver and kidneys (1-3)</li> <li>Gastroduodenal ulcers (1)</li> <li>Hypersensitivity to the drug</li> </ol>	<ol> <li>Hypersensitivity to the drug</li> <li>Neutropenia, granulocytopenia, anemia</li> <li>(8)</li> </ol>	<ol> <li>Leukopenia, anemia (11, 12)</li> <li>Chronic hepatitis and cirrhosis of liver, renal failure (11)</li> <li>Hypersensitivity</li> </ol>	<ol> <li>Pronounced diseases of the liver and kidneys (16, 17)</li> <li>Thyrotoxicosis (16)</li> <li>Heart failure, decompensation (17,18)</li> </ol>

Antifungal agents (antimycotics) — medicines that suppress the growth and reproduction of pathogenic fungi and are used for the prevention and treatment of mycoses.

Classification	Polyene antibiotics and others *	Azoles	Allylamines	Derivatives of undecylenic aci
Drugs	<ol> <li>Amphotericin B (Fungizone)</li> <li>Nystatin</li> <li>Levorin</li> <li>Mycoheptin</li> <li>Griseofulvin *</li> </ol>	<ul> <li>Imidazole derivatives:</li> <li>6. Clotrimazole (Kanesten)</li> <li>7. Ketoconazole (Nizoral)</li> <li>8. Miconazole (Dactarine) Triazole derivatives:</li> <li>9. Fluconazole (Diflucan)</li> <li>10. Itraconazole (Orungal)</li> </ul>	11. Terbinafine (Lamisil) 12. Naphthifin (Exoderyl)	13.NitrofunginNeo14.Undecine15.MycoSepti
Mechanism of action	<ol> <li>Bind to ergosterol of the fungal membrane → ↑ its permeability → death of a fungal cell (1-4)</li> <li>Inhibits the synthesis of nucleic acids → disrupts the reproduction of fungal cells (5)</li> </ol>	Inhibition of the conversion of lanosterol to ergosterol (the main sterol of the cytoplasmic membrane of the fungal cells) $\rightarrow$ disruption of the formation of the fungal cell membrane	Inhibit the enzyme squalene epoxidase catalyzing (with the squalene cyclase) the conversion of squalene to lanosterol $\rightarrow$ ergosterol deficiency $\rightarrow$ squalene intracellular accumulation $\rightarrow$ death of the fungus	Bind to ergosterol fungal membrane $\rightarrow \uparrow$ its permeability $\rightarrow$ death of a fungal cell
Pharmacological effects	Antimycotic effect: fungicidal action (1–4,6–12–15); fungistatic action (5–10,13–15), antibacterial (3,6–10,12,13)			
Indications	<ol> <li>Systemic mycoses: (blastomycosis, cr</li> <li>Candidomycosis (1–4,6,7,9,10)</li> <li>Trichomoniasis (3.6)</li> <li>Onychomycosis (5,7,10–12)</li> <li>Dermatomycosis (trichophytosis, micr</li> <li>Fungal eczema (13)</li> </ol>	yptococcosis, histoplasmosis, etc.) (1–4 rosporia) (5–8,10–15)	,7,9,10)	
Side effects	<ol> <li>Nausea, vomiting 2. Dysfunction of the liver (1) 3. Impaired renal function (1.4) 4. Anemia, thrombocytopenia (1)</li> <li>Candidiasis of the oral cavity (5)</li> </ol>	<ol> <li>Local reactions when applied to the skin (6,8)</li> <li>Nausea, vomiting (7–10)</li> <li>Arthralgia (7)</li> <li>Dysfunction of the liver (7, 10) 5. Edema, dysmenorrhea (10)</li> </ol>	<ol> <li>Nausea, vomiting (11) 2. Neutropenia (11)</li> <li>Local reactions when applied to the skin (12)</li> </ol>	1. Topical reactions when applied to the skin (13, 14)
Contraindication s	<ol> <li>Diseases of the kidneys, liver (1,3-5)</li> <li>Diseases of the hematopoietic system (1.5)</li> <li>Diabetes mellitus (1,5)</li> </ol>	<ol> <li>Pregnancy, breast-feeding (6–9)</li> <li>Dysfunction of the liver (7,8,10)</li> <li>Herpetic fever (8) 4.</li> <li>Hypersensitivity to the drug</li> </ol>	<ol> <li>Severe renal and hepatic insufficiency (11) 2. Diseases of the blood (11)</li> <li>Pregnancy, breast-feeding</li> </ol>	1. Hypersensitivity to the drug 2. Acute inflammatory skin diseases (14,15)

# 12. ANTIPROTOZOIC AND ANTIPARASITIC DRUGS. ANTISEPTICS AND DISINFECTANTS

Antimalarials — drugs used for the prevention and treatment of malaria.

Classification	Blood schizonticides	Tissue schizonticides					
	1. Quinine	5. Primaquine					
	2. Chloroquine (hingamin)						
Drugs	3. Mefloquine						
	4. Hydroxychloroquine (plaquenil)						
	6. Pyrimethamine						
	1. Suppress the synthesis of nucleic acids (1–5)						
Mechanism of action	2. Blocks dehydrofolate reductase, which disrupts the transformation of	lehydrofolic acid into tetrahydrofolic acid, which is necessary for the					
	development of plasmodia (6)						
Pharmacological	1. Antiprotozoal;						
effects	2. Antiarrhythmic (1, 2), 3. Uterotonic (1), 4. Anti-inflammatory, immunosuppl	ressive (2, 4).					
	1. Malaria						
	2. Prevention of transmission (5, 6)						
	3. Pre-travel chemoprophylaxis (2, 3, 6) 4. SLE, rhoumetoid orthritis (2, 4)						
Indications	4. SLE, rheumatoid arthritis (2, 4)	4. SLE, meumatoid annifilis (2. 4) 5. Violation of the rhythm of the heart (extrasystole, atrial fibrillation, etc.) (1. 2)					
	5. violation of the rhythm of the heart (extrasystole, atrial fibrillation, etc.) (1, 2) 6. Extraintectinal amphiasis (2)						
	<ul> <li>0. EXtraintestinal amediasis (2)</li> <li>7. Prophylaxis of distant relapses with quartan and tertian malarias (5)</li> </ul>						
	1. Noise in the core, polnitations, trembling of hands, insemnia (1)						
	2 Dermetitis (with prolonged use) (2.4)						
	2. Definations (with protonged use) (2.4) 3. Dizziness headache (1, 2, 6)						
Side effects	4 Dyspentic phenomena (1, 3, 5, 6)						
	5 Ataxia hearing and vision impairment (3)						
	6. Megaloblastic anemia (6)						
	1. Deficiency of glucose-6-phosphate dehydrogenase, diseases of the middle a	nd inner ear. cardiac decompensation (2) 2. Diseases of the hematopoietic					
	organs (2, 4, 5, 6)						
Contraindications	3. Kidney disease (2–6), a violation of liver function (2-4)						
	4. Heart disease (2 - 4)						
	5. Acute infectious diseases (except malaria), blood diseases, angina pectoris (5	i)					
	Primaquine is lethal to P. vivax and P. ovale in the liver stage, and also to P.	vivax in the blood stage; due to the emergence of pyrimethamine-resistant					
NRI	strains of P. falciparum, pyrimethamine alone is seldom used now.						
1 <b>1D</b> .	Combined drugs: Metakelfin (pyrimethamine + sulfametapirazin), Fansidar (py	rimethamine + sulfadoxine).					

Anti-amoebic drugs — drugs used for the treatment of amebiasis.



#### Localization of amoebae

#### Other antiprotozoal agents



Drugs for trichomoniasis, bacterial vaginosis and nonspecific urethritis: metronidazole, ornidazole, tinidazole, furazolidone.

1. Drugs for giardiasis: metronidazole, ornidazole, furazolidone, aminoquinol.

2. Drugs for toxoplasmosis: pyrimethamine, sulfonamides.

3. Drugs for leishmaniasis: salusurumin, sodium stiboglucate (visceral and cutaneous forms), monomycin, paromomycin, meglumine antimonate, mepacrine hydrochloride.

4. Drugs for balantidiasis: monomycin, tetracyclines, hiniofon.

Classification	Intestinal nematodes	Intestinal cestodiasis	Extraintestinal helminthiases
	(ascaridosis, enterobiasis, trichocephalosis)	(Diphyllobothriasis, teniosis, teniarinhosis)	(opisthorchis, fasciolosis, schistosomiasis)
	1. Mebendazole, albendazole	5. Nichlosamide	7. Ditrazine citrate
D	2. Levamisole	6. Cucurbin (drug from pumpkin seed)	8. Chloxyl
Drugs	3. Piperazine adipate		
	4. Pyrantel	9. Praziquantel	
	1. Violate the synthesis of helminth tubulin, $\downarrow$	1. Paralytic effect on helminths and $\downarrow$ their	1. Disruption of motor activity of helmintes (7)
	helminth absorption of glucose and the formation of	resistance to proteolytic enzymes of the	2. Destruction of nucleoproteins of epithelium
Machaniam of action	ATP (1)	gastrointestinal tract (5, 6)	and parenchyma of helminths, violates their
Witchamsm of action	2. Paralysis of the musculature of helminths (2–4)	2. ↑ permeability of cell membranes of	carbohydrate metabolism (8)
	3. Inhibition of succinate dehydrogenase $\rightarrow$	parasites for Ca ions $\rightarrow$ muscle contraction-	
	disturbance of bioenergetic processes of helminths (2)	tours $\rightarrow$ spastic paralysis (9)	
Pharmacological	1. Anthelmintic		
effects	2. Immunostimulating (2)		
	1. Ascariasis	1. Taeniasis (5, 6, 9)	1. Filariasis: lymphatic filariasis
Indications	2. Enterobiasis (pinworm infection) (1, 3, 4)	2. Diphyllobothriasis (5, 6, 9)	(elephantiasis), onchocerciasis (7)
	3. Trichocephalosis (1. 4)		2. Opisthorchiasis (8, 9)
	4. Trichinosis (1)		3. Fascioliasis (8, 9)
	5. Ancylostomiasis (1, 2, 4)		4. Schistosomiasis (9)
	1. Dyspeptic disorders	1. Nausea (5, 9)	1. $\uparrow$ liver size (7.8)
Side effects	2. Agranulocytosis (2)	2. Allergic reactions (5, 9)	2. Impaired heart rhythm, pain in the heart (8)
	3. Allergic reactions		3. Proteinuria (8)
	4. Headache, dizziness (1,4)		4. Skin itching, skin rashes (7)
	1. Hypersensitivity to the drug	1. Pregnancy (5, 9)	1. Liver diseases not associated with helmints (8)
Contraindications	2. Agranulocytosis (2)	2. Gastroduodenal ulcers (5)	2. Pregnancy
	3. Pregnancy, breast-feeding $(1, 2, 4)$	3. Anemia $(5)$	3. Cysticercosis of the eye (9)
	4. Organic diseases of the central nervous system (3)	4. Liver distunction (9) $1.11 - 2.5 - 4$	4. Eye disorders in onchocerciasis (7)
NB!	Levamisole - single administration before bedtime for ad	lults 0.15 g (150 mg), children 2.5 mg/kg. If neces	ssary, the intake is repeated after a week.
	Mebendazole is prescribed once a day for 3 days for asc	ariasis and enteroblasis	

## Anthelmintic drugs — agents used to treat helminthiases.

**Disinfectants** are applied to the surface of non-living objects to destroy microorganisms. **Antiseptics** are applied to living tissue/skin to reduce the possibility of infection.

Classification	Halogen-containing substances	Oxidizing agents	Acids and alkalis	Metal compounds
Drugs	<ul> <li>Preparations of chlorine:</li> <li>1. Chloramine</li> <li>2. Chlorhexidine</li> <li>Iodine preparations:</li> <li>3. Tincture of iodine 5 %</li> <li>4. Lugol's iodine</li> <li>5. Iodinolum</li> <li>6. Povidone-iodine</li> </ul>	<ol> <li>7. Hydrogen peroxide</li> <li>8. Potassium permanganate</li> </ol>	<ul><li>9. Salicylic acid</li><li>10. Boric acid</li><li>11. Sodium tetraborate (borax)</li></ul>	Silver preparations: 12. Silver nitrate 13. Protargol (silver proteinate) 14. Colloidal silver <i>Copper preparations:</i> 15. Copper sulfate <i>Zinc preparations:</i> 16. Zinc sulfate
Mechanism of action	<ol> <li>Chlorine replaces the hydrogen atom, the secondary structure of the protein is disrupted</li> <li>Active molecular iodine interacts with NH-groups of protein molecules, causing denaturation of proteins</li> </ol>	Release of atomic oxygen, oxidation of the substrate of a microbial cell, death of microorganisms	Denaturation of the protoplasmic protein of the microbial cell	Denaturation of protein, blockade of sulfhydryl groups of enzyme systems of the protoplasm of the microbial cell, formation of albuminates
Pharmacological effects	<ol> <li>Antimicrobial</li> <li>Deodorizing (1)</li> <li>Spermicidal (1)</li> </ol>	<ol> <li>Antimicrobial</li> <li>Deodorizing (7)</li> <li>Astringent (8)</li> </ol>	<ol> <li>Antimicrobial</li> <li>Irritating (9)</li> <li>Keratolytic (9)</li> <li>Anti-pediculosis (10)</li> </ol>	<ol> <li>Antimicrobial</li> <li>Astringent (12,13,15,16)</li> <li>Anti-inflammatory (12,13)</li> </ol>
Indications	<ol> <li>Infected wounds (1, 2, 6)</li> <li>Hand scrubbing (1, 3)</li> <li>Skin preparation for the prevention of surgical site infection (2, 3)</li> <li>Sterilization of surgical instruments (2)</li> </ol>	<ol> <li>Treatment of wounds, ulcers (7, 8)</li> <li>Rinse the mouth and throat (7, 8)</li> <li>Bleeding wounds and capillary bleeding (7)</li> <li>Sprinkling in gynecology and urology (8)</li> </ol>	<ol> <li>Removal of corns (9)</li> <li>Conjunctivitis, otitis media (10)</li> <li>Pediculosis (10)</li> <li>Fatigue, pressure sores (11)</li> <li>Infectious and inflammatory skin diseases</li> </ol>	<ol> <li>Conjunctivitis</li> <li>Washing of the bladder and urethra</li> <li>Erosions, ulcers, cracks (12)</li> <li>Purulent wounds (14)</li> <li>Nesting baldness (16)</li> <li>Acne (16)</li> </ol>
Side effects	<ol> <li>Dryness and itching of the skin, dermatitis (2)</li> <li>Allergic reaction</li> <li>Irritation at the site of application (1,3–6), iodism (3–6)</li> </ol>	<ol> <li>Burning in the application area</li> <li>Allergic reaction</li> </ol>	<ol> <li>Nausea, vomiting, diarrhea</li> <li>(10)</li> <li>Burning, itching at the site of exposure</li> </ol>	1. Allergy
Contraindications	<ol> <li>Hypersensitivity</li> <li>Dermatitis (2)</li> <li>Pregnancy (3–6)</li> <li>Chronic kidney failure (6)</li> </ol>	<ol> <li>Individual intolerance</li> <li>Damage to surrounding tissues at a strong concentration (8)</li> </ol>	<ol> <li>Impaired renal function (9, 10)</li> <li>Pregnancy, breast-feeding</li> </ol>	<ol> <li>Pregnancy and lactemia (13)</li> <li>Hypersensitivity</li> </ol>

Classification	Phenols	Dyes	Aldehydes and	Detergents	Nitrofurans	Tar
Drugs	<ol> <li>Phenol, tricresol</li> <li>Resorcin</li> <li>Pheresolum</li> <li>Phenyl salicylate (salol)</li> <li>Policresulen</li> </ol>	<ul><li>6. Methylene blue</li><li>7. Brilliant green</li><li>8. Ethacridine lactate (rivanol)</li></ul>	<ul><li>9. Formaldehyde (formalin)</li><li>10. Hexamethylene tetramine (urotropin)</li><li>11. Ethyl alcohol</li></ul>	<ol> <li>Bar soap</li> <li>«Hibiscrub» base</li> <li>LIC 76</li> <li>Myramistin</li> </ol>	<ul><li>16. Nitrofural</li><li>(furacilin)</li><li>17. Furazolidone</li><li>18. Furazidine</li><li>(furagin)</li></ul>	<ol> <li>Tar birch</li> <li>Ichthyol</li> <li>Vinisol</li> <li>Citral</li> <li>Sülsen</li> </ol>
Mechanism of action	Block the enzymatic activity of dehydrogenase, cause protein denaturation	Inhibit enzymatic processes, form hardly soluble complexes	Denaturation of cell proteins	↓ surface tension at the interface $\rightarrow$ The permeability of the microbial cell membrane is disturbed, the osmotic equilibrium $\rightarrow$ the death of the bacterium	Reduce nitro- group in the amino group $\rightarrow$ violate the function of DNA, inhibit the cellular respiration of microbes	The action is provided by a complex of bioactive substances
Pharmacological effects	<ol> <li>Antimicrobial</li> <li>Irritating (1, 11, 19),</li> <li>Local anesthetizing (2, 20)</li> <li>Trichomonasidic (5),</li> <li>Deodorizing (9),</li> <li>Tanning (11),</li> <li>Washing, foaming (12–1):</li> <li>Anti-inflammatory (20,22)</li> <li>Analgesic (22)</li> </ol>	)), 5), 2),	,091			
Indications	<ol> <li>Disinfection of premises, hands (1)</li> <li>Skin diseases (eczema, seborrhea) (2)</li> <li>Removal of papillomas (3)</li> <li>Diseases of the intestines, cystitis, pyelonephritis (4)</li> <li>Inflammatory diseases of the vagina, cervix (5)</li> </ol>	<ol> <li>Burns, pyoderma, folliculitis (6.7)</li> <li>Cystitis, urethritis (6)</li> <li>Poisoning by cyanide, carbon monoxide, hydrogen sulphide (6)</li> <li>Treatment of wounds, cleansing cavities in surgery (8)</li> <li>Diseases of the oral cavity and nasopharynx (8)</li> </ol>	<ol> <li>Disinfection of surgical instruments (9, 11)</li> <li>Increased sweating (9)</li> <li>Urinary tract infections, eyes diseases (10)</li> <li>Compresses (11)</li> <li>Pulmonary odema (vapour) (11)</li> </ol>	<ol> <li>Desinfection of hands (12–14)</li> <li>Syphilis, gonorrhea (15)</li> <li>Fungal skin lesions (15)</li> <li>Diseases of the ENT organs (15)</li> </ol>	<ol> <li>Purulent wounds, ulcers, pressure ulcers, burns (16)</li> <li>Infectious bowel disease (17)</li> <li>Urinary infections (18)</li> <li>Conjunctivitis, blepharitis (16)</li> </ol>	<ol> <li>Skin diseases (19)</li> <li>Mialgia, neuralgia</li> <li>(20)</li> <li>Burns, trophic ulcers, pressure ulcers (21)</li> <li>Keratitis, conjunctivitis (22)</li> <li>Seborrhea of the scalp (23)</li> </ol>

## Disinfectants and antiseptics (cont.)

Classification	Phenols	Dyes	Aldehydes and	Detergents	Nitrofurans	Tar
	1. Allergic reactions	1. Allergic reactions	1. Irritation of the skin	1. Allergic reactions	1. Allergic reactions	1. Allergic reactions
Sido offoats	2. Redness, swelling of		(9, 10)	2. Nausea, vomiting	2. Nausea, vomiting	2. Diarrhea (22)
Side effects	the vagina and vulva (5)		2. Hematuria (10)	(13)		
			3. Skin burn			
	1. Extensive lesions of the	1. Hypersensitivity	1. Inflammatory	1. Hypersensitivity	1. Allergic dermatoses	1. Hypersensitivity
	skin and mucous	2. Kidney disease (8)	processes of skin (9)	2. Application with	2. Increased sensitivity	
	membranes (1)		2. Hypersensitivity	soap, nitrates, iodides,	to nitrofuran and its	
Contraindications	2. The nevuses (3)			potassium	derivatives	
	3. Chronic renal failure			permanganate, alkalis		
	(4)			(13)		
	4. Menstruation (5)					

# **13. ANTINEOPLASTIC AGENTS**

Antineoblastic agents are drugs affecting the cell devision. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells.

	1. Alkylating agents							
Classification	Nitrogen mustards	Triazenes	Alkyl sulfonates	Nitrosoureas	Alkylating agents	of a different chemical ructure		
Drugs	<ol> <li>Cyclophosphamide (cytophosphane)</li> <li>Chlorambucil (Leukeran)</li> <li>Melphalan (Alkeran, Sarcolysin)</li> </ol>	4. Dacarbazine 5. Temozolomide	6. Busulfan (Myleran)	<ol> <li>7. Streptozocin</li> <li>8. Lomustine</li> <li>9. Carmustine</li> <li>10. Thiophosphamide</li> </ol>	11. Cisplatin 12. Pipobroman			
Mechanism of action	Binding of alkyl groups all phases of the cell cy	s to nucleic acids and procle.	oteins $\rightarrow$ fragmentation of	of DNA strands $\rightarrow$ Violat	ion of the structure and	function of DNA Affect		
Classification	2. Antimetabolites			3. Plant alkaloids				
Classification	Folic acid analogues	Purine analogues	Pyrimidine analogue	Vinca alkaloids	Taxanes	Podophyllotoxins		
Drugs	13. Methotrexate e	14. Mercaptopurin	15. Fluorouracil	16. Vincristine 18. Paclitaxel	19.Teniposide	17. Vinblastine		
Mechanism of action	Antagonists of natura processes in the cell – specific – specifically a (S phase)	al cell components $\rightarrow$ $\rightarrow$ violate the synthesis of ttack cells in a particula	inhibition enzymatic of nucleic acids. Cyclo- r phase of the cell cycle	Inhibit the division of t specific.	tumor cells at various st	tages of mitosis. Cyclo-		

			1. Alkylat	ing agents	
Classification	Nitrogen mustards	Triazenes	Alkyl sulfonates	Nitrosoureas	Alkylating agents of a different chemical structure
Pharmacological effects	1. Antiblast 2. Cytotoxic 3. Cytostatic 4. Immunodepressive			7	5
Side effects	<ol> <li>Nausea, vomiting</li> <li>Inhibition of bone mand</li> <li>Immunodepression</li> <li>Alopecia</li> <li>Neuritis, myalgia, arth</li> <li>Hepatotoxicity</li> <li>Nephrotoxicity</li> </ol>	rrow hematopoiesis Iralgia		A	
Indications	<ol> <li>Hemoblastoses (1–3,6</li> <li>Myeloma disease (1, 3</li> <li>Melanoma (4–5, 7–10</li> <li>Soft tissue sarcoma (4</li> <li>Genital tumors (3,11,</li> <li>Colorectal cancer (4,5</li> </ol>	,12,14,16,17) ,9) ,16) –5, 12, 16,17) 16–19) 7. Brain tumoi ,15)	rs (7–10)		
Contraindications	<ol> <li>Individual intolerance</li> <li>Pregnancy and lactatic</li> <li>Severe liver and / or k</li> <li>Bone marrow hypopla</li> <li>Acute infectious disea</li> </ol>	on idney dysfunction isia ses	091		
	Res	03/			

## Antineoblastic agents (cont.)

				4.1 Hormo	onal agents			
Classification	Glucocorticosteroids		Androgens	Estrogens		Gestagens		Gonadotropin-releasing hormone analogues
Drugs	<ol> <li>Prednisolone</li> <li>Hydrocortisone</li> </ol>	3. Tes propio	tosterone onate	<ol> <li>Phosphastro</li> <li>Extramustin</li> </ol>	ol ne	<ol> <li>6. Megestrol</li> <li>7. Medroxyprogestero</li> <li>8. Gepostet</li> </ol>	one	9. Goserelin 10. Leuprolide
Mechanism of action	Reduce the production of gon regulation $\rightarrow$ slowing the growth rate of ho	adotrop rmone-c	ic hormones of the pitu lependent tumors	itary gland and t	he correspondi	ng hormones of the gona	ads acco	rding to the feedback
Classification	4.2 Antihormonal agents		16					
	Adrenal cortex hormones anta	igonist	Antiandrogens		Antiestrogens	<u> </u>	Aroma	tase inhibitors
Drugs	<ol> <li>11. Mitotane</li> <li>12. Ketoconazole</li> <li>13. Mifepristone</li> </ol>		14. Cyproterone 15. Flutamide		16. Tamoxife 17. Tremifene	n e	18. An	astrozole 19. Exemistan
Mechanism of action	Inhibit corresponding hormor	e recep	tors on tumor cells $\rightarrow$ s	lowing the grow	th rate of horm	one-dependent tumors		
Pharmacological effects	<ol> <li>Antiblast 2. Antiandrogenic (4–5, 14,15)</li> <li>Androgenic (3)</li> <li>Estrogenic (4,5)</li> <li>Antiestrogenic (6–8,16,17,11–13)</li> <li>Pharmacological castration (9,10)</li> </ol>							
Side effects	<ol> <li>Dyspepsia</li> <li>Ulceration of the gastrointe</li> <li>Steroid diabetes mellitus (1</li> <li>Cushing's syndrome (1–2)</li> </ol>	stinal m –2)	nucosa (1–2)	K	<ol> <li>5. Virilization</li> <li>6. Gynecomas</li> <li>7. Uterine ble</li> <li>8. Thrombosis</li> </ol>	n (3) stia (4–8, 14, 15) eeding (3-5,16–17) s (4–8)		
Indications	<ol> <li>Leukemia (1–2)</li> <li>Lymphomas (1–2)</li> <li>Prostate cancer (4–8,10,15)</li> <li>Breast cancer (3, 6–9, 16–1)</li> </ol>	9)	3		<ol> <li>5. Uterine car</li> <li>6. Kidney can</li> <li>7. Tumor of the</li> </ol>	ncer (6–8, 16, 17) ncer, nephroblastoma (W he adrenal cortex (11–13	Villiams ( 3)	tumor) (16, 17)
Contraindications	<ol> <li>Individual intolerance</li> <li>Pregnancy and lactation</li> <li>Severe liver and / or kidney</li> <li>Bone marrow hypoplasia</li> <li>Acute infectious diseases</li> <li>Ulcerative lesions of the gate</li> </ol>	dysfun strointe	ection stinal tract (1–2)					
NB!	<ol> <li>Hormonal antimicrobial ag</li> <li>In hormone-dependent tum</li> </ol>	ents difi ors, inh	fer from cytostatics by s ibition of the synthesis	significantly less of a hormone or	toxicity its action leads	to a decrease or even a	complet	e regression of the tumor

Classification	5. Antibiotics	6. Enzymes	7. Substances of different chemical structure	8. Radioactive isotopes		
Drugs	I generation anthracyclines 1.Doxorubicin (Adryblastin) 2. Daunorubicin 4. Idarubicin (Vfend)	7. Asparaginase	<ul><li>8. Hydroxycarbamide (Hidroxyurea)</li><li>9. Procarbazine (Natulan)</li></ul>	10. Radium 11. Cobalt 12. Gold 13. Phosphorus 14. Iodine		
	5. Bleomycin 6. Mitomycin					
Mechanism of action	Bind to DNA $\rightarrow$ violation of DNA transcription $\rightarrow$ inhibition of RNA synthesis. Non-cyclo-specific, except bleomycin (specifically inhibits G2 phase).	Destruction of plasma asparagine $\rightarrow$ termination of protein synthesis $\rightarrow$ inhibition of tumor cells growth. Affect G1 phase.	Inhibition of the enzyme ribonucleotide $\rightarrow$ inhibition of DNA synthesis. Affect S phase.	The ionizing radiation $\rightarrow$ the formation of free radicals and oxidants $\rightarrow$ damage to the structure of DNA $\rightarrow$ the death of tumor cells.		
Pharmacological effects	<ol> <li>Antineoplastic</li> <li>Antibacterial (1–6)</li> <li>Cytotoxic</li> <li>Cytostatic</li> <li>Immunosupressive</li> </ol>					
Side effects	<ol> <li>Nausea, vomiting</li> <li>Inhibition of bone marrow hematopoie</li> <li>Alopecia</li> <li>Cardiotoxicity (1–4)</li> </ol>	<ul><li>5. Neuritis, myalgia, arthralgia</li><li>sis</li><li>6. Hepatotoxicity</li><li>7. Nephrotoxicity</li></ul>				
Indications	<ol> <li>Thyroid gland tumors (1, 5, 14) 4. Tumors of the head and neck (1,3,5,8) 7. Brain tumors (1–5,8,10–12)</li> <li>Hemoblastoses (1–4, 7, 8)5. Testicular cancer (5,8) 8. Pulmonary cancer (1–3,5,8,10–12)</li> <li>Sarcoma (1, 3) 6. Melanoma (1, 3, 8) 9. Stomach cancer (1,3,5,8,10–12) 10. Tumor diagnostics (10–14)</li> </ol>					
Contraindications	<ol> <li>Pregnancy</li> <li>Lactation.</li> <li>Individual intolerance</li> </ol>	<ul><li>4. Severe impairment of liver a</li><li>5. Bone marrow hypoplasia</li><li>6. Acute viral infections</li></ul>	nd renal function			
NB!	<ol> <li>Dosage of cytostatics is based on the a</li> <li>Cyclo-specific agents are used for rag growing tumors.</li> </ol>	rea of the body. idly growing tumors (leukemia, meland	oma, sarcoma, etc.), non-cyclo-specific	agents are effective in fast-and slow-		
# **14. PRINCIPLES OF TREATMENT OF ACUTE DRUGS INTOXICATIONS**

**Poison** is a toxic alien substance impairing biochemical processes in the body.

**Poisoning classification** 

By origin						
Unintentional			Intentional			
Industrial Household Iatrogenic (medical error)			Homicida	Suicidal		

By the route of poison entry					
Oral	Inhalational	Percutaneous (through the skin)	Parenteral		

By area of application						
Industrial poisons	Agricultural poisons	Household poisons	Biological poisons	Medicinal products	Chemical warfare agents	

	By selective toxicity						
	Cardiotoxic	Neurotoxic	Nephrotoxic	Hepatotoxic	Hematotoxic	GIT-toxic	Pulmonary
Mechanism of action	Cause disorders of rhythm and conduction, toxic dystrophy of the myocardium	Cause disruption of mental activity, toxic hyperkinetic diseases, paralysis	Cause toxic nephropathy	Cause toxic hepatopathy	Cause hemolysis and methemoglo- binemia	Cause toxic ga- stroenteritis, mucous burns	Cause laryngeal and bronchospasm, toxic edema, pulmonary fibrosis
Toxic substances	Cardiac glycosides, adrenoblockers, calcium channel blockers, tricyclic antidepressants, hellebore	Psychotropics, organophosphorus compounds, isoniazid, alcohol and its surrogates	Salts of heavy metals, chlorinated hydrocarbons, oxalic acid	Chlorinated hydrocarbons, muschrooms, phenols, aldehydes	Carbon monoxide, nitrates, arsenic hydride, phenacetin, aniline	Salts of heavy metals, acid and alkali, arsenic	Chemical warfare agents, chlorine and nitrogen oxide

By the toxicity					
Extremely toxic: Lethal dose < 15 mg / kg	Highly toxic: Lethal dose 15–150 mg / kg	Moderately toxic: Lethal dose 150-1500 mg/kg	Low-toxic: Lethal dose > 1500 mg / kg		

# **Basic principles of acute intoxication treatment**

**Toxicokinetics** is a section of toxicology that studies the patterns of resorption, distribution, biotransformation and ruutes of eliminating xenobiotics from the human body.

**Toxicodynamics** is a section of toxicology that studies the mechanism of toxic action, the patterns of development and manifestations of various forms of the toxic process.

Antidote is a remedy that can eliminate or reduce the specific action of the poison by its immobilization, reducing the penetration to the effector receptors by reducing its concentration or which is an antidote at the level of the receptor (WHO International Program on Chemical Safety, 1996)

1. Evaluation of vital functions and correction of their disoeders	Correction of life-threatening respiratory and circu	latory disorders (providing airway	patency, cardiopulmonary resuscit	ation if necessary)		
2. Cessation of poison intake into the body	Removal of the victim from the zone of toxic pollution; use of personal protective equipment (gas mask); termination of injection of toxic substance					
3. Removal of unabsorbedpoison from the body	<ul> <li>From the stomach</li> <li>1. Simple lavage NB! Contraindicated: when poisoning with acids, alkalis, gasoline, turpentine → repeated damage to mucous membranes; when poisoning with cardiotoxic chrononegative poisons → pronounced bradycardia.</li> <li>2. Disadvantage of the method: gastric spasm → toxin remains in the gastric folds → preservation of xenobiotic in the body.</li> <li>3. Tube gastric lavage Basic principles of gastric lavage: T0fluid 18–24 0C, Vsingle &lt; 600 ml, Vtotal ~7–15 1</li> <li>After gastric lavage, a suspension of activated carbon (0.5–1.0 / kg body weight) is given</li> </ul>	<ul> <li>From the intestine <ol> <li>Siphon enema</li> <li>Intestinal lavage</li> <li>Saline laxatives</li> </ol> </li> <li>From the lungs <ol> <li>Removal of the victim from the zone of toxic pollution</li> <li>Use of personal protective equipment (gas mask)</li> <li>Ventilation, assisted breathing, oxygen inhalation</li> </ol> </li> </ul>	From the surface of the skin and mucous membranes 1. Washing with running water (T0 < 200 T0C) or fluid from the skin decontamination kit. 2. Chemical neutralization of poison (acids - alkali and vice versa). NB! ↑ risk of localized skin and mucous membrane damage	Whenadministeredsubcutaneously1. Cooling the injection site(icepack)2. Injections of the adrenalinesolution around the site ofadministration of the toxicsubstance3. Overlapping of thetourniquet above the injectionsite $\rightarrow$ venous stasis $\rightarrow$ slowingthe flow of poison into thesystemic circulation		
4. Removal of absorbed poison from the body	<ul> <li>Acceleration of excretion of poison from the body:</li> <li>1. Infusion therapy</li> <li>2. Forced diuresis - hydration therapy followed by intravenous injection of osmotic (mannitol) or loop (furosemide) diuretics → substances that do not bind to proteins and lipids of the blood plasma are eliminated.</li> <li>NB! Contraindications: acute cardiac insufficiency, pronounced impaired renal function, danger of cerebral andpulmonary edema</li> <li>3. Methods of intraocorporal correction of homeostasis: peritoneal dialysis, enterosorption using adsorbents; intravenous administration of rheopolyglucin, gemodez or preparations based on polyethylene starch.</li> </ul>					

	<ul> <li>4. Methods of extracorporeal correction of homeostasis: hemodialysis, plasmapheresis, lymphophoresis, hemosorption, plasmosorption and others.</li> <li>5. Hyperventilation of the lungs. NB! is effective in poisoning with toxic substances that are largely removed from the body through the lungs (means for inhalation anesthesia</li> </ul>					
5. Etiotropic therapy (Specific antidote	Antidote type	The mechanism of action	Antidotes	Type of poisoning		
therapy)	1. Chemical	Directly bind to toxicants → neutralization of free-circulating poison	<ol> <li>Calcium gluconate</li> <li>Deferoxamine</li> <li>D-Penicillamine</li> <li>UnitiolAnti-ophidic serum</li> <li>Black widow antidote</li> </ol>	<ol> <li>Fluoride poisoning</li> <li>Poisoning with iron compounds</li> <li>Poisoning with copper, bismuth, arsenic</li> <li>Poisoning with heavy metals, cardiac glycosides</li> <li>Snake bites</li> <li>Bites of the black widow</li> </ol>		
	2. Biochemical	Displace the toxicant from its bond with the target molecules $\rightarrow$ restore normal biochemical processes	<ol> <li>Oxygen</li> <li>Cholinesterase reactivators</li> <li>Methylene blue</li> </ol>	<ol> <li>Carbon monoxide poisoning</li> <li>Poisoning with organophosphorus compounds</li> <li>Poisoning with methaemoglobin-forming agents</li> </ol>		
	3. Physiological	Normalize the conduct of nerve impulses in synapses that цуку affected by toxins	<ol> <li>Atropine</li> <li>Flumazenil</li> <li>Naloxone, naltrexone</li> </ol>	<ol> <li>Poisoning with organophosphorus compounds, muscarinic agonists</li> <li>Poisoning with benzodiazepines</li> <li>Poisoning with opioids</li> </ol>		
	4. Metabolism modifiers	Prevent the transformation of xenobiotic into highly toxic metabolites, or accelerate biodetoxication	<ol> <li>Sodium thiosulfate</li> <li>Acetylcysteine</li> <li>Ethyl alcohol</li> </ol>	<ol> <li>Cyanide poisoning</li> <li>Poisoning with paracetamol, dichloroethane</li> <li>Poisoning with methanol, ethylene glycol</li> </ol>		
6. Pathogenetic therapy	It is aimed at the pathogenesis of the development of some syndromes, for example, partial elimination of signs of cerebral hypoxia caused by asphyxiating substances during inhalation of oxygen					
7. Symptomatic therapy	<ul> <li>Elimination or weakening of certain manifestations of intoxication when they occur:</li> <li>1. Treatment of psychoneurological disorders (intravenous tranquilizers, neuroleptics)</li> <li>2. Seizures treatment (intravenous tranquilizers or non-inhalational anesthetics)</li> <li>3. Management of pain syndrome (narcotic or non-narcotic analgesics)</li> <li>4. Treatment of respiratory disorders (ventilation, oxygen therapy, prevention of aspiration complications)</li> <li>5. Therapy of cardiovascular complications (the introduction of cardiotonic drugs, antiarrhythmic, plasma-substituting agents)</li> <li>6. Tretment of hyperthermic syndrome (methods of physical cooling, introduction of a lytic mixture)</li> </ul>					

\* Therapy of the most common poisonings is discussed in other topics.

# **RECCOMENDED READING**

#### **Basically:**

1. Kharkevich, D. A. Pharmacology: textbook or medical students / D. A. Kharkevich. - M.: GEOTAR-Media, 2017. - 680 p.

# Additional:

2. Basic & Clinical Pharmacology / edit. by Bertram G. Katzung, associate edit. Anthony J. Trevor. — 13th ed. — New York: McGraw-Hill Education, 2017. — 1203 p.

# Electronic databases:

3. Oxford Medicine Online [Electronic resource] / Oxford University Press. — Access mode: www.oxfordmedicine.com. — Date of access: 09.11.2017.

4. Oxford ACADEMIK Journals [Electronic resource] / Oxford University Press. — Access mode: http://www.oxfordjournals.org. — Date of access: 09.11.2017.

5. Scientific electronic library eLIBRARY.RU [Electronic resource]. — Access mode: https://elibrary.ru/. — Date of access: 09.05.2017.

6. Student consultant. Electronic library of medical high school [Electronic resource] / Publishing group «GEOTAR-Media», LLC «IPPO». — Access mode: http://www.studmedlib.ru. — Date of access: 09.05.2017.

7. Springer Link [Electronic resource] / Springer International Publishing AG. — Access mode: https://ink.springer.com. — Date of access: 09.11.2017.

8. Scopus [Electronic resource] / Mode of access: https:// www.scopus.com. — Date of access: 09.11.2017.

9. The BMJ (British Medical Journal) [Electronic resource] // Mode of access: http://www.bmj.com/archive. — Date of access: 09.11.2017.

Учебное издание

Михайлова Елена Ивановна Саварина Валерия Александровна Бронская Галина Михайловна и др.

КРАТКО О ЛЕКАРСТВЕННЫХ СРЕДСТВАХ

> В двух частях Часть 2 (на английском языке)

Учебно-методическое пособие для студентов 3 и 6 курсов факультета иностранных студентов учреждений высшего медицинского образования

> Редактор *Т. М. Кожемякина* Компьютерная верстка *Ж. И. Цырыкова*

Подписано в печать 04.04.2020. Формат 60×84<sup>1</sup>/<sub>8</sub>. Бумага офсетная 70 г/м<sup>2</sup>. Гарнитура «Таймс». Усл. печ. л. 8.84. Уч.-изд. л. 9.66. Тираж 160 экз. Заказ № 147.

Издатель и полиграфическое исполнение: учреждение образования «Гомельский государственный медицинский университет». Свидетельство о государственной регистрации издателя, изготовителя, распространителя печатных изданий № 1/46 от 03.10.2013. Ул. Ланге, 5, 246000, Гомель